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N-truncated Aβ4-42 has been identified as a particular abundant Aβ species in the 
hippocampus and cortex of AD patients. However, relatively little is known about the 
contribution of Aβ4-42 to the development and progression of AD. In order to study the 
effects of chronic exposure of Aβ4-42 the transgenic mouse model Tg4-42 was generated. 
The Tg4-42 mouse model, expressing exclusively human Aβ4-42, allows to investigate the 
neurotoxic effects of Aβ4-42 in vivo. 
In the present work, it could be shown that Tg4-42 mice show region-specific 
intraneuronal accumulation of Aβ accompanied by gliosis. Tg4-42 mice showed strong 
intraneuronal Aβ immunoreactivity predominantly in the CA1 pyramidal cell layer of the 
hippocampus. Strikingly, transgenic mice expressing Aβ4-42 develop a massive CA1 
neuron loss. The progressive neuron loss in the hippocampus of Tg4-42 mice correlates 
strongly with intraneuronal Aβ4-42. The behavior analysis of Tg4-42 mice revealed 
hippocampus-dependant memory deficits similar to AD patients. Importantly, the observed 
memory deficits in Tg4-42 mice are not confounded by motor impairments or abnormal 
anxiety. Mice are profoundly impaired in their spatial reference memory assessed in the 
Morris water maze. Moreover, aged Tg4-42 showed a decline in contextual fear memory. 
The over-expression of Aβ4-42 in this mouse model induces severe age-dependant 
memory deficits that can be attributed to the massive neuron loss in the hippocampus. 
The transgenic mouse model Tg4–42 is unique as it harbors no mutations in the Aβ 
sequence. In summary, Tg4-42 is a valid AD mouse model showing key features of 
sporadic AD.  
One of the central research questions on the etiology of AD is the elucidation of 
the molecular signatures triggered by the amyloid cascade of pathological events. Next 
generation sequencing allows the identification of genes involved in disease processes in 
an unbiased manner. The gene expression profiles of Tg4-42 mice were compared to the 
widely used 5XFAD mouse model using next-generation sequencing. The comparison 
with 5XFAD, an established plaque-developing AD mouse model, revealed a remarkable 
overlap in the molecular signature. The jointly differentially expressed genes might 
indicate common pathways that are involved in the comparable learning and memory 
decline apparent at twelve months of age in both transgenic models. The pool of genes 
that showed differential expression exclusively in Tg4-42 is likely associated to soluble Aβ 
as no extracellular plaques are found in this model. In addition, the robust CA1 neuron 
loss could also contribute to the differential expression profile. As most of the genes with 




pathways, it can be concluded that the majority of these genes are regulated in 
connection with plaque formation in this model and are not associated with neuron loss 
and memory decline. Furthermore, the deep sequencing approach identified a plethora of 
genes that have so far not been linked to AD and therefore open up new avenues of 
research into the etiology of this devastating neurodegenerative disorder.  
In summary, the results of this thesis demonstrate Aβ4-42 as a toxic Aβ variant that 
likely plays an important role in triggering AD pathology.  
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1.1 Alzheimer's disease  
 
In 1906, at the 37th meeting of the Society of Southwest German Psychiatrists in 
Tübingen, Alois Alzheimer presented the case of his patient Auguste Deter. In this single 
case, he described the main clinical and neuropathological characteristics of a disease 
that was later named after him: memory disturbance, neuron loss, miliary bodies (plaques) 
and dense bundles of fibrils (tangles) (Alzheimer, 1907; Alzheimer et al., 1995; Goedert, 
and Spillantini, 2006). Alois Alzheimer would likely not have imagined that today 
Alzheimer (AD) is the most common neurodegenerative disease, with nearly 30 million 
cases worldwide (Alzheimer's Association, 2012). 
 




According to the World Health Organization (WHO) 35.6 million people worldwide were 
living with dementia in 2012. Due to an aging population this number is predicted to 
increase more than triple by the year 2050 (WHO, 2012). Currently, more than 1.4 million 
people are diagnosed with dementia in Germany (Deutsche Alzheimer Gesellschaft, 
2014). Alzheimer's disease (AD) is the most common form of dementia and accounts for 
approximately 60 - 80 % of the cases (Alzheimer's Association, 2012). To date, 
approximately 5.4 million Americans suffer from AD, which is the sixth leading cause of 
death in America. The health-care costs associated with AD already add up to more than 
$200 billion and are expected to increase to $1.1 trillion in 2050 in the United States alone 
(Alzheimer's Association, 2012). 
 
1.2.2 Non-genetic risk factors 
 
The greatest and most obvious risk factor of AD is aging (Blennow et al., 2006). Although 




aging process. While one in eight people over the age of 65 years suffers from AD, nearly 
45 % of the over 85-year-olds have AD (Alzheimer's Association, 2012). 
Epidemiological studies have suggested further risk factors for AD besides aging. 
Vascular diseases like atherosclerosis, hypercholesterolemia and coronary heart disease 
or heart failure elevate the risk of developing dementia (Kivipelto, 2001; Kivipelto et al., 
2005; Qiu et al., 2006). There is also evidence that obesity, smoking and type II diabetes 
are associated with an increased risk for AD (Prince et al., 1994; Leibson et al., 1997; 
Kivipelto et al., 2005). Furthermore, several studies showed that head injury and traumatic 
brain injuries could be risk factors for AD (Plassman et al., 2000; McCullagh, 2001; 
Sivanandam and Thakur, 2012). 
In contrast, several studies suggest that a healthy and physically active lifestyle, an 
antioxidant-rich Mediterranean diet and cognitive stimulating activities can reduce the risk 
of developing AD (Fratiglioni et al., 2004; Hall et al., 2009; Gu et al., 2010). 
 
1.2.3 Disease progression 
 
AD is a slowly progressive disease. The complex progression of neurodegeneration in AD 
patients results in memory impairment and decline in other cognitive abilities, often 
combined with non-cognitive symptoms like mood- and personality changes (Alzheimer's 
Association, 2012). Patients progress from mild and moderate AD to severe AD in the 
average time course of 7 to 10 years (Holtzman et al., 2011; Alzheimer's Association, 
2012). 
In 2011, the Alzheimer's Association and the National Institute on Aging (NIA) 
proposed new guidelines for the classification and diagnosis of AD identifying three 
different stages of AD. These stages are preclinical AD, mild cognitive impairment (MCI) 
due to AD and dementia due to AD. (Albert et al., 2011; Jack et al., 2011; McKhann et al., 
2011; Sperling et al., 2011). During the preclinical phase, individuals do not present any 
measurable symptoms. However, it is estimated that changes in the brain and 
neurodegeneration already start 20 years before the initial clinical diagnosis of AD 
(Blennow et al., 2006). Patients with MCI display a noticeable but mild cognitive decline 
compared to same-aged healthy individuals (Alzheimer's Association, 2012). Each year 
10 - 15 % of MCI cases convert into AD and in these cases MCI is an early stage of AD 
(Petersen, 2004; Visser et al., 2005). In the final stage, patients develop dementia due to 
AD. This stage is characterized among others through memory decline, language 
dysfunction, personality changes, motor impairments and visuo-spatial difficulties 
(Holtzman et al., 2011; Alzheimer's Association, 2012). At the terminal stage of the 




functions like swallowing. AD is not only a progressive disease but ultimately fatal, often 
caused by pneumonia (Wada et al., 2001). 
 




To date, a definite diagnosis of AD can only be made post mortem by neuropathological 
examination. The criteria for the neuropathological confirmation of AD are based on the 
analysis of amyloid plaques and neurofibrillary tangles (NFT) formation in the brain 
(McKhann, 1984; Braak and Braak, 1991).  
However, cognitive and behavior changes as well as the family history of an 
individual can be used to make a probable diagnosis of AD prior to death (Alzheimer's 
Association, 2012). In the early stages of AD physical and multiple cognitive deficits are 
important requirements for an initial MCI diagnosis (Waldemar et al., 2007). For diagnosis 
patients must show, besides memory deficits, impairments in agnosia, aphasia, apraxia or 
executive functioning (organizing, etc.). These deficits must be gradual and severe 
enough to affect the abilities of an individual to carry out daily activities (American 
Psychiatric Association, 1995). A number of tests are available to evaluate the mental 
status of individuals over the course of the disease. Screening tests for AD include the 
Mini-Mental State Examination (MMSE), Clock Drawing Test (CDT), and Cambridge 
Cognitive Examination (CAMCOG) (Schmand et al., 2000; Aprahamian et al., 2010; 
Martinelli et al., 2014). Next to neuropsychological tests, neuroimaging methods play an 
important role in the diagnosis of AD and the exclusion of alternative causes of dementia 
like brain tumours, hydrocephalus or subdural hematomas (Waldemar et al., 2007; Ballard 
et al., 2011). Magnetic resonance imaging (MRI), computed tomography (CT) and 
positron emission tomography with radiolabeled glucose (FDG‐PET) or an 
amyloid‐binding dye (PiB‐PET) are used to diagnose MCI due to AD and the transition 
into AD (Blennow et al., 2006; Perrin et al., 2009; Ballard et al., 2011). In addition, 
cerebral spinal fluid (CSF) biomarkers have been examined as a valuable diagnostic tool 
for AD in several studies. Diagnosis of MCI and AD could be achieved through detection 
of reduced Aβx-42 as well as increased tau and phosphorylated tau levels (Mattsson et al., 




Currently, there is no cure for AD. Available medications only help to alleviate the 




two types of drugs available for AD: memantine and three different acetylcholinesterase 
inhibitors.  
The cholinergic system is involved in memory and behavior (Bartus et al., 1982). 
According to the cholinergic hypothesis, a dysfunction of cholinergic neurons in AD leads 
to memory and cognitive impairments (Terry and Buccafusco, 2003). The routinely 
prescribed drugs donepezil, rivastigmine and galantamine are used to increase the 
availability of acetylcholine by inhibiting the catalytic function of acetylcholinesterase the 
enzyme that degrades acetylcholine in the synaptic cleft. There is evidence, that the 
acetylcholinesterase inhibitors can temporarily stabilize or even moderate the symptoms. 
However, all three drugs do not cure the disease or prevent its progression (Rogers, 
1998; Bullock and Dengiz, 2005; Bullock et al., 2005; Wallin et al., 2011).  
Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist 
that is prescribed to patients with moderate to severe AD (Tariot et al., 2004). In AD 
glutamate-mediated excitotoxicity is increased. Memantine is used to protect neurons 
from this excitotoxicity without disturbing the physiological function of NMDA receptors 
(Parsons et al., 2007). It is reported that memantine has a modest beneficial effect in 
patients with moderate to severe AD and is suggested to be used in combination with 
cholinesterase inhibitors (Orgogozo et al., 2002; McShane et al., 2006; Peskind et al., 
2006; Parsons et al., 2013).  
 
1.3 Neuropathological hallmarks of Alzheimer's disease 
 
1.3.1 Amyloid plaques 
 
Amyloid plaques are one of the key neuropathological features in AD. The main 
proteinaceous components of these extracellular deposits are Aβ peptides. Aβ peptides 
are generated by enzymatic cleavage of the amyloid precursor protein (APP) (Holtzman et 
al., 2011; Serrano-Pozo et al., 2011). Amyloid plaques can be divided into two groups: 
diffuse and neuritic (Yamaguchi et al., 1988b; Holtzman et al., 2011). 
Diffuse plaques (FIGURE 1.1 B) consist of non-fibrilar depositions of Aβ with 
nearly no detectable neuritic dystrophy. They vary in size from 50 µm to several hundred 
µm (Yamaguchi et al., 1988a; Duyckaerts et al., 2009). Diffuse plaques are also found in 
the cortex of cognitive normal aged individuals (Serrano-Pozo et al., 2011). 
Neuritic plaques (FIGURE 1.1 A) are one of the major hallmarks of AD and can be 
detected with β-sheet staining dyes like Thioflavin-S and Congo Red (Serrano-Pozo et al., 
2011). These extracellular Aβ plaques consist of highly aggregated fibrillary Aβ and are 




plaques degenerated neurons, as well as astro- and microgliosis are observed (Holtzman 
et al., 2011; Selkoe, 2011). The density of amyloid fibrils varies as well as its size (10 to 
120 μm) (Thomas and Fenech, 2007). Next to Aβ other proteins including APP, tau and 
ubiquitin are found in neuritic plaques (Su et al., 1998; Duyckaerts et al., 2009). Plaque 
pathology commonly starts in the neocortex and later progresses to the hippocampus, 
basal ganglia and cerebellum (Serrano-Pozo et al., 2011). In the end stages of the 
disease, neuritic plaques are also found in the brainstem and other subcortical structures 
(Thal et al., 2002; Aldwin and Gilmer, 2013). However, the plaque load correlates poorly 
with the cognitive decline and severity of the disease (Billings et al., 2005; Schaeffer et al., 
2011; Villemagne et al., 2011).  
 
 
1.3.2 Neurofibrillary Tangles 
 
One of the neuropathological hallmarks of AD are neurofibrillary tangels (NFTs) that were 
first described by Alois Alzheimer as 'intraneuronal filamentous inclusions' within the 
perikaryal region of pyramidal neurons (Alzheimer, 1907). Subsequently, ultrastructural 
studies revealed that the major component of NFTs are paired helical filaments (PHFs), 
which are mainly constituted of hyperphosphorylated tau (Goedert and Spillantini, 2006; 
Castellani et al., 2008). 
Tau is a phosphoprotein that is abundant in neurons and produced in all nucleated 
cells (Duyckaerts et al., 2009; Galimberti and Scarpini, 2012). The normal function of tau 
is to bind to tubulin assembling and stabilizing microtubules (Goedert and Spillantini, 
2006). However, in AD tau is abnormally hyperphosphorylated (FIGURE 1.2 A). The 
phosphorylation of tau reduces its microtuble binding activity and supports its self-
FIGURE 1.1 Amyloid plaques. (A) Photomicrograph of a neuritic amyloid plaque. Plaque is 
marked by a dashed circle. Arrow shows neurofibrillary tangle. Modified after Holtzman et al., 
2011. (B) Diffuse Aβ plaques. Modified after Duyckarts et al., 2009. Reprinted with permission of 




aggregation forming PHFs in cell bodies and dystrophic neurites (Alonso et al., 1996; 
Holtzman et al., 2011).  
The relevance and contribution of tau dysfunction to the pathogenesis of AD 
remains unclear. It is well established that the tau pathology appear later in the 
progression of AD than Aβ deposition (Galimberti and Scarpini, 2012). However, 
neurofibrillary tangles, unlike the plaque pathology, correlate better with the severity of 




Inflammatory processes are another pathological characteristic of AD (FIGURE 1.2 B). 
Microglia, astrocytes, the complement system as well as cytokines and chemokines are 
involved in the inflammatory reaction of the brain. Activated astrocytes and microglia are 
found in close proximity to neuritic plaques in AD, suggesting that Aβ is a major trigger of 
glial activation (Itagaki et al., 1989; Pike et al., 1995a; Krause and Müller, 2010). Following 
activation, glial cells produce proinflammatory signal molecules including complement 
molecules as well as cytokines and chemokines (Tuppo and Arias, 2005; Rubio-Perez 






FIGURE 1.2 Tau and inflammation. (A) Hyperphosphorylated tau accumulation in neuronal cell 
bodies. Modified after Holtzman et al., 2011. (B) Confocal image of astrocyted labeled with 
GFAP (green) and plaques (red). Modified after Verkhratsky et al., 2010. Reprinted with 





1.3.4 Neuron loss 
 
In addition to plaques and tangles, neuron loss is a main pathological hallmark of AD. 
Areas that are particular affected by neuron loss are the pyramidal layers of the 
hippocampus, the layer II of the entorhinal cortex, and some areas of the temporal, 
parietal and frontal neocortex (Holtzman et al., 2011; Serrano-Pozo et al., 2011). For 
example, stereology showed a significant neuron loss in the entorhinal cortex (EC) of 
patients with very mild AD (Gomez-Isla et al., 1996). While no neuron loss was observed 
in the CA1 in preclinical AD a profound neuron loss was reported in AD patients (West et 
al., 2004). Early studies suggested a correlation between the number of NFT in a region 
and the loss of neurons within the same region (Cras et al., 1995). Using unbiased 
stereology, it could be shown that the neuron loss in the superior temporal sulcus in fact 
partly correlates with the formation of NFT but exceeds it eminently. Strikingly, more than 
50 % of neurons in the superior temporal sulcus are lost in patients with AD (Gomez-Isla 
et al., 1997). Most recent reports suggest that intraneuronal or oligomeric Aβ are instead 
crucial for cell death and neuron loss in AD (Bayer and Wirths, 2011; Larson and Lesné, 
2012). 
Cortical atrophy, that is mainly caused by neuron loss, is the most evident 
macroscopic characteristic of AD. Atrophy affects mainly the hippocampus, amygdale and 
entorhinal cortex and can be measured by MRI (Bottino et al., 2002). AD can be 
diagnosed with 80 to 90 % accuracy through hippocampal atrophy measured by MRI 
(Jagust, 2006). Hippocampal atrophy also allows to predict the progression from MCI to 
AD to a certain degree (Jack et al., 2005).  
Synapse loss also contributes to the cortical atrophy of the AD brain. The number 
of lost synapses exceeds the decrease of neurons in the cortical area. Therefore, it can be 
assumed that synapse loss occurs before neuron loss (Serrano-Pozo et al., 2011). 
Synapse loss is an early indicator of the pathological processes in AD. It could be shown 
that patients with mild AD have fewer synapses in the CA1 of the hippocampus than 
individuals with MCI or healthy controls (Scheff et al., 2007). Decreased synaptic density 
correlates directly with the severity of AD. Actually, synaptic density is a better correlate of 
cognitive decline than NFTs or neuron loss. (DeKosky and Scheff, 1990; Scheff et al., 
1990; Scheff and Price, 1993; Ingelsson et al., 2004).  
 
1.4 The amyloid precursor protein 
 
The amyloid precursor protein (APP) is a highly conserved transmembrane, type-1, 




(Selkoe et al., 1988; Tharp and Sarkar, 2013). In human the APP gene is located on 
chromosome 21. APP is sequentially cleaved to generate Aβ, the main component of 
plaques (Korenberg et al., 1989).  
Through alternative splicing 8 isoforms of APP are generated. Among these, 
APP695, APP751 and APP770 are the three major isoforms containing 695, 751, and 770 
amino acids, respectively (Sandbrink et al., 1996). APP695 is mainly expressed in the 
CNS, particularly in neurons, while APP751 and APP751 are also widely expressed in 
other tissues (O'Brien and Wong, 2011). The highest levels of APP695 expression in the 
brain could be detected in the cerebellum, cortex and hippocampus (Sola et al., 1993).  
APP belongs to a family of conserved type-I transmembrane proteins with the two 
mammalian homologs, APP-like protein 1 (APLP1) and 2 (APLP2) (Wasco et al., 1993; 
Slunt et al., 1994; Coulson et al., 2000). These proteins are processed in a similar way 
and have several common conserved motifs. However, the Aβ domain in not conserved 
and unique to the APP protein (Bayer et al., 1999).  
The physiological function of APP is still not understood. APP knockout mice are 
viable and fertile, indicating that APP does not play a role in vital functions or embryonic 
development. However, APP deficit mice show a moderate abnormal phenotype with 
cerebral gliosis, impaired learning and LTP, reduced body and brain size (Zheng et al., 
1995; Dawson et al., 1999; Ring et al., 2007). The lack of a lethal phenotype in APP 
knockout mice may be attributed to the homologous amyloid precursor like proteins 
(APLPs) (Slunt et al., 1994; Heber et al., 2000). Although the physiological role of APP 
remains unclear, several function have been attributed to APP. These include neuronal 
protein trafficking along the axon, neurite outgrowth and synaptogenesis, transmembrane 
signal transduction, cell adhesion and calcium metabolism (Zheng and Koo, 2006).  
 
1.4.1 APP processing  
 
1.4.1.1 Non-amyloidogenic pathway 
 
APP can be processed via two major alternative pathways: the non-amyloidogenic and 
the amyloidogenic pathway (De-Paula et al., 2012). 
In the non-amyloidogenic pathway (FIGURE 1.3), APP is cleaved by a α-secretase 
releasing a large soluble N-terminal fragment called sAPPα and a smaller C-terminal 
fragment (C83) (Esch et al., 1990; Sisodia et al., 1990). Three members of the disintegrin 
and metalloproteinase ADAM family have been suggested as the α-secretase: the type-I 
transmembrane proteins ADAM-9, ADAM-10 and ADAM-17 (Asai et al., 2003). Recent 




2010). While sAPPα is released into the extracellular space, the 83-residue C-terminal 
fragment (C83) is membrane-bound. C83 is further cleaved by γ-secretase into the 
soluble, 3 kDa C-terminal fragment (p3) and the APP intracellular domain (AICD). The p3 
peptide is rapidly degenerated (De-Paula et al., 2012; Sisodia, 1992; Zheng and Koo, 
2011). While AICD is subjected to act as a transcriptional regulator, the function of p3 is 
unknown (Chow et al., 2010). The cleavage of APP by α-secretase occurs within the Aβ 
domain, preventing the generation of amyloid peptides (Sisodia, 1992). In contrast to Aβ, 
several studies suggest that sAPPα is neuroprotective. sAPPα plays a role in neuronal 
plasticity, synaptogenesis, cell adhesion as well as early CNS development (Furukawa et 
al., 1996; Mattson, 1997; Chow et al., 2010). Interestingly, in APP deficient mice the 
expression of sAPPα was sufficient enough to rescue behavior and electrophysiological 
abnormalities suggesting that sAPPα accounts for most of the physiological functions of 





FIGURE 1.3 APP processing. Schematic diagram showing non-amyloidogenic and amyloidogenic 
APP processing. In the non-amyloidogenic processing APP is sequentially cleaved by α-secretase 
and γ-secretase (left) releasing the p3 fragment. In the amyloidogenic processing the Aβ peptide 




1.4.1.2 Amyloidogenic pathway 
 
In the amyloidogenic pathway (FIGURE 1.3), APP is cleaved by a β-secretase releasing a 
soluble N-terminal fragment (sAPPβ) and a longer C-terminal 99-residue fragment (C99). 
β-secretase cuts APP 16 amino acids upstream from the α-secretase cleavage site. The 
resulting C99 fragment remains membrane associated and is subsequently cleaved within 
the transmembrane domain at different sites by γ-secretase generating Aβ peptides of 
various lengths and AICD. Aβ peptides rage from 37 to 43 amino acids in length (Citron et 
al., 1995; Wolfe, 2007; Zhang et al., 2011; De-Paula et al., 2012). Under normal 
physiological conditions Aβ is mainly 40 amino acids long and the 42 amino-acid long Aβ, 
the main component of amyloid plaques, represent only a minor portion of the total Aβ 
(Zhang et al., 2011).  
The β-site cleaving enzyme 1 (BACE1) was identified by several groups as the 
primary β-secretase (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et 
al., 1999). BACE1 is a membrane-bound aspartyl protease that is highly expressed in the 
brain, especially in regions affected by AD including the cortex and the hippocampus 
(Vassar et al., 1999; Yang et al., 2003; Johnston et al., 2005). BACE1 is able to cleave Aβ 
at two known positions: the aspartate at position 1 and the glutamate at position 11 (Sinha 
et al., 1999; Vassar et al., 1999). Next to BACE1, BACE2 (a homolog of BACE1) and 
cathepsin B have been suggested as additional β-secretases. In several studies the 
inhibition of the protease cathepsin B reduced Aβ generation in vivo and in vitro. (Hook et 
al., 2005; Hook et al., 2009). However, the physiological contribution of these enzymes to 
APP cleavage requires further investigation.  
The γ-secretase is a multiprotein complex of at least four components: presenilin 1 
(PSEN-1) or presenilin 2 (PSEN-2), the type I transmembrane glycoprotein nicastrin (Nct) 
and the two multipass transmembrane proteins anterior pharynx-defective-1 (Aph-1) and 
presenilin enhancer-2 (Pen-2) (O'Brien and Wong, 2011). γ-secretase also cleaves a 
variety of other type I integralmembrane proteins including the Notch receptor, cadherin, 
tyrosinase and CD44 (Wolfe, 2010; Strooper et al., 2012).  
 
1.5 The amyloid cascade hypothesis 
 
The amyloid cascade hypothesis has been proposed more than 20 years ago by Hardy 
and Higgins (1991) to explain the etiology and pathogenesis of AD. According to the 
amyloid cascade hypothesis the deposition of Aβ is the causative event of AD pathology 
leading to NFTs, neuron loss, vascular damage and cognitive deficits (FIGURE 1.4). The 




accumulation of hydrophobic Aβ40 and Aβ42 and the formation of insoluble extracellular 
plaques. Plaques then trigger a cascade of mischievous changes eventually resulting in 
synapse loss, neuron loss, brain atrophy and dementia (Hardy and Allsop, 1991; 
Pimplikar, 2009). Several observations support this theory. Genetic studies of familial AD 
cases are probably the strongest arguments supporting the amyloid hypothesis. Inherited 
mutations in APP, PSEN-1 and PSEN-2 alter the Aβ levels and lead to increased 
depositions of Aβ in plaques (Pimplikar, 2009; Bertram et al., 2010). In addition, many AD 
mouse models harboring familial AD mutations develop an age-dependant pathology 
similar to the one seen in AD patients including Aβ plaques, gliosis and memory deficits 
(Duyckaerts et al., 2008; Pimplikar, 2009). Down syndrome patients exhibit a triplication of 
the APP gene as it is located on chromosome 21. The triplication leads to an AD 
pathology with amyloid plaques and NFTs in these patients (Rumble et al., 1989; Schupf, 
2002). Furthermore, apolipoprotein E ε4 allele (ApoEε4), the most important risk factor for 
late-onset AD (LOAD), is associated with increased Aβ deposition and reduced Aβ 
clearance (see section 1.9) (Bickeboller et al., 1997; Castellano et al., 2011). In contrast, 
mutations in tau lead to tauopathies like frontotemporal dementia instead of AD, 
suggesting that NFTs are not responsible for initiating AD and rather occur subsequent to 
Aβ aggregation (Hutton et al., 1998; Goedert and Jakes, 2005; Iqbal et al., 2005a). 
However, the amyloid cascade hypothesis has several major flaws. First of all, the 
plaque load does not correlate well with the severity of dementia. Furthermore, a robust 
plaque pathology could also be observed in otherwise cognitive normal individuals who 
show no signs of dementia (Snowdon, 2003; Villemagne et al., 2008; Pimplikar, 2009). 
Moreover, in many AD mouse models memory impairment and pathological changes 
occur long before the appearance of plaques (Walsh and Selkoe, 2007; Lesne et al., 
2008). Additionally, in an anti-Aβ active vaccine trial (AN1792) patients showed no 
cognitive improvements although a massively reduced plaque pathology could be 
observed (Holmes et al., 2008). 
 
1.5.1 Intraneuronal amyloid hypothesis 
 
Growing evidence points to intraneuronal Aβ as a key contributor in AD pathology. The 
first observations of intracellular Aβ in neurons were made nearly 30 years ago by 
Masters et al. (1985). It was later shown that intraneuronal Aβ accumulates in AD 
vulnerable brain regions including pyramidal neurons of the hippocampus and entorhinal 
cortex. Intracellular Aβ depositions were detected prior to the development of NFTs and 
extracellular plaques (Gouras et al., 2000; Fernandez-Vizarra et al., 2004). Similar 




plaques showed intracellular Aβ (Gyure et al., 2001; Mori et al., 2002). Furthermore, 
decreased intraneuronal Aβ is accompanied by increased plaque pathology and may 
therefore have a role in the development of extracellular plaques (Gyure et al., 2001; 
Gouras et al., 2010). The appearance of intracellular Aβ prior to PHF and plaques 
indicates that it represents one of the earliest pathological events in the AD brain (Wirths 
and Bayer, 2012).  
Several animal models reinforced the important role of intracellular Aβ in AD by 
showing a correlation between intracellular Aβ and neuron loss (Casas et al., 2004; 
Christensen et al., 2008; Jawhar et al., 2010). In vitro studies in cultured human neurons 
also showed accumulation of intracellular Aβ (Skovronsky et al., 1998; Takahashi et al., 
2004). Increased Aβ42 levels and an elevated Aβ42/Aβ40 ratio was shown in neurons from 
sporadic and familial AD cases using laser capture microdissection of pyramidal neurons 
in AD brains (Aoki et al., 2008). 
Intraneuronal Aβ can origin from two distinct sources. In addition to intracellular 
cleavage of APP, the reuptake from the extracellular space represents the second source 
of intraneuronal Aβ (Wirths et al., 2004). Several receptors have been proposed to 
facilitate the reuptake of Aβ, including ApoE receptors, nicotinic acetylcholine (nAChR) 
receptors, integrins and N-methyl-D-aspartate (NMDA) receptors as well as advanced 
glycation end product receptors. Aβ42 is degraded poorly and its accumulation inside 
neurons has a variety of severe consequences (Mohamed and Posse de Chaves, 2011). 
Primary neuronal cell culture experiments showed intraneuronal Aβ localization in 
endosomes, lysosomes and multivesicular bodies (MVBs) (Runz et al., 2002; Takahashi 
et al., 2004; Almeida et al., 2006). Accumulation of Aβ in lysosomes leads to loss of 
lysosomal impermeability and leakage of lysosomal contents like proteases and 
cathepsins resulting in apoptosis and necrosis (Ditaranto et al., 2001; Nixon, 2005; Liu et 
al., 2010). Due to its high quantity of membranes and low pH, neuronal MVBs are a good 
location for Aβ aggregation. Accumulation of Aβ in MVBs can impair their trafficking and 
degradative function (Takahashi et al., 2002; Mohamed and Posse de Chaves, 2011). 
Furthermore, a correlation between intracellular Aβ and apoptotic markers was observerd 
in AD patients as well as AD mouse models (Chui et al., 2001; Mohamed and Posse de 
Chaves, 2011). Taken together, the findings from AD and DS patients, mouse models and 
in vitro studies emphasized the role of intracellular Aβ as a potential key player in the 
development and progression of AD. Based on these perceptions a modified Aβ 





FIGURE 1.4 Amyloid hypothesis. Schematic diagram illustrating the amyloid cascade hypothesis 





1.6 Amyloid beta aggregation 
 
Soluble Aβ monomers have a molecular weight of 4 kDa and a high tendency to 
polymerize and aggregate. The formation of plaque-forming, insoluble Aβ fibrils from 
these monomers is complex. Monomeric Aβ can self-associate to form dimers, trimers or 
higher-order aggregates larger than 100 kDa (Benilova et al., 2012). The majority of Aβ 
appears as lower oligomers from dimers to octamers. Soluble oligomers are non-fibrillar 
structures that remain stable in aqueous buffers even after high speed centrifugation 
(Walsh and Selkoe, 2007).  
Monomers are assumed to be in equilibrium with different oligomeric forms. 
However, when a certain threshold is reached, a polymerization process into paranuclei is 
initiated. These paranucleis self-associate into protofibrils and ultimately fibrils, the major 
component of plaques. Alternatively, protofibrils can dissociate again into lower-order 
species (Walsh and Selkoe, 2007; Roychaudhuri et al., 2009). The aggregation of Aβ can 
be divided in two kinetic phases. Aβ monomers accumulate slowly to form oligomers 
during the ‘lag phase'. In the ‘elongation phase', oligomeric nuclei promote protofibrils 
formation and create mature amyloid fibrils (FIGURE 1.5) (Kumar et al., 2011).  
 
 
FIGURE 1.5 Schematic diagram of Aβ aggregation. Aβ monomers accumulate slowly to form 
oligomers during the 'lag phase' (dashed line). In the 'elongation phase' (straight line), oligomeric 
nuclei promote protofibril formation. Protofibrils aggregate creating mature amyloid fibrils. Figure 
created after Kumar et al., 2011.  
 
Increased formation and aggregation of neurotoxic Aβ oligomers have been reported to be 
crucially involved in the initiation and progression of AD (Kayed et al., 2003; Haass and 
Selkoe, 2007; Li et al., 2009). Further, it has been demonstrated that soluble oligomeric 
Aβ42 rather than plaques correlates best with the synaptic loss and cognitive decline in AD 
patients (McLean et al., 1999; Bayer and Wirths, 2010). Oligomers are able to disrupt 




nature, Aβ aggregates and forms higher oligomers in vitro (Pimplikar, 2009). These 
oligomers could also be isolated from AD brain extracts and AD mouse models (Lesne et 
al., 2008; Shankar et al., 2008).  
 
1.7 Amyloid beta variants 
 
1.7.1 Truncated amyloid beta species 
 
Aβ peptides are a heterogeneous set of peptides. Two major Aβ forms are 40 and 
respectively 42 residues long. It was shown that Aβ40 is the major component of cerebral 
vascular amyloid deposits, while Aβ42 is the main component of neuritc plaques (Iwatsubo 
et al., 1994; Suzuki et al., 1994). Aβ42 species are more hydrophobic and have a higher 
tendency to aggregate than Aβ40. Furthermore, Aβ42 is more neurotoxic and crucial for 
plaque formation (Jarrett et al., 1993; Jan et al., 2008). Next to Aβ1-40 and Aβ1-42 a variety 
of C-terminal truncated Aβ forms have been reported including Aβ1-15/16 and Aβ1-37/38/39 
(Wiltfang et al., 2002; Portelius et al., 2012). In vitro studies identified a number of longer 
Aβ variants like Aβ43, Aβ45, Aβ46 and Aβ48 in cell lines. Longer Aβ variants have also been 
identified in AD mouse models (Esh et al., 2005; Van Vickle, G D et al., 2008; Welander et 
al., 2009). In sporadic and familial AD cases Aβ43 was detected and even more prevalent 
than Aβ40 in plaque cores (Welander et al., 2009). 
Several N-terminal truncated Aβ variants have been reported in AD. Instead of 
aspartate that is normally found at the first position of Aβ, these Aβ forms possess a 
variety of different N-termini (Masters et al., 1985; Selkoe et al., 1986; Mori et al., 1992; 
Sergeant et al., 2003). In vitro experiments showed that shortening of the N-terminus 
enhances Aβ aggregation (Pike et al., 1995b). Several proteases have been proposed to 
be involved in the generation of N-truncated Aβ species (FIGURE 1.6). However, the 
exact enzymatic activities are in most cases not fully understood (Bayer and Wirths, 
2014). BACE1 is the major protease responsible for the generation of Aβ1–x in AD. In 
addition, BACE1 is also able to cleave Aβ between Tyr-10 and Glu-11, leading to the 
release of Aβ11–x peptides (Vassar et al., 1999). Aβ2-x species have been detected to be 
elevated in brains and decreased in the CSF of AD patients. It has been proposed that 
these peptides arise from a combination of BACE1 followed by aminopeptidase A 
(Wiltfang et al., 2001; Bibl et al., 2012). Recently, it was demonstrated that the 
metalloprotease meprin β may also be involved in the generation of Aβ2-x species (Bien et 
al., 2012). Aβ3-x has been observed in plaques in LOAD patients and AD mouse models 
(Casas et al., 2004; Guntert et al., 2006). Another important protease involved in             




(NEP). NEP cleaves Aβ peptides between Arg-2 and Glu-3 , Glu-3 and Phe-4 or Arg-5 
and His-6 while leaving full-length APP intact (Howell et al., 1995; Iwata et al., 2001; 
Bayer and Wirths, 2014). Furthermore, the myelin basic protein has been reported to 
cleave Aβ between Phe-4 and Arg-5 in the N-terminus of the Aβ-sequence (Liao et al., 
2009). Aβ4-x species (section 1.7.1.1) are one the first Aβ discovered and very abundant in 
AD and vascular dementia (Masters et al., 1985; Lewis et al., 2006), while Aβ5-x was 
detected in AD patients and non-demented controls (Sergeant et al., 2003; Murayama et 
al., 2007). Except for the generation of Aβ11-x, the largest known amino-truncations occur 
before the amino acids Asp-7, Ser-8 and Gly-9. Angiotensin-converting enzyme has been 
proposed as an enzyme involved in the generation of Aβ8-x (Kalback et al., 2002; Sergeant 
et al., 2003; Kummer and Heneka, 2014). Taken together, N-truncated Aβ variants are the 
main constituent of amyloid plaques in AD and can also be detected intraneuronal 







FIGURE 1.6 Schematic overview of proteases and cleavage sites involved in generation of          
N-truncated Aβ. Sequence of the first 15 amino acids of the N-terminus of human Aβ presented in 
the one-letter-code. Color code for amino acids: pink indicates uncharged polar side-chains, green 
uncharged polar side-chains and blue hydrophobic non-polar side-chains. Figure created after 




1.7.1.1 Amyloid beta 4-42 
 
Aβ4-42 is very abundant in AD and was discovered as early as 1985 (Masters et al., 1985). 
However, relatively little is known about the contribution of Aβ4-42 to the development and 
progression of AD. Masters et al. (1985) identified 64 % of Aβ peptides started with a Phe-
4 in plaque cores of two sporadic AD cases. Furthermore, this N-truncated Aβ variant 
beginning with phenylalanine was found relatively prevalent in AD, vascular dementia 
patients and aged controls (Lewis et al., 2006). While the exact amount of Aβ4-42 is not 
clear, a recent study, using immunoprecipitation and mass spectroscopy, showed that 
Aβ4-42 is one of the major fractions in the cortex and hippocampus of AD patients 
(Portelius et al., 2010). Aβ4-42 has also been identified in amyloid deposits from familial 
Danish dementia and vascular dementia patients (Tomidokoro et al., 2005; Lewis et al., 
2006). Furthermore, Aβ4-42 was detected in cotton wool plaques in FAD patients with a 
V261I PSEN-1 mutation (Miravalle et al., 2005). It is proposed that the degrading 
enzymes neprilysin is responsible for the cleavage of Aβ1-42 (FIGURE 1.6) and the 
generation of Aβ4-42 (Howell et al., 1995; Iwata et al., 2001; Carson and Turner, 2002).  
Sedimentation studies indicate that Aβ4-42 aggregates faster than longer N-termini 
Aβ variants (Pike et al., 1995b). Moreover, the N-terminus specifies fibrillization behavior 
(Haupt et al., 2012). Recently, it was demonstrated through short-term treatment of 
primary cortical neurons, that Aβ4-42 is as toxic as pyroglutamate Aβ3-42 and Aβ1-42. 
Furthermore, treatment of wild-type mice using intraventricular Aβ injection with Aβ4-42 
induced significant working memory deficits. These deficits were similar to the ones 
induced through pyroglutamate Aβ3-42 and Aβ1-42 (Bouter et al., 2013). 
 
1.7.2 Modified amyloid beta species 
 
Various post-translational modifications of Aβ have been described (Kummer and Heneka, 
2014). Besides pyroglutamylation, phosphorylation and oxidation, these modifications 
include nitration, racemization, isomerization and glycosylation (FIGURE 1.7). Oxidation 
and nitration of Aβ are induced in response to the inflammatory milieu in AD (Heneka et 
al., 2010). Increased oxidative stress has been observed in MCI and AD brains. The 
oxidation of methionine at position 35 is the most abundant Aβ oxidation (Naslund et al., 
1994; Kummer and Heneka, 2014). Oxidation of Aβ has been described to prevent the 
formation of protofibrils (Hou et al., 2002).  
Phosphorylation can occur at three different sites in the Aβ peptide. 
Phosphorylation of serine at position 8 increases the formation of oligomeric Aβ 




and serine residues were detected in AD patients and could be induced by radicals in vitro 
(Shapira et al., 1988; Tomiyama et al., 1994; Tambo et al., 2013). Furthermore, peptides 
are vulnerable to spontaneous isomerization especially at asparagine and aspartate. The 
formation of isoaspartate effects the secondary structure and influence the aggregation 
properties of Aβ (Szendrei et al., 1994; Kummer and Heneka, 2014).  
Probably the most important modification of Aβ is the formation of pyroglutamate 
(pGlu)-modified amyloid peptides. After removal of the first two amino acids, presumedly 
through aminopeptidase A, glutamate is converted to pyroglutamate in a dehydration 
reaction. In addition, it was proposed that spontanous Cu2+-mediated amide hydrolysis 
may be resposible for the removal of the fist two residues from Aβ1-x (Drew et al., 2010). 
The pGlu formation is then catalyzed by glutaminyl cyclase (QC), that is incread in AD 
patients (Schilling et al., 2004; Schilling et al., 2008). Besides AβpE3, pyroglutamate 
modifications at Asp-11 were discovered (AβpE11) that seem to emerge through alternative 
BACE1 cleavage in APP (Liu et al., 2002). pGlu modifications lead to an increased 
aggregation propensity, disturbed proteolytical degradation and increased toxicity (Pike et 
al., 1995b; Kummer and Heneka, 2014). It has been shown that AβpE3 oligomerizes more 
quickly and forms fibrillar, β-sheet structures more rapidly than Aβ1-x in vitro (He and 
Barrow, 1999; Harigaya et al., 2000; Schlenzig et al., 2009). AβpE3 is a major Aβ species 
in AD and a main component of plaques. Saido et al. (1995) showed that AβpE3 was found 
in an equal or greater amount in senile plaques than Aβ1-x. They further suggested that 
AβpE3 deposition precede that of other Aβ species (Saido et al., 1995).  
 
 
FIGURE 1.7 Schematic overview of post-translational modifications in Aβ1-42. Sequence of the 
amino acids of human Aβ1-42. Red letters indicate amino acids that are subjected to post-
translational modifications. Amino acids are represented in the one-letter code. Figure created 




1.8 Transgenic mouse models of Alzheimer's disease 
 
The detection of mutations in the APP and PSEN genes in patients with familial AD led to 
the generation of a variety of transgenic animal models. A wide range of transgenic 
mouse models have been developed expressing mutant human APP. The first AD 
transgenic mouse model based on mutant APP was the PDAPP model. These mice 
express human APP with the Indiana mutation (V717F) under the platelet derived growth 
factor promoter. PDAPP mice develop an age-dependant extracellular plaque pathology in 
addition to dystrophic neurites, astrocytosis and microgliosis. (Games et al., 1995; Reilly 
et al., 2003). Moreover, they show progressive synaptic loss and develop age-dependant 
memory deficits without neuron loss (Irizarry et al., 1997; Chen et al., 2000; Dodart et al., 
2000). The Tg2576 mouse also possesses a single APP mutation and is one of the most 
widely studied AD models. Human APP containing the Swedish FAD mutation 
(K670N/M671L) is overexpressed in these mice under the control of the hamster prion 
promoter. Tg2576 mice develop an age-dependant plaque pathology along with 
dystrophic neuritis and gliosis similar to PDAPP mice. A significant plaque pathology in 
Tg2576 mice can be detected between 11 and 13 months. Strikingly, these mice develop 
working and spatial reference memory deficits prior to a significant plaque pathology 
(Hsiao et al., 1996; Holcomb et al., 1998; Elder et al., 2010). Subsequently, several other 
AD mouse models were generated with human APP containing one or more FAD 
mutations. Generally speaking, these mice show elevated Aβ levels and extracellular Aβ. 
Furthermore, many of these mice also show signs of inflammation and develop behavior 
and cognitive deficits (Sturchler-Pierrat et al., 1997; Chishti et al., 2001; Games et al., 
2006; Elder et al., 2010). 
Next to APP transgenic mouse models, many PSEN mice have been developed. 
Transgenic mice expressing mutated human PSEN consistently show elevated Aβ42 levels 
without developing a plaque pathology (Cavanaugh et al., 2014). The lack of plaques may 
be due to lower levels of Aβ42 in the PSEN lines in comparison to APP models. It could 
also be explained through the different solubility of human and murine Aβ (Jankowsky et 
al., 2007). However, a number of PSEN models develop altered axonal transport, 
impaired calcium homeostasis in the ER and mild cognitive deficits (Duyckaerts et al., 
2008).  
In order to create a more aggressive AD pathology mouse models with a 
combination of multiple APP mutations or APP and PSEN mutations were created. Double 
transgenic mice expressing mutated PSEN and APP develop plaques earlier than single 
transgenic APP mice and show increased inflammation and behavior deficits (Duff et al., 




mouse models show a wide spectrum of AD pathology, they lack some key feature of AD 
including NFT formation. To overcome the lack of NFTs in AD mouse models, FAD and 
tau mutations from frontotemperal dementia have been combined. The 3xTg model is an 
example for a triple transgenic mouse model. These mice, generated by injecting two 
transgenes containing APP-Swedish and P301L mutations into a PS1M146V knock-in 
mice, show next to plaque depositions, a NFT pathology  (Oddo et al., 2003). 
Furthermore, most AD mouse models do not exhibit the significant neuron loss seen in AD 
patients. Neuron loss could be mainly detected in mice with a combination of APP and 
PSEN mutations. APP751SL/PS1M146L, APP/PS1K1 and 5XFAD mice are some 
examples for AD models with neuron loss (Casas et al., 2004; Schmitz et al., 2004; 
Oakley et al., 2006; Jawhar et al., 2010).  
The use of transgenic mouse models has led to new insights regarding the role of 
intraneuronal Aβ accumulation in AD. Intraneuronal Aβ has been reported in variety of 
mouse models including Tg2576, 3xTg, APP/PS1K1 and 5XFAD (Casas et al., 2004; 
Billings et al., 2005; Oakley et al., 2006; Takahashi et al., 2013). Furthermore, several 
mouse models showed a link between significant neuron loss and intraneuronal Aβ 
accumulation (Wirths and Bayer, 2012). 
Familial AD accounts for a minor fraction of all AD cases, however all of the 
previously described AD mouse models rely on one or more FAD mutations. Rodents do 
not develop a spontaneously AD pathology as they age (Sarasa and Pesini, 2009). To 
date, there has been nearly no success in the generation of sporadic AD mouse models. 
A rodent model that shows at least some aspects of SAD has been generated by 
intracerebroventricular (icv) injection of streptozotocin (STZ). These mice are generated 
based on the detection of an insulin-resistant brain state in SAD. STZ is injected to induce 
such a brain insulin resistant state. These icv-STZ mice show memory and learning 
deficits, decreased energy metabolism, neuroinflammation, altered synaptic proteins and 
increased hyperphosphorylated tau in the brain (Salkovic-Petrisic et al., 2006; de la 
Monte, Suzanne M. and Wands, 2008; Chen et al., 2012; Chen et al., 2013). 
Next to mice, a variety of other animals have been proposed to study AD including 
dogs, rats, rabbits, primates and even dolphins. However, mice remain the most 
commonly used vertebrates to study AD especially due to their relatively short 
reproductive cycle, their small size, large litters and easy handling (Sarasa and Pesini, 
2009). Several non-vertebrates, like the Caenorhabditis elegans and Drosophila 
melanogaster have also be used and genetically manipulated to study certain aspects of 
AD (Wu and Luo, 2005; Prüßing et al., 2013). AD mouse models, as well as other animal 




none of the animal model mimics all human AD features, they rather reflect various parts 
of the disease and therefore provide insights in different aspects of AD.  
 
1.8.1 The 5XFAD mouse model 
 
The 5XFAD mouse model, first described by Oakley et al. (2006), is a double transgenic 
APP/PS1 mouse model that coexpresses five familial Alzheimer's disease (FAD) 
mutations. 5XFAD mice overexpress the 695 amino acids isoform of human APP carrying 
the Florida (I716V), London (V717I) and Swedish (K670N/M671L) mutations, together 
with mutant PSEN-1 (M146L; L286V) under the control of the murine Thy-1 promoter 
(FIGURE 1.8). Mice showed stable germline transmission and coinheritance of the APP 
and PSEN-1 transgenes over multiple generations. Therefore, mice breed as if they are a 
single transgenic mouse model (Oakley et al., 2006; Eimer and Vassar, 2013). In order to 
facilitate a better comparison with other AD mouse models 5XFAD mice, that were 
originally generated as a C57/B6xSJL strain, were backcrossed onto a C57BL/B6 
background (Jawhar et al., 2010). 
The Florida, London and the two PSEN mutations result in an increased 
production of Aβx-42, while the Swedish mutation increases the levels of total Aβ. Plaque 
pathology in these mice starts between two and three months of age and is accompanied 
by astrocytosis and microgliosis. These features increase massively with age (Oakley et 
al., 2006). Extracellular plaques have also been detected in the spinal cords of three 
months old 5XFAD mice (Jawhar et al., 2010). In addition to extracellular plaques, 5XFAD 
exhibit intracellular Aβ in the cortical Layer 5 and the subiculum starting at 1.5 months of 
age (Eimer and Vassar, 2013). Intraneuronal Aβ precedes plaque formation and 
correlates well with neuron loss in these brain regions. The 5XFAD mouse is one of a few 
mouse models exhibiting significant neuron loss. Unbiased stereology revealed a 
significant neuron loss in the pyramidal neurons of the Layer 5 cortex and the subiculum 
starting at 9 months of age (Eimer and Vassar, 2013). Strikingly, the CA1 region of the 
hippocampus lacking intraneuronal Aβ shows amyloid plaques but no neuron loss (Jawhar 
et al., 2010). 
Furthermore, 5XFAD develop age-dependant synaptic degeneration indicated by 
the reduction of synaptic markers including synaptophysin, syntaxin, and postsynaptic 
density protein 95 (Oakley et al., 2006). Swollen presynaptic terminals and axonal 
processes develop intraneuronal BACE1 and Aβ prior to plaque formation. Swelling and 
dystrophic changes in these structures are associated with deposition of extracellular Aβ 




5XFAD mice develop age-dependant progressive behavior deficits. Working 
memory, spatial memory and episodic memory deficits have been described in these mice 
as well as decreased anxiety. They show among others impairments in the Y-maze, 
Morris mater maze, the conditioned taste aversion task and contextual fear conditioning 
(Ohno et al., 2006; Devi and Ohno, 2010; Jawhar et al., 2010; Devi and Ohno, 2013). 
Next to cognitive impairments, 5XFAD mice also show a decline in motor function. The 
motor phenotype correlates well with extensive spinal cord pathology, including age-
dependent axonal degeneration and intraneuronal Aβ accumulation (Jawhar et al., 2010). 
 
FIGURE 1.8 The 5XFAD transgenes. Schematic diagram of (A) Thy-1 APP and (B) Thy-1 PSEN-1 
transgenes in the 5XFAD mouse model. FAD mutations are indicated by arrows. Abbreviations: Sw 





Based on the age of onset, AD can be divided into early (EOAD) and late-onset AD 
(LOAD). Both forms of AD have a genetic component (Bettens et al., 2013). While EOAD 
and LOAD cannot be clinical distinguished, EOAD usually shows a more rapid 
progression than LOAD (Reitz and Mayeux, 2014).  
EOAD accounts for 5 - 10 % of all AD cases and patients are typical younger than 
65 years old when the disease manifests. Nearly half the patients with EOAD have at 
least one first-degree relative that is also affected by the disease. The autosomal-inherited 
form of EOAD is the so called familial form of AD (FAD) (Campion et al., 1999). Only a 




single mutations in either the amyloid-protein-precursor (APP) or the presenilin 1 (PSEN-
1) and presenilin 2 (PSEN-2) genes. To date, more than 160 mutations in these three 
genes, encoding for proteins involved in APP processing and Aβ generation, have been 
described (Bertram and Tanzi, 2005; Blennow et al., 2006; Bettens et al., 2013).  
APP was the first gene associated with EOAD and the responsible mutations are 
located in and near the Aβ sequence. The majority of these mutations are heterozygous 
missense mutations in or around amyloid-β-coding exons 16 and 17 (Goate et al., 1991; 
Bettens et al., 2013). So far, 32 missense mutation have been identified in the APP gene 
(Ryan and Rossor, 2010). Moreover, whole-gene duplications, recessive missense 
mutations and small deletions have been described (Rogaev et al., 1995; Sleegers et al., 
2006; Di Fede et al., 2009; Kasuga et al., 2009; Thonberg et al., 2011). Most APP 
mutations occur in the vicinity of the secretase cleavage sites and thereby affecting the 
APP cleavage and altering the overall Aβ levels or the Aβ42/Aβ40 ratio (Holtzman et al., 
2011). The first APP missense mutation was discovered in a British kindred and therefore 
named London mutation (Goate et al., 1991). This mutation (APP717) near the                
γ-secretase sites alters secretase cleavage leading to an increased Aβ42/Aβ40 ratio without 
effecting the total Aβ production (Suzuki et al., 1994). The Florida mutation (APP716) 
increases the Aβ42 levels in a similar way (Eckman et al., 1997; Jonghe et al., 2001). In 
contrast, the Swedish mutation (KM670/671NL) near the β-secretase cleavage site 
increases the production of all Aβ species (Citron et al., 1992; Mullan et al., 1992). 
Furthermore, mutations also occur within the Aβ sequence C-terminal to the α-secretase 
cleavage site. These mutations can modify the properties of Aβ leading to increased 
aggregation and oligomer/protofibril generation as well as a less effective Aβ clearance 
(Grabowski et al., 2001; Nilsberth et al., 2001; Van Nostrand et al., 2001; Stenh et al., 
2002). 
Most mutations are reported in the PSEN-1 gene and these mutations account for 
the majority of AD cases with an onset even prior the age of 50. Mutations in the PSEN-1 
and PSEN-2 gene result in an impairment of the γ-secretase mediated cleavage of APP. 
The partial loss of function of the γ-secretase leads to an increased Aβ42/Aβ40 ratio (Wolfe, 
2007). The shift is caused by an increased production of Aβ42 and/or decreased 
production of Aβ40 (Scheuner et al., 1996; Holtzman et al., 2011). 
The majority of AD cases occur after the age of 65 (LOAD). The vast majority of 
AD patients displays no known mutations and therefore suffers from the sporadic late-
onset form of AD (SAD) (Blennow et al., 2006). Although the exact causes of LOAD are 
unknown, it is most likely caused by a combination of several genetic and environmental 
factors. Twin studies prognosticated a 80 % heritability of LOAD forms (Gatz et al., 2006). 




for sporadic AD (Blennow et al., 2006; Selwood et al., 2009). The ApoE gene is located on 
chromosome 19q13 and there are three common alleles of ApoE in humans. The variants 
ε2, ε3 and ε4 only differ from each other by one amino acid at position 112 or 158 of the 
protein. While the ε4 variant is a genetic risk factor for LOAD, the ε2 allele is protective 
against LOAD (Corder et al., 1993; Holtzman et al., 2011). Individuals with one ApoE ε4 
allele have a three times higher risk of developing AD than non-carriers. For homozygous 
ε4 carriers the risk increases even 15-fold (Bickeboller et al., 1997). However, not all ε4 
carriers develop AD and ε4 is neither sufficient nor necessary for developing LOAD (Reitz 
and Mayeux, 2014). ApoE is a lipid-binding protein that is highly expressed in the CNS. 
(Strittmatter et al., 1993) While its precise function is not clear, ApoE plays a role in 
neuronal plasticity, cholesterol transport and inflammation. It is suspected that the ApoEε4 
leads to decreased clearance and/or increased Aβ aggregation as well as cholesterol 
homeostasis (Bertram and Tanzi, 2005; Kim et al., 2009). However, a variety of additional 
genetic loci have been proposed to be involved with LOAD (Bertram and Tanzi, 2001). 
 
1.9.1 From genome-wide association studies to next-generation 
sequencing  
 
Commercially available microarray chips containing more than 1.2 million single 
nucleotide polymorphism (SNPs) initiated the era of genome wide association studies 
(GWAS) (Sherva and Farrer, 2011). Since 2009, several large GWAS were performed to 
search for genes that are involved in AD. These studies revealed 20 novel potential loci 
for LOAD and suggested new pathways that may be involved in AD. The first studies 
identified CLU (clusterin), PICALM (phosphatidylinositol-binding clathrin assembly 
protein), CR1 (Complement receptor type 1) and BIN1 (amphiphysin II) as susceptibility 
loci (Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010). Clusterin is a 
lipoprotein that is involved in lipid transport and Aβ aggregation. CR1 is a cell surface 
receptor that is part of the complement system. It can bind Aβ oligomers and therefore 
may play a role in Aβ clearance (Tosto and Reitz, 2013). These initial studies recognized 
loci mainly associated with the following pathways: immune response, APP processing, 
lipid metabolism, and endocytosis (Reitz and Mayeux, 2014). The second set of GWAS 
identified five additional susceptibility loci (ABCA7, CD2AP, CD33, EPHA1 and 
MS4A4A/MS4A4E/MS4A6E cluster) that are all presumably involved in the immune 
system (Hollingworth et al., 2011; Naj et al., 2011). In addition, ABCA7 is also involved in 
APP processing and lipid metabolism  (Kaminski et al., 2000; Kielar et al., 2003). The 
most recent and largest GWAS by the International Genomics of Alzheimer's Project 




DRB5/HLA-DRB1, INPP5D, MEF2C, NME8, PTK2B, SLC24A4/RIN3, SORL1 and 
ZCWPW1). Besides ApoE, the study confirmed eight of the nine previously described 
candidate-genes, with the exception being CD33. The associated loci reinforced pathways 
identified by the earlier GWAS and highlighted additional pathways including hippocampal 
synaptic function and axonal transport (Lambert et al., 2013). However, all new detected 
loci have only a small effect size with odds ratio ranging from 1.1 to 1.5 and low-risk 
factors for AD. Therefore, ApoE is still by far the strongest risk factor for LOAD (Tosto and 
Reitz, 2013).  
It seems that the limit to the number of GWAS detectible variants is reached, while 
a large percentage of the heritability of AD is still unknown. Next-generation sequencing 
(NGS) may be able to contribute to the remaining 'missing heritability' and identify rare 
variants that are not yet captured (Sherva and Farrer, 2011; Medway and Morgan, 2014). 
NGS allows affordable and fast massive-scale DNA sequencing. The principle behind all 
NGS methods is to randomly fragment DNA into smaller pieces to create a library. 
Libraries are then sequenced at a high coverage in millions of parallel reactions (Metzker, 
2010; Berglund et al., 2011). The identified strings of bases, called reads, are mapped into 
the reference genome of the species. In the absence of a reference genome reads can 
also be assembled de novo (Magalhães et al., 2010).  
NGS has not only the potential to detect new risk factors in large samples, it can 
also be beneficial in small patient groups. The technique can give new insights into 
families with an unexplained AD cause as well as in groups of unrelated cases. NGS has 
the potential to identify rare variants with moderate effects through assessment of the 
entire exomes or genomes of individuals. Furthermore, NGS can be applied for re-
sequencing the top loci revealed by GWAS (Bettens et al., 2013; Medway and Morgan, 
2014; Sharma et al., 2014). The triggering receptor on myeloid cells 2 (TREM2) gene was 
the first LOAD susceptibility locus identified via NGS approach (Medway and Morgan, 
2014). Two groups independently reported variants of TREM2 gene as a new risk factor 
for LOAD in white populations (Guerreiro et al., 2013; Jonsson et al., 2013). TREM2 has 
been associated with immune response and inflammation and is involved in phagocytosis 
of apoptotic neurons (Takahashi et al., 2005; Hsieh et al., 2009; Slattery et al., 2014). It 
could be shown that NGS whole-exome sequencing is capable of identifying not only very 
rare mendelian causes of AD but also low-frequency variabilities with medium-effect sizes 
(Jin et al., 2012). This example highlights that NGS has the potential to play a crucial role 







1.9.2 Transcriptome profiling: RNA-Sequencing  
 
The transcriptome reflects the cellular activity as it shows the genes that are expressed 
within a tissue at any given time point. Northern blots, reverse-transcription PCR, 
expressed sequence tags (ESTs) and serial analysis of gene expression (SAGE) made it 
possible to analyze RNA expression (Krumlauf, 1994; Velculescu et al., 1995; Ginzinger, 
2002; Milla et al., 2002). However, only the development of microarrays allowed rapid 
large-scale studies of gene expression. Microarrays are able to simultaneously analyze 
large numbers of transcripts while relying on previous knowledge about the genome 
sequence. Several studies using transcriptome microarray analyses were performed over 
the last years to identify genes that are differentially expressed and therefore may be 
involved in the pathogenesis of AD (George et al., 2010).  
The recent developments in NGS offer a more comprehensive and most of all 
unbiased approach for transcriptome analysis. NGS is not restricted to sequencing DNA 
and can be used in a similar fashion to perform transcriptome sequencing (RNA-Seq). In 
addition to mRNA, non-coding RNA, microRNA and whole RNA can be sequenced 
(Eminaga et al., 2013; Handel et al., 2013). This enables to investigate changes in gene 
expression and to look at post-transcriptional modifications, mutations and SNPs as well 
as alternative gene spliced transcripts. Importantly, unlike microarrays, RNA-Seq is not 
limited to the detection of transcripts that match with existing genomic sequences (Wang 
et al., 2009). NGS can be used to compare the gene expression profiles between different 
cell types or genotypes. It can access the absolute transcript levels of already sequenced 
as well as unsequenced organisms (Mutz et al., 2013). Furthermore, multiple studies 
already indicate that next-generation sequencing is more useful and particularly suitable 
to investigate the pathogenesis of complex neurodegenerative diseases like AD (Twine et 
al., 2011). For example, Sultan et al. (2008) claimed that deep sequencing of non-
ribosomal RNA can detect up to 25 % more genes than microarrays analyses. The 
quantification of transcript isoforms is also a strength of RNA-Seq (Malone and Oliver, 
2011). Variances in gene expression might contribute to the initiation or progression of 
AD. Especially alternative splicing might play an important role in LOAD (Twine et al., 
2011). RNA-Seq facilitates direct access to reads spanning exon/exon boundaries. That 









1.10 Project objectives 
 
The aim of this thesis was to investigate the role of Aβ4-42 in the etiology of AD.                
N-truncated Aβ4-42 is highly abundant in the brain of AD patients (Portelius et al., 2010). 
However, a possible role in AD etiology has largely been neglected.  
The thesis is divided in two parts (FIGURE 1.9). The aim of the first project was to 
study the effects of chronic exposure of Aβ4-42 in vivo. Therefore the recently generated 
mouse model Tg4-42 that over-expresses Aβ4-42 was used (Bouter et al., 2013). Next to 
heterozygous Tg4-42 mice a new homozygous Tg4-42 line was generated (Tg4-42hom). 
Characterization of 3-, 8- and 12-month-old heterozygous mice was performed. Moreover, 
homozygous mice were assessed with three and eight months of age. Using 
immunohistochemistry the brain pathology was examined in these mice. Furthermore, a 
battery of motor and cognitive tasks was conducted to assess behavioral performance in 
Tg4-42 and Tg4-42hom mice. Moreover, using unbiased stereology the number of neurons 
in the CA1 region of the hippocampus was determined in heterozygous and homozygous 
mice at different time points. In addition, the new monoclonal antibody NT4X-167 that 
recognizes the N-terminus of N-truncated Aβ was generated. NT4X-167 was used to 
assess Aβ4-x pathology in Tg4-42 and 5XFAD mice via immunohistochemistry. In 
summary, the main aim of the first part of the thesis was to provide a detailed behavioral 
neuropathological, and stereological analysis of Tg4-42 and Tg4-42hom in an age-
dependant manner.  
In the second part of the thesis, a comparative gene expression analysis of brain 
tissue of two different AD mouse models using next-generation sequencing was 
performed. The transcriptome includes all RNA transcripts expressed in a given tissue 
and renders a profile of genes that are expressed at the studied time point. Altered gene 
expression profiles may therefore provide information about the genes and mechanisms 
involved in the molecular pathogenesis of diseases like AD. Technical approaches using 
transcriptome microarray analyses were performed over the last years to identify genes 
that are differentially expressed and therefore may be involved in the pathophysiology of 
AD (George et al., 2010). The recent developments in next-generation sequencing (deep 
sequencing) offer a more comprehensive and most of all unbiased approach for 
transcriptome analysis. Multiple studies already indicate that next-generation sequencing 
is more useful and particularly suitable to investigate the pathogenesis of complex 
neurodegenerative diseases like AD (Twine et al., 2011). The Tg4-42 mouse model was 
compared with the well-established, plaque-developing 5XFAD mouse model (Oakley et 
al., 2006). Brain transcriptomes of young and old Tg4-42, 5XFAD and WT control mice 




expression analysis, comparing transgenic mice with age-matched WT mice was 
performed. The aim of this part was to elucidate the similarities and distinctions in 
expression profiles of Tg4-42 and 5XFAD mice. Furthermore, the behavior of these two 
mouse models was compared using the fear conditioning and Morris water maze task. 
 
 
Objectives of Project I: 
 Generate a homozygous Tg4-42 mouse line 
 Develop a novel antibody, which recognizes the N-terminus of N-truncated Aβ 
 Examine Aβ4-x pathology in 5XFAD and Tg4-42 mice using the novel antibody 
NT4X-167 
 Examine the neuropathology resulting from Aβ4-42 expression in Tg4-42 and     
Tg4-42hom mice 
 Determine if age-dependent motor or memory changes occur in Tg4-42 and     
Tg4-42hom mice 
 Investigate if Aβ4-42 pathology causes neuron loss 
 
Objectives of Project II: 
 Compare the behavior deficits of Tg4-42 and 5XFAD mice 
 Perform deep-sequencing of non-ribosomal RNA on 5XFAD, Tg4-42 and WT mice 
 Verify differentially expressed genes by qRT-PCR 







FIGURE 1.9 Schematic overview of the projects presented in this thesis. The thesis is divided in 
two parts with Aβ4-42 as the focus of interest. Parts of project 1 have been publishes in Bouter et 
al., 2013 and Antonios et al., 2013. Project 2 has recently been published in Bouter et al., 2014.  
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2.1.1 General considerations and housing 
 
All animals used in this study were of the species Mus musculus (common house mouse). 
Wild-type mice were of the inbred strain C57Bl/6J (Jackson Laboratories, Bar Harbor, ME, 
USA). All mice were bred and housed under specific-pathogen-free (SPF) conditions in 
the central animal facility of the University Medicine Göttingen. Mice were kept in 
individually ventilated cages (IVC, 32 x 16 x 14 cm; Tecniplast, Hohenpeißenberg, 
Germany) in groups up to five. Water and food were available ad libitum. 
All animals were handled according to the guidelines of the 'Society for Laboratory 
Animals Science' (GV-SOLAS) and the guidelines of the 'Federation of European 
Laboratory Animal Science Association' (FELASA). Furthermore, all experiments were 
approved by the 'Lower Saxony State Office for Consumer Protection and Food Safety' 
(LAVES). All efforts were made to minimize suffering and the number of animals used for 
this study. If not stated otherwise males and female mice were used for all test. 
 
2.1.2 Tg4-42 transgenic mice 
 
Tg4-42 mice were previously generated in our lab and express human Aβ4-42 fused to the 
murine TRH signal peptide under the control of the neuronal Thy-1 promoter (FIGURE 
2.1) (Wittnam, 2012; Bouter et al., 2014).  
In addition to hemizygous Tg4-42 mice, a homozygous Tg4-42 mouse line was 
generated and named Tg4-42hom. Therefore, hemizygous mice were crossed to produce 
potential homozygous mice. Subsequently, real-time quantitative PCR (qRT-PCR, section 
2.3.5.2) was performed on tail-derived DNA (section 2.3.1) to validate homozygosity. 
Presumptive homozygous mice were backcrossed with wild-type mice (C57Bl/6J) to test 
for true homozygosity. Once homozygous males and females were confirmed, they were 
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2.1.3 5XFAD transgenic mice  
 
5XFAD mice overexpress the 695 amino acids isoform of the human amyloid precursor  
protein (APP695) carrying the Swedish, London and Florida mutations under the control of 
the murine Thy1-promoter (Vidal et al., 1990; Moechars et al., 1996; Oakley et al., 2006). 
In addition, human presenilin-1 (PSEN-1) carrying the M146L/L286V mutations is also 
expressed under the control of the murine Thy1-promoter (Oakley et al., 2006). 5XFAD 
mice used in the current study were backcrossed for more than eight generations to 
C57Bl/6J wild-type mice (Jackson Laboratories, Bar Harbor, ME, USA) to obtain an 
incipient congenic line on a C57Bl/6J genetic background (Jawhar et al., 2010). Female 
hemizygous 5XFAD mice and male homozygous 5XFAD mice were used in this study as 
indicated the results part. 
 
 
FIGURE 2.1 The Tg4-42 transgene. The murine Thy1 promoter drives the neuronal expression of 
the pre-pro-TRH-Aβ4-42 fusion peptide. Aβ4-42 is fused to pre-pro-TRH for liberation within the 
secretory pathway. An N-terminal signal sequence routes the pre-pro-TRH-Aβ4-42 fusion peptide 
into the endoplasmic reticulum where a signal peptidases releases the pro-TRH-Aβ4-42 peptide. In 
the trans-Golgi and secretory vesicles the rest of the TRH signal peptide is cleave by prohormone 
convertases. Aβ4-42 is released and can be secreted from the cell (Alexandru et al., 2011; Wittnam, 
2012). Figure generated after Wittnam, 2012.  
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2.1.4 Preparation of mouse brain tissue for biochemistry 
 
Mice were sacrificed via CO2 anesthetization followed by cervical dislocation. Brains were 
rapidly and carefully dissected on ice after the mouse cadavers were decapitated with a 
large surgical scissor. Briefly, one incision was made over the dorsal midline of the skull 
with fine surgical scissors to remove the skin and tissue surrounding the skull. Lateral 
incisions were made along the temporal bones and a dorsal incision along the median 
fissure to fracture the skull bones. The skull fragments were removed with tweezers 
before the whole brain was removed from skull with a small spatula. The cerebellum as 
well as the olfactory bulb were removed and the brain hemispheres were separated with a 
surgical scalpel. Brain hemispheres were frozen on dry-ice and stored at -80°C for 
subsequent use. 
 




Mice were sacrificed and the brain was dissected as described in section 2.1.4. The 
respective brain hemispheres were placed into embedding cassettes (Simport, Beloeil, 
QC, Canada). Cassettes were stored for at least 96 hours in a histofix solution containing 
4 % formalin prepared in phosphate buffered saline (Roth, Karlsruhe, Germany) at 4 °C 
until being embedded in paraffin (Roth, Karlsruhe, Germany) (Section 2.4.1) using an 




A fast and uniform fixation of mouse tissue was achieved through perfusion via the 
vascular system through the heart. The perfusion pump was set up and a sterile perfusion 
needle was attached to one end of the pump's tube. Approximately 20 ml 0.01 Dulbecco's 
phosphate buffered salt solution (PBS; PAN-Biotech, Aidenbach, Germany) were run 
through the tubing to remove any residues and air bubbles. Mice were anesthetized with a 
mixture of 10 % ketamine (Medistar, Ascheberg, Germany) and 2 % xylariem 
(Xylazinhydrochlorid, 23.3 mg/ml; Ecuphar, Oostkamp, Belgium) in molecular-grade 
water. The anesthetic mixture was given intraperitoneally at a dosage of 100 mg/kg 
ketamine and 10 mg/kg xylazine body weight. After mice were fully anesthetized and 
showed no pinch-response they were placed on the perfusion board. Mice were pinned by 
their limbs to the perfusion board. The abdominal wall of the mouse was opened with 
surgical scissors. The diaphragm and the connective tissue at the bottom of diaphragm 
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were cut to allow access to the rib cage. The rib cage was opened to allow access to the 
beating heart. While holding the heart steady with forceps the needle attached to the 
tubing of the peristaltic pump was directly inserted into the left ventricle.  An incision was 
made in the right atrium to allow for blood to drain from the circulatory system. Then the 
mouse was perfused with 50 ml ice-cold 0.01 M PBS. When blood was cleared from the 
body, perfusion continued with 50 ml ice-cold 4 % paraformaldehyde (PFA; Roth, 
Karlsruhe, Germany). Spontaneous movement of the tail and discoloring of the liver 
indicated a successful perfusion.  
After perfusion the mouse was removed from the perfusion board and decapitated. 
Brain tissue was prepared as described as in section 2.1.4. The right hemisphere of the 
brain was embedded in paraffin (section 2.4.1) while the left hemisphere (including the 
cerebellum) was cryoprotected. Therefore the brain was first post-fixed in 10 ml PFA 
overnight at 4 °C. The tissue was then transferred to 10 ml 30 % sucrose (Roth, 
Karlsruhe, Germany) solution prepared in 0.01 M PBS and stored at 4 °C until the brain 
sunk to the bottom of the container. The brain was removed from the sucrose solution, 
frozen on dry ice and stored at -80 °C for subsequent use. 
 
 
2.2 Behavior analyses of mice  
 
For phenotyping, mice were kept on a 12 hour / 12 hour inverted light cycle. All behavior 
experiments were performed during the dark phase between 8 a.m. and 8 p.m.. 
Weight gain of mice was monitored as part of a general physical assessment. 
Furthermore, a clasping test was performed to test for functional impairments caused by 
spinal cord pathology (Jawhar et al., 2010). In order to assess motor and memory deficits 
in transgenic mice a battery of several tests was performed. Motor coordination of mice 
was measured by the balance beam and string suspension task. To evaluate behavior 
and memory, mice were subjected to cross maze, elevated plus maze, Morris water maze 
and fear conditioning tasks. During a single day of testing mice were subjected to no more 
than one motor and one memory test. If not stated otherwise males and female mice were 
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2.2.1 Paw-clasping test 
 
Mice were suspended by their tail for 30 sec to provoke a clasping phenotype. Clasping 
behavior was scored on a scale from zero to three, where 0 demonstrates no clasping 
behavior, 1 = forepaws clasping, 2 = one hind paw and forepaws clasping, and 3 = 
clasping of all paws (Miller et al., 2008). Healthy mice generally do not show any clasping 
behavior and rather try to escape the grip by kicking their paws and twisting their whole 
body. 
  
2.2.2 String suspension 
 
Motor coordination and grip strength were assessed using the string suspension task 
(Hullmann, 2012; Arendash et al., 2001b). The string suspension apparatus consists of a 
50 cm cotton string (2 mm in diameter) tied between two wooden beams 35 cm above a 
padded surface. Mice were permitted to grasp the string by their forepaws and then 
released. Their ability to climb across the string was assessed using a 0 to 5 rating score 
(TABLE 2.1) (Moran et al., 1995). During a single day of testing each mouse was given 
three 60-second trials with a minimum of 10 minutes between the trials. The average 
score of all three trials was taken as the score for each mouse. Between each trial the 
apparatus was cleaned with 70 % ethanol (Merck, Darmstadt, Germany) to diminish odor 
cues. 
 
TABLE 2.1 String suspension rating score (Moran et al. 1995) 
Score Description 
0 falls of string 
1 hangs onto string by fore- or hindpaws 
2 hangs onto string by fore- or hindpaws and attempts to climb onto string 
3 hangs onto string by all four paws but no lateral movement 
4 hangs onto string using all four paws and tail and moves laterally 
5 escapes to the edge of string and touches wooden support beam 
 
2.2.3 Balance Beam 
 
Fine motor coordination and balance of mice were assessed using the balance beam test 
(Hau and Schapiro, 2002; Luong et al., 2011). The balance beam consisted of a 1 cm 
wide and 50 cm long dowel attached to two support columns 44 cm above a padded 
surface. A 9 x 15 cm escape platform was attached to both ends of the beam. The test 
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essentially examines the ability of a mouse to remain upright and to walk on the relatively 
narrow and elevated beam to one of the platforms. During a single day of testing each 
mouse was given three 60-second trials with a minimum of 10 minutes between the trials. 
The average time of all three trials was taken as the score for each mouse. A test trial was 
given to familiarize the mouse with the beam. For each trial the mouse was placed in the 
center of the beam facing one of the platforms and then released. The latency to fall from 
the beam was recorded. If a mouse escaped to one of the platforms or remained on the 
beam for the entire trial, the maximum time of 60 seconds was given. Between the trials, 
the beam was cleaned with 70 % ethanol (Merck, Darmstadt, Germany) to reduce odor 
cues. 
 
2.2.4 Cross maze 
 
Working memory in mice was assessed by analyzing their spontaneous alternation 
behavior in the cross maze. The spontaneous alternation paradigm is based on the 
natural tendency of mice to explore new environments: mice tend to alternate between the 
arms of a maze and typically prefer to explore the least recently visited arm of the maze 
rather than returning to the one previously visited (Wietrzych et al., 2005). 
The cross maze (FIGURE 2.2 A) consisted of four arms (30 cm length x 8 cm 
width x 15 cm height) arranged in 90° angles extending from a central region (8 cm length 
x 8 cm width x 15 cm height). The whole apparatus was constructed of black plastic. Each 
mouse was placed randomly at the end of one arm (facing the wall of the maze) to freely 
explore the maze for a single 10 min trial, with the experimenter out of the animal's sight. 
ANY-Maze video tracking software (Stoelting Co, Wood Dale, IL, USA) was used to 
record the sequence of arm entries and the distance travelled. Thereby, a successful arm 
entry was counted when all four paws of the mouse crossed the entrance of an arm and 
an immediate arm re-entry was defined as a single arm entry. Alternations were defined 
as successive entries into the four arms in overlapping quadruple sets (e.g., 1, 3, 2, 4 or 2, 
3, 4, 1 but not 1, 2, 3, 1) (Arendash et al., 2001b). The alternation percentage was 
calculated as the percentage of actual alternations to the possible number of alternations 
(= total arm entries – 3) (Wietrzych et al., 2005). The cross maze was cleaned with 70 % 
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2.2.5 Elevated plus maze 
 
The elevated plus maze test was used to assess anxiety-related behavior in mice 
(Campos et al., 2013). The test is based on the exploration behavior of mice and their 
aversion for open spaces (Komada et al., 2008).  
The apparatus consisted of four arms (15 cm length x 5 cm width) extending at 90° 
angles from a central area (5 cm length x 5 cm width) raised 75 cm above a padded 
surface (FIGURE 2.2 B). The maze was composed of two oppositely positioned enclosed 
arms that were surrounded by a 15 cm high translucent plastic wall on three sides and two 
open arms. Mice were placed in the central area of the maze facing one of the open arms 
and allowed to freely explore the apparatus for 5 minutes. ANY-Maze video tracking 
software (Stoelting Co, Wood Dale, IL, USA) was used to record the distance travelled 
and the percentage spent in the open arms. Anxiety-like behavior can be measured by the 
time spent in the open arms as lower anxiety levels correspond to longer time spent in 
open arms (Karl et al., 2003). Between mice the maze was cleaned with 70 % ethanol 





FIGURE 2.2 Cross maze and elevated plus maze. (A) Working memory in mice can be assessed in 
the cross maze. Typically mice prefer to visit a new arm of the maze rather than returning to the 
one that was previously visited (B) Anxiety-related behavior can be analyzed in the elevated plus 
maze. The maze contains open and enclosed arms. Mice will naturally spend most of their time in 
the enclosed arms due to their reluctance to open spaces.  
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2.2.6 Morris water maze 
 
Spatial reference memory of mice was evaluated using the Morris water maze (Morris, 
1984). In this task, mice learn to use spatial cues to locate a hidden, circular platform (10 
cm) in a circular pool (110 cm diameter) filled with tap water. The water was made opaque 
by adding non-toxic white paint and maintained at 20°C ± 2°C for the whole test duration. 
The pool was divided into four virtual quadrants that were defined based on their spatial 
relationship to the platform: left, right, opposite and target quadrant, which contains the 
goal platform. ANY-Maze video tracking software (Stoelting Co, Wood Dale, IL, USA) 
connected with a camera (Computar, Commack, NY, USA) was used to record escape 
latency, path length, swimming speed and quadrant preference. In order to minimize the 
number of animals that were tested hemizygous Tg4-42 mice were examined together 
with Katharina Dietrich.  
 
 
FIGURE 2.3 Morris Water Maze. (A) Mice perform 3 days of cued training. During these trials the 
escape platform is marked with a triangular flag. (B) For the five days of acquisition training the 
flag is removed from the platform. Proximal visual cues are attached to the outside of the pool. 
(C) During a single probe trial the platform is removed from the pool. Mice are allowed to swim 
freely for one minute while their swimming path is recorded. Abbreviations for quadrants: T = 
target, L = left, R = right, O = opposite.  
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Testing began with three days of cued training (FIGURE 2.3 A). For these trials the 
platform was marked with a triangular flag. Mice were introduced into the water at the 
edge of the pool facing the wall. They were then given one minute to find the submerged 
platform. Mice that failed to find the platform in 60 seconds were gently guided to it. All 
mice were allowed to sit on the platform for 10 seconds before being removed from the 
pool. To prevent hypothermia, all mice were kept in front of a heat lamp for 3 minutes 
before being returned to their home cage. Each mouse received four training trials per day 
with an average inter-trial interval of 15 minutes. Both the location of the platform and the 
position at which mice were introduced into the pool changed between trials. All mice had 
to show a significantly increased learning curve or find the platform in under 15 seconds in 
order to continue testing. 
Twenty-four hours after the last day of cued training, mice performed five days of 
acquisition training. For this part of testing, the flag was removed from the platform 
(FIGURE 2.3 B). In addition to the distal cues existing in the room proximal visual cues 
were attached to the outside of the pool. The platform location remained stationary for 
each mouse throughout training. At the start of every trial, mice were introduced into the 
pool from one of four predefined entry points. The order in which these entry points were 
used varied between training days (Vorhees and Williams, 2006). To avoid quadrant bias, 
the experimental cohorts were randomly split and trained to find one of two different 
platform locations. Trials were conducted as during the cued training phase.  
Twenty-four hours after the last acquisition trial, a probe test was performed to 
assess spatial reference memory. The platform was removed from the pool (FIGURE 2.3 
C) and mice were introduced into the water from a novel entry point. Mice were then 
allowed to swim freely for one minute while their swimming path was recorded. Mice that 
successfully acquired a spatial search strategy show a clear preference for the goal 
quadrant. 
 
2.2.7 Contextual and Tone Fear Conditioning 
 
Mice were subjected to contextual fear conditioning (CFC) and tone fear conditioning 
(TFC). A three-day delay fear conditioning protocol was used to assess conditional 
learning and memory. Thereby, the conditioned stimulus (CS) is presented and 
overlapped by the presentation of the unconditioned stimulus (US) (Ohno, 2009).  
The experiments were performed using a standard conditioning chamber (17 cm x 
17 cm x 26 cm) with a stainless steel grid floor connected to a shock generator (Ugo 
Basile Sound and Shocker Generator, Comerio, Italy). The walls were covered with black 
and white checkered paper (CS). The chamber was housed in a soundproof isolation 
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cubicle. A digital camera (Unibrain, San Ramon, CA, USA) and an additional light source 
were attached to the ceiling of the cubicle. ANY-Maze video tracking software (Stoelting 
Co.,Wood Dale, IL, USA) was used to record freezing behavior of animals.  
On day one, mice were placed in the conditioning chamber and allowed to explore 
the box for 150 seconds. After the habituation period a tone (2000 Hz, 80 dB; CS) was 
presented for 30 seconds that simultaneously ended with a two second foot-shock (0.7 
mA, US; FIGURE 2.4 A). Mice were allowed to recover after the foot-shock for an 
additional 30 seconds before being returned to their home cage. Baseline freezing was 
recorded before the presentation of the tone/shock. 
Twenty-four hours after the training mice were placed back in the familiar fear 
conditioning chamber, but in the absence of tone and foot-shocks (FIGURE 2.4 B). 
Freezing behavior was measured for 210 seconds to test contextual memory retrieval.  
For the tone fear retrieval trial on day three, mice were placed for three minutes in 
an altered conditioning chamber with white walls, a covered floor and an acetic acid scent. 
After 150 seconds baseline recording, a tone similar to the one used during the fear 
conditioning trial was presented for 30 seconds (FIGURE 2.4 C). The freezing behavior 
before and during the conditioned stimulus tone was measured. Freezing is characterized 
by the absence of movement apart from respiration and shivering in combination with 
crouching (Wehner and Radcliffe, 2004). Between mice the maze was cleaned with 70 % 






FIGURE 2.4 Fear conditioning. (A) During the training trial a tone is presented for 30 seconds that 
simultaneously ends with a two second foot-shock. (B) 24 hours after the training trial mice are 
placed back in the familiar fear conditioning chamber to test for contextual learning. No tone and 
foot-shock is presented. (C) 48 after the training trial mice are placed in an altered conditioning 
chamber. A tone is presented to test for tone learning (A-C) Freezing is recorded at all times. 
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2.3 Molecular Analyses 
 
2.3.1 DNA isolation from mouse tails 
 
Prior further use in any experiment all mice were genotyped. For genotyping DNA was 
isolated from mouse tail biopsies. 500 µl lysis buffer [100 mM Tris/HCl (pH 8.5; Roth, 
Karlsruhe, Germany), 5 mM EDTA (AppliChem, Darmstadt, Germany), 0.2 % sodium 
dodecyl sulfate (SDS; Biomol, Hamburg, Germany) 200 mM NaCl (Roth, Karlsruhe, 
Germany)] and 5 µL Proteinase K (20 mg/ml stock; Peqlab, Erlangen, Germany) were 
added to every tail biopsy. Samples were incubated for 20 hours at 55 °C and 400 rpm in 
a Thermomixer Compact (Eppendorf, Hamburg, Germany). After incubation samples were 
centrifuged for 20 minutes at 4 °C and 17,000 rpm (Heraeus Biofuge Stratos, Thermo 
Fisher Scientific, Waltham, MA, USA). The supernatant was transferred into a new 1.5 ml 
Eppendorf tube containing 500 µl cold isopropanol (Roth, Karlsruhe, Germany). Samples 
were vortexed (Vortex Genie 2, Scientific Industries, Bohemia, NY, USA) until DNA 
precipitate was visible and centrifuged for 10 minutes at 13,000 rpm at room temperature 
(RT) (Biofuge Pico, Heraeus). After centrifugation, the supernatant was discarded and the 
remaining DNA pellet was washed with 500 µl cold 70 % absolute ethanol (Merck, 
Darmstadt, Germany). Following another centrifugation step at 13,000 rpm for 10 minutes 
at RT, the supernatant was discarded and the pellet dried at 37 °C in a Thermomixer 
Compact for 45 minutes. The DNA pellet was resuspended in 30 µl molecular grade water 
(Braun, Melsungen, Germany) and dissolved overnight at 55 °C in a Thermomixer 
Compact before being stored at 4 °C. DNA concentration was determined via photometry 
(Eppendorf, Hamburg, Germany) at OD260 (section 2.3.3) and samples were diluted to a 
concentration of 20 ng/µl with molecular grade water.  
 
2.3.2 RNA isolation from mouse brain 
 
Isolation of RNA from mouse brains were performed under a fume hood. Brains were 
homogenized with 10 strokes of a R50D homogenizer (CAT Scientific, Paso Robles, CA, 
USA) set at 800 rpm in 1.5 ml ice-cold TriFast® (Peqlab, Erlangen, Germany) in a 2.0 ml 
Eppendorf tube. 300 µl Chloroform (Merck, Darmstadt, Germany) was added to each 
sample and inverted by hand. After 10 minutes incubation the samples were centrifuged 
at 12,000 rpm for 15 minutes at 4 °C to separate the RNA. The upper RNA-containing 
aqueous phase was transferred into a new Eppendorf tube, vigorously mixed with 500 µl 
Isopropanol (Roth, Karlsruhe, Germany) and incubated for 20 minutes on ice. After 
centrifugation at 12,000 rpm for 10 minutes at 4 °C the supernatant was discarded. RNA 
pellets were washed twice with 500 µl 75 % absolute ethanol. After the pellet was air-dried 
2 Material and Methods 
41 
 
the RNA was dissolved in 30 µl of with molecular grade water and stored at 4 °C over 
night. The next day, RNA was subjected to digestion by DNase. Therefore, 3µl 10X 
DNAse Buffer (Thermo Fisher Scientific, Waltham, MA, USA), 2 µl DNAse I (1 U/µl; 
Thermo Fisher Scientific, Waltham, MA, USA) and 1 µL RNasin (40 U/µl; Promega, 
Fitchburg, WI, USA) were added to 24 µl of each RNA sample. After 90 minutes 
incubation at 37 °C 70 µl molecular grade water and 400 µl ice-cold TriFast were added to 
the mixture. The solution was incubated at room temperature for 5 minutes before mixed 
with 60 µl Chloroform. The solution was again incubated at room temperature for 3 
minutes and centrifuged at 12,000 rpm for 15 minutes at 4 °C. The clear supernatant RNA 
phase was transferred into a new 2.0 ml Eppendorf tube. 200 µl Isopropanol were added 
to the solution, mixed vigorously and stored on ice for 15 minutes before being centrifuged 
at 12,000 rpm for 10 minutes at 4 °C. After centrifugation the supernatant was discarded 
and the pellet was washed twice with 500 µl 75 % absolute ethanol. After the pellet was 
air-dried the RNA was resuspended in 30 µl of molecular grade water and dissolved at 4 
°C over night. RNA purity and yields were determined (section 2.3.3) and RNA was stored 
at -80°C until further use. 
 
2.3.3 Nucleic acid quantitation 
 
DNA and RNA purity and yields were determined by a Biophotometer (Eppendorf, 
Hamburg, Germany). 80 µl molecular grade water was used as a blank for the photometry 
settings. Afterwards, 2 µl of each sample was diluted with 78 µl molecular grade water in a 
Uvette® 220-1600 nm cuvette (Eppendorf, Hamburg, Germany). The A260/A230 
absorbance ratio and the A260/A280 absorbance ratio were measured in the photometer 
for each DNA and RNA sample, respectively. For DNA samples A260/A230 and 
A260/A280 ratios greater than 1.8 were considered as accurate. RNA samples that 
displayed A260/A230 ratios greater than 1.8 and A260/A280 ratios higher than 2.0 were 
considered as acceptable pure (Barbas et al., 2007). 
 
2.3.4 Detection of DNA 
 
2.3.4.1 Polymerase chain reaction (PCR) 
 
Genomic DNA extracted from tail biopsies (section 2.3.1) was used for genotyping. PCR 
reactions were performed in a LabCycler (SensoQuest, Goettingen, Germany) using 0.2 
µl PCR tubes (Greiner Bio-One, Kremsmuenster, Austria). DNA was added to a master 
mix containing 10X reaction buffer (Axon, Kaiserslautern, Germany), 25 mM MgCl2 
(Axon), Taq polymerase (5 U/µl; Axon), dNTPs (Invitrogen), water and the respective 
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primers. Reaction mixes and cycling conditions are given in TABLE 2.2, TABLE 2.3 and  
TABLE 2.4, respectively. Primer details are listed in TABLE 2.7. PCR products were 
loaded on agarose gels as described in section 2.3.4.2.  
 
  TABLE 2.2 Reaction mix for Tg4-42 PCR 
Reagent Volume 
DNA (20 ng/µl) 2.0 µl 
Aβ3-42 for2 primer  1.0 µl 
Aβ3-42 rev2 primer 1.0 µl 
dNTPs (2 mM) 2 µl 
MgCl2 (25 mM) 1.6 µl 
10X reaction buffer 2 µl 
ddH2O 10.2 µl 
Taq polymerase (5 U/µl) 0.2 µl 
Total volume per sample 20 µl 
 
 
  TABLE 2.3 Reaction mix for 5XFAD PCR 
Reagent Volume 
DNA (20 ng/µl) 2.0 µl 
hAPP for primer  0.5 µl 
hAPP rev primer  0.5 µl 
dNTPs (2 mM) 2 µl 
MgCl2 (25 mM) 3.2 µl 
10X reaction buffer 2 µl 
ddH2O 9.6 µl 
Taq polymerase (5 U/µl) 0.2 µl 
Total volume per sample 20 µl 
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TABLE 2.4 PCR cycling program for genotyping Tg4-42 and 5XFAD mice 
Step Temperature Duration 
1 94 °C 3 min 
2 94 °C 45 sec 
3 58 °C 1 min 
4 72 °C 1 min 
5 repeat steps 2 -4 a total of 35 times 
6 72 °C 5 min 
7 4 °C ∞ 
 
2.3.4.2 DNA gel electrophoresis 
 
Agarose gel electrophoresis was used to analyze the PCR products (Section 2.3.4.1). For 
a 2 % agarose gel 100 ml of 1XTBE buffer was mixed with 2.0 g agarose (Lonza, Basel, 
Switzerland) and boiled in a microwave at 560 W until the agarose was completely 
dissolved. Three µl ethidium bromide (10 mg/ml; Roth, Karlsruhe, Germany) was added to 
the mixture. The solution was poured into a casting tray with a 20-pocket sample comb 
and any air bubbles were removed. After the gel was set the comb was carefully removed 
and the gel was positioned into an electrophoresis chamber (Bio-Rad, Hercules, CA, 
USA) filled with 1XTBE buffer. Ten µl PCR product was mixed with 1 µl 10X agarose gel 
sample buffer (Life Technologies, Carlsbad, CA, USA) and loaded into a well. For sizing 5 
µl of a 100 bp DNA ladder (Bioron, Ludwigshafen, Germany) was added into the first well. 
The gel electrophoresis chamber was connected to a Power Pack P25 power supply 
(Biometra, Goettingen, Germany) and the gel was run for approximately 45 min at 120 V. 
Results were visualized under UV light (366 nm) using the Gel Doc 2000 (Biorad, 
Hercules, CA, USA) and analyzed with the Quantity One software program (Version 4.30; 
Biorad). 
 
10XTBE buffer: 108 g Tris (Roth, Karlsruhe, Germany) and 55 g boric acid (Sigma, St. 
Louis, MO, USA) were dissolved in 900 ml ddH2O. 40 ml 0,5 M Na2EDTA (pH 8.0; Roth, 
Karlsruhe, Germany) was added to the solution and the volume was adjusted to 1 l with 
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2.3.5 Detection of RNA 
 
2.3.5.1 Reverse transcription  
 
Total RNA isolated from mouse brain tissue (section 2.3.2) was subjected to reverse 
transcription to synthesize cDNA using the First Strand cDNA Synthesis Kit (Fermentas, 
St. Leon-Rot, Germany) according to the manufacturer's instructions. Therefore, 1 µl of 
random hexamer primer, 4 µl 5X reaction buffer, 1 µl RiboLock® RNase inhibitor (20 U/µl), 
2 µl of 10 mM dNTP mix and 1 µl RevertAid® reverse transcriptase (20 U/µl) were added 
to 11 µl DNase digested RNA template (1 µg). The reaction mixture was incubated 5 
minutes at 25 °C, 1 hour at 37 °C and 5 minutes at 70 °C in a LabCycle (SensoQuest, 
Goettingen, German). Generated cDNA was diluted 1:10 in molecular grade water and 
used as the sample template for qRT-PCR (section 2.3.5.2). The obtained cDNA was 
stored at -20°C until further use. 
 
2.3.5.2 Real-time quantitative PCR (qRT-PCR)  
 
Analysis of transgene expression in the Tg4-42 line for genotyping and gene expression 
levels in mice were analyzed through qRT-PCR. The diluted first-strand cDNA or DNA, 
respectively (section 2.3.5.1 and 2.3.1) were used for qRT-PCR using the SYBR-green 
based DyNAmo Flash SYBR Green qPCR Kit (Thermo Fisher Scientific, Waltham, MA, 
USA) containing ROX as an internal reference dye. Reaction mixes and cycling conditions 
are given in TABLE 2.5 and TABLE 2.6, respectively. cDNA dilutions were mixed with the 
qPCR reaction mix in 200 µl PCR tubes (Biozym, Oldendorf, Germany) and briefly 
centrifuged in a Spectrafuge Mini (Labnet Inc., Edison, NJ, USA). Samples were 
normalized to the housekeeping gene β-Actin. Primers were purchased from Eurofins 
(Ebersberg, Germany) as intron-spanning validated primer pairs (TABLE 2.7). CT values 
were measurements and all samples were run in duplicates. qRT-PCRs were performed 
in the MX3000P Real-Time Cycler (Stratagene, Santa Clara, CA, USA) and data collected 
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  TABLE 2.5 Reaction mix for qRT-PCR 
Reagent Volume 
1:10 cDNA solution (20 ng/µl) 1.0 µl 
Master Mix 12.5 µl 
forward primer  1.5 µl 
reverse primer 1.5 µl 
ROX  0.3 µl 
ddH2O 8.2 µl 
Total volume per sample 25 µl 
 
 
  TABLE 2.6 qRT-PCR cycling program 
Step Temperature Duration 
1 95 °C 10 min 
2 95 °C 15 sec 
3 58 °C 30 sec 
4 72 °C 30 sec 
5 repeat steps 2 - 4 for 39 cycles 
6 95 °C 1 min 
7 55 °C 30 sec 





All primers were used at a concentration of 10 pmol/µl (1:10 dilution of the 100 pmol/µl 
primer stock prepared in ddH2O). Primers were purchased from Eurofins (Ebersberg, 





2 Material and Methods 
46 
 
TABLE 2.7 List of primers used for mouse genotyping and qRT-PCR (in order of appearance) 
Name Sequence (5' → 3') Used for 
Aβ3-42 for GTGACTCCTGACCTTCCAG Genotyping (Amplicon size 248 bp),  
qRT-PCR 
Aβ3-42 rev GTTACGCTATGACAACACC Genotyping (Amplicon size 248 bp),  
qRT-PCR 
hAPP for GTAGCAGAGGAAGAAGTG Genotyping (Amplicon size 250 bp) 
hAPP rev CATGACCTGGGACATTCTC Genotyping (Amplicon size 250 bp) 
Aldoa for AGCTCCTTCTTCTGCTCCG qRT-PCR 
Aldoa rev TTAGTCCTTTCGCCTACCCA qRT-PCR 
Rps2 for TTGGAGATGGCATCAAAGGT  qRT-PCR 
Rps2 rev ATTGTCTCTGCTCCTGTGCC qRT-PCR 
Ide for CAGGCATCGTTCATCACATT  qRT-PCR 
Ide rev ACAGGTTTGCGCAGTTTTTC  qRT-PCR 
Rpl7a for TCTTGCTTTGTCTCTGGCCT qRT-PCR 
Rpl7a rev ATCCTCTACAAGCGGCTCAA qRT-PCR 
Ttr for GGTGCTGTAGGAGTATGGGC qRT-PCR 
Ttr rev GGAAGACACTTGGCATTTCC qRT-PCR 
Sgk1 for CCGTGTTCCGGCTATAAAAC qRT-PCR 
Sgk1 rev GCCTGAGTATCTGGCTCCTG qRT-PCR 
Rpl21 for TTCCTTTTTGAACAGTGCCC qRT-PCR 
Rpl21 rev GCACCCGGTACATGTTCTCT  qRT-PCR 
Pafah1b2 for GAATAGCTGCTGGGTTCGAG qRT-PCR 
Pafah1b2 rev GATCAAGCGAGCGACTGAA  qRT-PCR 
Psap for ACAGTCCACCGCCGTCTT qRT-PCR 
Psap rev CTCTTCGCCAGCCTTCTG  qRT-PCR 
Ubqln2 for TTGAGCTGTTCCAGTTGCTG qRT-PCR 
Ubqln2 rev ACCCAACCAGCAGTTCATTC qRT-PCR 
Spnb3 for CTGTACTGGCCCTGGATCTC qRT-PCR 
Spnb3 rev CTTTGAAAAGGAAACGGAGG qRT-PCR 
GFAP for CCTTCTGACACGGATTTGGT  qRT-PCR 
GFAP rev ACATCGAGATCGCCACCTAC qRT-PCR 
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Atp1a3 for CATCCAGCAGAATCATGTCG  qRT-PCR 
Atp1a3 rev GATGGTGTGAATGACTCCCC qRT-PCR 
Calm3 for TCCTTGTCGAAGAGGGAGAA  qRT-PCR 
Calm3 rev CAGAGTAACCTCGACCCCC qRT-PCR 
Fbxo2 for CACATCTTCGTTCTCCGACA qRT-PCR 
Fbxo2 rev TGGGAGGAGCTACTGGACAC qRT-PCR 
Aldoa for AGCTCCTTCTTCTGCTCCG qRT-PCR 
Aldoa rev TTAGTCCTTTCGCCTACCCA qRT-PCR 
Gmp6a for GGAATACCTCCCAGGCATTTA qRT-PCR 
Gmp6a rev ACTAATACCGTGCGCCAGAT qRT-PCR 
Ncor2 for TACACTGGGACACGGTCTTG qRT-PCR 
Ncor2 rev AGTTCTCGCTGGACTGAGGA qRT-PCR 
Flrt1 for CAGAGTGTGCCACCACCAT qRT-PCR 
Flrt1 rev GAAGCAGTGACCAGTGGGAC qRT-PCR 
Dcx for TCATCTTGAGCATAGCGGAA qRT-PCR 
Dcx rev GGAAACCGGAGTTGTCAAAA qRT-PCR 
Syn3 for GTCCTGGTAGTCGTGCTGGT qRT-PCR 
Syn3 rev ACATTTTTCCCCAACCACAA qRT-PCR 
 
2.3.7 Detection of Peptides 
 
2.3.7.1 Monomerization of Synthetic Peptides 
 
The amyloid β variants Aβ4-38, Aβ4-40, Aβ4-42, AβpE3-42 and Aβ1-42 were monomerized 
(Peptide Specialty Laboratory PSL, Heidelberg, Germany). First, peptides were dissolved 
in 10 mM NaOH at a concentration of 1 mg/ml and aliquoted in 50 μl volumes. For 
monomerization, peptides were sonicated for 5 minutes (Sonorex RK 100H; Bandelin 
electronic, Berlin, Germany), flash-frozen in liquid nitrogen and stored at -80 °C until 
further use. 
 
2.3.7.2 Western Blot Analyses 
 
For Western blot analysis under reducing conditions, 1 µg monomerized peptides (section 
2.3.7.1) were mixed 1:1 with Vario Gel SDS loading buffer (Anamed, Rodau, Germany) in 
0.5 ml reactions tubes and incubated for 10 minutes at 95 °C in an Uno-Thermoblock 
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(Biometra, Goettingen, Germany). Samples were loaded on 4 - 12 % sodium 
dodecylsulfate–polyacrylamide VarioGels (Anamed) in a X-Cell II TM SureLock chamber 
(Invitrogen, Carlsbad, CA, USA) filled with 500 ml 1X Tricin SDS running buffer (Anamed). 
Additionally, 5 µl low and broad range marker (Thermo Fisher Scientific, Waltham, MA, 
USA) were loaded on each gel. Electrophoresis was performed at 60 V for 45 minutes 
followed by 120 V for 1 hour. After electrophoresis, gels were immersed in transfer buffer 
and proteins were transferred to 0.45 µm Hybond-ECL nitrocellulose membranes (GE 
Healthcare, Chalfont St. Giles, GB) by semi-dry blotting at 25 V for 45 min in a Trans-Blot 
SD Semi-Dry Transfer cell (Bio-Rad, Hercules, CA, USA). Membranes were washed twice 
for 10 minutes in 1XTBS-T (0.01 M TBS containing 0.05 % Tween) and heated for 5 
minutes in 0.01 PBS (800 W until boiling followed by 80 W) to allow better Aβ detection. 
Membranes were blocked in 10 % non-fat dry milk (Roth,  Karlsruhe, Germany) in TBS-T 
over night at 4 °C on a nutating shaker (GFL, Burgwedel, Germany). On the second day, 
membranes were incubated with the primary antibody of interest (TABLE 2.8) in TBS-T for 
5 hours at RT. Membranes were washed twice with the TBS-T, incubated with the 
appropriate peroxidase-conjugated secondary antibody (TABLE 2.9) for 1.5 hours at RT 
and washed again twice with the TBS-T. Blots were developed using chemiluminescence 
solution Luminata Crescendo Western HRP substrate (Merck, Darmstadt, Germany) and 
standard emulsion film (Kodak, Rochester, NY, USA) in a Curix60 developing machine 




2.4.1 Paraffin embedding and sectioning of mouse brain 
 
After fixation of brain tissue (section 2.1.5.1) embedding cassettes containing the tissue 
were placed in the TP 1020 Automatic Tissue Processor (Leica, Wetzlar, Germany) for 
dehydration and paraffin immersion. The following dehydration protocol was used: 5 
minutes in 4 % histofix (Roth, Karlsruhe, Germany); 30 minutes in tap water; 1 hour in 50 
%, 60 %, 70 %, 80 % and 90 % EtOH solutions (CVH, Hannover, Germany); twice 1 hour 
in 100 % EtOH; 1 hour in xylol (Roth) and twice 1 hour in melted paraffin (Roth). After 
dehydration samples were kept in melted paraffin for 1 hour before embedded in paraffin 
blocks using an EG1140 H Embedding Station (Leica). 
Paraffin embedded brains were cut in 4 µm sagittal sections using a HM 335E 
microtome (Thermo Fisher Scientific, Waltham, MA, USA). Sections were mounted onto 
Superfrost® slides (Thermo Fisher Scientific) in a ddH20 water bath at RT. Then the 
sections were fixed onto the slides by dipping them in a 52 °C water bath (Medax, 
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Olching, Germany). Before being used for immunohistochemistry (sections 2.4.2 and 
2.4.3) slides were dried for 10 minutes on a 52 °C hot plate (Medax) and overnight at 37 
°C. 
 
2.4.2 3.3'-Diaminobenzidine (DAB) immunohistochemistry 
 
3.3'-Diaminobenzidine (DAB) immunohistochemistry was performed on 4 µm paraffin 
sections (section 2.4.1). First, sections were deparaffinized and rehydrated using the 
following treatments: 2 x 5 minutes in xylol (Roth, Karlsruhe, Germany); 10 minutes in  
100 % EtOH (CVH, Hannover, Germany); 5 minutes in 95 % EtOH; 5 minutes in 70 % 
EtOH and 1 minute in ddH2O. Then, sections were incubated for 30 minutes in a solution 
of 0.3 % H2O2 (Roth, Karlsruhe, Germany) in 0.01 M PBS to block endogenous 
peroxidases. Antigen retrieval was achieved by heating the sections in 0.01 M citrate 
buffer (pH 6.0; Roth) for 10 minutes (800 W until boiling followed by 80 W for 8 minutes). 
After the sections were cooled down they were dipped for 1 minute in ddH2O and 
permeabilized for 15 minutes in 0.1 % Triton X-100 (Roth) in 0.01 M PBS. Sections were 
washed for 1 minute in 0.01 M PBS. To reveal intracellular Aβ, slides were incubated for 3 
minutes in 88 % formic acid (Roth). Two 5 minutes washing steps with 0.01 M PBS were 
performed to remove any formic acid residues. Sections were circled with a lipid pen (Pap 
Pen; Kisker Biotech, Steinfurt, Germany) and incubated for 1 hour at RT with a solution of 
10 % fetal cow serum (FCS; Thermo Fisher Scientific, Waltham, MA, USA) and 4 % low-
fat dried milk powder (Roth) in 0.01 M PBS to block unspecific antigens. Primary 
antibodies (TABLE 2.8) were diluted to the desired concentration in 0.01 PBS containing 
10 % FCS. After removing the blocking solution sections were incubated overnight at RT 
with 90 µl of the diluted primary antibody. 
On the second day of the staining, sections were washed three times for 5 minutes 
in 0.01 M PBS with 0.1 % Triton and briefly with 0.01 M PBS. After washing, the sections 
were incubated for 1 hour at 37 °C with the respective biotinylated secondary antibodies 
(TABLE 2.9). The secondary antibodies were diluted with 0.01 PBS containing 10 % FCS 
to the desired concentration. Avidin-biotin complex (ABC) solution was prepared 
according the instructions of the manufacturer using the VECTASTAIN Elite ABC Kit 
(Vector Laboratories, Burlingame, CA, USA). Briefly, each component of the kit was 
added to a solution of 0.01 M PBS containing 10 % FCS at a dilution of 1:100. The ABC 
solution was incubated for 30 °C at 4 °C prior use. The sections were washed three times 
with 0.01 M PBS before each section was incubated for 1.5 hour at 37 °C with 90 µl of 
ABC solution. After incubation the slides were washed three times for 5 minutes with 0.01 
M PBS to remove the ABC solution. Staining was visualized using DAB as a chromagen. 
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The DAB containing solution was prepared by adding 100 µl of DAB stock solution (25 
mg/ml DAB in 50 mM Tris/HCl; Sigma, St. Louis, MO, USA) and 2.5 µl 30 % H2O2 to 5 ml 
50 mM Tris/HCl (pH 7.5; Roth). Sections were incubated in 100 µl DAB solution until the 
desired staining pattern was seen. After staining with DAB the sections were washed  3 
times for 5 minutes in 0.01 M PBS and counterstained for 40 seconds with hematoxylin 
(Roth). Sections were dipped in tab water and washed for 5 minutes under running tap 
water. After washing, sections were dehydrated using the following incubations: 1 minute 
in 70 % EtOH; 5 minutes in 95 % EtOH; 10 minutes in 100 % EtOH and 2 x 5 minutes in 
xylol. Stained slides were mounted with 2 drops of Roti®-Histokitt mounting medium 
(Roth) before a cover slip was added to each slide. 
Bright field images of DAB-immunostained tissue were acquired using an BX-51 
microscope equipped with a Camera (Olympus, Tokio, Germany). Figures were generated 
using Adobe Illustrator CS6 (Adobe Systems, San Jose, CA, USA).   
  
2.4.3 4'.6-diamidino-2-phenylindole (DAPI) staining 
 
4'.6-diamidino-2-phenylindole (DAPI) staining was performed on 4 µm paraffin sections 
(section 2.4.1). First, sections were deparaffinized and rehydrated using the following 
treatments: 2 x 5 minutes in xylol (Roth, Karlsruhe, Germany); 10 minutes in 100 % EtOH 
(CVH, Hannover, Germany); 5 minutes in 95 % EtOH; 5 minutes in 70 % EtOH; 1 minute 
in ddH2O and 1 minute in 0.01 M PBS. DAPI staining was performed by dipping the 
sections for 1 minute in a solution of 1.5 mg/l DAPI (Sigma, St. Louis, MO, USA) dissolved 
in ddH2O. The slides were washed twice for 1 minute with 0.01 M PBS. One drop of 
fluorescence mounting media (Dako, Glostrup, Denmark) was added to each section 
before a cover slip was applied. 
Fluorescent images were acquired using an BX-51 microscope equipped with a 
camera (Olympus, Tokio, Germany). The mercury arc lamp and the filter cube set 
included in the BX51 system were used to generate pictures. Figures were generated 














2.5.1 Generation of NT4X-167 antibody 
 
The novel oligomeric Aβ specific antibody NT4X-167 (IgG2b; official name of cell line   
Aβ4-40 NT4X-167; DSM ACC3162) was generated by immunizing three Balb/c mice with 
unconjugated Aβ4-40. In order to generate hybridoma cells the lymph nodes were prepared 
and fused with myeloma cell line P3-X63-Ag8 The hybridoma supernatants of mixed 
clones were screened by immunohistochemistry and enzyme-linked immune-absorbent 
assay (ELISA) and then subcloned. The hybridoma cells were screened by an ELISA for 
antibodies that bind Aβ4-10 and Aβ4-40, but not Aβ36-40. Positive antibody clones were further 
screened by immunohistochemical staining of human brain sections. Finally, the 
monoclonal antibody NT4X-167 that recognizes the N-terminus of N-truncated Aβ was 
identified. NT4X-167 binds most efficiently to Aβ4-x (Antonios et al., 2013). 
Briefly, in order harvest the antibody hybridoma cells were routinely cultivated in 75 
cm² standard cell culture flaks (Greiner Bio-One, Kremsmuenster, Austria) and kept at 37 
°C, 5 % CO2 in a humidified atmosphere (HERAcell 150 CO2 Incubator, Thermo Fisher 
Scientific). Cells were cultivated in Opti-MEM reduced serum media (Life Technologies, 
Carlsbad, CA, USA) supplemented with 10 % fetal calf serum (FCS, Biochrom, 
Cambridge, UK) and 100 U/ml Penicillin and 100 U/ml Streptomycin (PAN-Biotech, 
Aidenbach, Germany). Media was changed two times a week and cells were split every 
10 days using Trypsin/EDTA (PAN Biotech). Cells were stepwise acclimated to 5 % FCS, 
3 % FCS and finally 1 % FCS media. After cells were acclimated in 1 % FCS media, 
supernatant containing the antibody was collected and stored at -20°C until further use.  
 
2.5.2 Primary Antibodies 
 
TABLE 2.8 Primary antibodies used for immunohistochemistry (IH) and Western Blots (WB) 
Antiserum Host Isotope 
Working 
dilution 
Immunogen Source Used for 
24311 rabbit polyclonal 1:500 Pan-Aβ AG Bayer IH, WB 
1–57 mouse monoclonal 1:500 AβpE3-x Synaptic 
Systems 
IH 






GFAP mouse polyclonal 1:500 GFAP Chemicon IH 
IC16 mouse monoclonal 1:1,000 Aβ1-x generous gift 
of S. Weggen 
IH 
IBA1 rabbit polyclonal 1:500 IBA1 Waco IH 
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2.5.3 Secondary Antibodies 
 
TABLE 2.9 Polyclonal secondary antibodies used for immunohistochemistry (IH) and Western 
Blots (WB horseradishperoxidase [HRP]‐conjugated) 
Antiserum Host Conjugate 
Working 
dilution 
Company Used for 
anti-mouse, 
 
rabbit biotinylated 1:200 Dako IH 
anti-rabbit, 
 
swine biotinylated 1:200 Dako IH 
anti- rabbit swine HRP 1:3,000 Dianova WB 
 
 
2.6 Quantification of neuron numbers 
 
2.6.1 Sample preparation 
 
Frozen left brain hemispheres (section 2.1.5.2) were cut frontally into entire series of 30 
μm thick sections on a CM1850 UV cryostat (Leica, Wetzlar, Germany). Every tenth 
section was systematically sampled, stained with cresyl violet (section 2.6.2) and used for 
stereological analysis (section 2.6.3).  
 
2.6.2 Cresyl violet staining 
 
Sections (section 2.6.1) were delipidated using the following treatments: 2 x 10 minutes in 
work solution A followed by 20 minutes in work solution B and 2 x 10 minutes in work 
solution A. Then the sections were stained twice for 10 minutes with cresyl violet staining 
solution. Sections were washed three times with work solution A to remove cresyl violet 
residues. After washing, sections were dehydrated using the following incubations: 3 x 10 
minutes 100 % ethanol (CVH, Hannover, Germany), 10 minutes isopropanol (Roth, 
Karlsruhe, Germany) and 2 x 5 minutes xylol (Roth). Stained slides were mounted with 2 
drops of Roti®-Histokitt mounting medium (Roth) before a cover slip was added to each 
slide. During the whole staining process brain slides were covered with aluminum foil to 
avoid light exposure. 
 
Work solution A: 13.61 g Natrium Acetate Trihydrate (Roth) was diluted in 100 ml ddH2O. 
40 ml of the generated 1 M Natrium Acetate solution was mixed with 9.6 ml 100 % Acetic 
Acid (Merck, Darmstadt, Germany). The volume was adjusted to 1 l with ddH2O. 
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Work solution B: 2.0 ml Triton X-100 (Roth) were dissolved in 10 ml ddH2O. 2.5 ml of this 
stock solution were mixed with 50 ml ddH2O and 150 ml 100 % ethanol.   
Staining solution: 0.1 g cresyl violet (Fluka, St. Louis, MO, USA) was added to 1 l work 
solution A and stirred for 1 hour.  
 
2.6.3 Microscopy and quantification of neurons 
 
Design-based stereology was performed on cresyl violet stained brain sections (section 
2.6.2) to quantify the neuron numbers in the CA1 of the hippocampus in an unbiased way. 
Therefore a BX51 stereology workstation (Olympus, Shinjuku, Japan) with a motorized 
specimen stage for automatic sampling and Stereo Investigator 7 software (MBF 
Bioscience, Williston, VT, USA) were used.  
 
 
The hippocampal pyramidal cell layer CA1 (Bregma −1.22 to −3.80 mm) (FIGURE 2.5 C) 
were delineated at low magnification (4x) and cell counts were performed at high 
FIGURE 2.5 Procedure of design-based stereology of the CA1. (A) Brain hemispheres are frontally 
cut and sampled at a defined frequency (every 10th section). (B) The number of cells are counted 
under high magnification. Cells that are in the box or partially within but touching the green line 
are counted. All cells that are outside the box or touch the red line are excluded from counting.    
Counting areas in the CA1 are selected by the software in a systematic random manner. (C) 
Coronal slices of mouse brain (adapted from Franklin and Paxinos, 2012). CA1 is outlined from left 
to right: Bregma −1.22, -2.46, -3.08 and −3.80 mm. 
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magnification (100x) (Franklin and Paxinos, 2012). A 14 μm x 14 μm counting frame was 
applied within a 49 μm x 105 μm sampling grid to count neurons in the CA1. Neuronal 
nuclei were sampled randomly using optical disector probes and the total number of 
neurons was subsequently estimated by the optical fractionator method using a 2 μm top 
guard zone (West et al., 1991). Section thickness was measured on every grid site with a 
5 µm dissector height (Z). Samples were blinded to avoid bias counting. Neurons were 
counted according to the principles of stereology (West et al., 1991; Schmitz and Hof, 
2005) and the total number of neurons (N) was calculated by formula (1) and (2). The 
remainig stereological parameters are explained in TABLE 2.10 and the parameters for 
counting the CA1 are given in TABLE 2.11. 
 
(1)                   
 
(2) 
          
 




           TABLE 2.10 Definition of stereological parameters 
Stereological parameters 
asf area sampling fraction (xy/XY) 
ssf section sampling fraction 
tsf thickness sampling fraction (T/Z) 
Z dissector height 
P number of neurons 
T mean section thickness 
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      TABLE 2.11 Parameters for stereological analysis of neurons in the CA1 
Parameter CA1 
Sampling Grid (x) (µm) 49 
Sampling Grid (y) (µm) 105 
Sampling Grid Area (xy) (µm²) 5145 
Counting Frame Width (X) (µm) 14 
Counting Frame Height (Y) (µm) 14 
Counting Frame Area (XY) (µm²) 196 
asf 26,25 
ssf 10 
T (µm) [average value]  9,6 
Z (µm) 5 
 
 
2.7 Deep Sequencing of mouse brains 
 
2.7.1 RNA expression profiling 
 
RNA expression profiling was performed by next-generation sequencing on a SOLiD 
5500xl Genetic Analyzer (Life Technologies, Carlsbad, CA, USA). RNA was extracted 
from frozen mouse brain hemispheres (section 2.1.4) as follows. The tissue was 
homogenized using a Polytron (VWR, Radnor, PA, USA) device and then treated with 
TRIzol (Life Technologies, Carlsbad, CA, USA). Next, 5 µg of each total RNA sample 
were spiked with ERCC spike-in control mixes (Life Technologies, Carlsbad, CA, USA) 
before removal of the rRNA by use of a RiboZero Kit (Epicentre, Madison, WI, USA). The 
RNA was prepared for sequencing following the protocol provided by the manufacturer of 
the sequencer. In brief, the rRNA depleted RNA was fragmented by chemical hydrolysis, 
phosphorylated and purified. Adaptors were ligated to the RNA fragments which 
subsequently were reverse transcribed into cDNA. The cDNA was purified and size-
selected using two rounds of Agencourt AMPure XP bead purification (Beckman Coulters 
Genomics, Danvers, USA) and released from the beads. The sample was amplified by 12 
PCR cycles in the presence of primers that contained unique sequences (barcoding). The 
size distribution and concentration of the fragments were determined with an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, USA) and the corresponding chemicals 
(Agilent Technologies). 
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The cDNA fragments were pooled in equimolar amounts and diluted to 76 pg/µl 
corresponding to a concentration of 500 pM. 50 µl of this dilution was mixed with a freshly 
prepared oil emulsion, P1 and P2 reagents and P1 beads in a SOLiD EZ Bead Emulsifier 
(Life Technologies) were prepared according to the E80 scale protocol (Life 
Technologies). The emulsion PCR was carried out in a SOLiD EZ Bead Amplifier (Life 
Technologies) using the E80 setting. To enrich for the beads that carried amplified 
template DNA, the beads were purified on a SOLiD EZ Bead Enricher using the 
recommended chemicals and software (Life Technologies). The purified beads were 
loaded onto a SOLiD 6-lane Flowchip (Life Technologies) and incubated upside down for 
1 hour at 37 °C. The Flowchip was positioned in the 5500xl SOLiD System and the DNA 
was sequenced using the settings and recommended chemicals for sequencing 75 
nucleotides in the forward direction and 35 nucleotides in the reverse direction (Life 
Technologies). 
Sequence reads were mapped to the mouse genome reference sequence mm101 
using the workflow 'whole.transcriptome.pe' of analysis software LifeScope-v2.5.1-r0 (Life 
Technologies). Reads mapping to RefSeq coding exons (accessed 2012-06-27)2 and 
matching the coding strand were considered coding RNAs. All other mapping reads were 
considered non-coding. RNA expression profiling of mouse brain tissue was carried out by 
the group of Prof. Andreas W. Kuss at the Ernst-Moritz-Arndt University Greifswald, 
Germany.  
 
2.7.2 Differential Expression Analysis 
 
RNASeq read data were normalized within and between lanes for GC-content using 
EDASeq's full-quantile normalization (Risso et al., 2011). The differential expression 
analysis was done with DESeq (Anders and Huber, 2010). All samples were treated as 
replicates of a single condition for the estimation of the dispersion. Only the fitted 
dispersion values were used in the following analyses. The significance of differential 
expression was determined by the Benjamini-Hochberg corrected p-values of the negative 
binomial test between two conditions. The threshold for significance was set to p = 0.05. 
Differential expression analysis was carried out by Tim Kacprowski of the group of Mario 








 http://hgdownload.cse.ucsc.edu/goldenPath/mm10 /database/refGene.txt.gz. 




2.7.3 Annotation analysis 
 
In order to gain insight in the biological function and to understand the biological 
significance of differentially expressed genes (DEGs), the functional annotation of DEGs 
was obtained using Source3, GeneCards4, Wiki-Pi5 and Mouse Genome Informatics6 as 
well as the literature.  
2.8 Statistical analysis 
 
Details of statistical analysis, methods and parameters are given in the respective results 
sections where data is described. The number of biological replicates (n) is given at the 
base of figures where necessary. Significance levels are given as follows: ***p < 0.001; 
**p < 0.01; *p < 0.05. Unless stated otherwise, data are given as means ± standard error 
of the mean (SEM). 
All statistics for behavior experiments were calculated using GraphPad Prism 
version 5.04 for Windows (GraphPad Software, San Diego, CA, USA) and Statistica 
version 12.0 (StatSoft, Tulsa, OK, USA). Differences between groups were tested with 
unpaired t-test, paired t-test, one-way analysis of variance (ANOVA) followed by 
Bonferroni multiple comparison or two-way ANOVA followed by Bonferroni multiple 
comparison as indicated in the results part.  
Statistical analysis of quantitative RT-PCR measurements was performed using 
the Relative Expression Software Tool V1.9.6 (REST, Qiagen, Hilden, Germany) (Pfaffl et 
al., 2002). The expression ratio results of the studied transcripts were tested for 
significance by Pair Wise Fixed Reallocation Randomization Test. Statistical analysis of 
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3.1 Project 1: Characterization of the Tg4-42 mouse model 
 
Aβ4-42 represents a major N-truncated Aβ isoform in the cortex and hippocampus of AD 
patients (Portelius et al., 2010). However, little is known about the role of this peptide to 
the progression of AD. In order to investigate the consequences of chronic expose of Aβ4-
42 in vivo the transgenic mouse model Tg4-42 was generated (Wittnam, 2012). The main 
objectives of this part of the project were the generation of homozygous Tg4-42 mice 
(Tg4-42hom) and the characterization of Tg4-42 and Tg4-42hom mice. Among others, the 
amyloid pathology in these mice was examined and the behavior phenotype analyzed. 
Furthermore, the question was addressed whether Aβ4-42 or AβpE3-42 may precede the 
other in AD pathology in the 5XFAD mouse model using the newly generated antibody 
NT4X-167.  
 
3.1.1 Aβ4-42 elicits stable aggregates similar to Aβ1-42 and AβpE3-42  
 
The aggregation properties of freshly prepared and aged Aβ4-42 were compared with      
Aβ1-42, AβpE3-42, Aβ4-38, Aβ4-40 peptides. Therefore, peptides were subjected to SDS-PAGE 
Western Blot (FIGURE 3.1). Under denaturing conditions freshly dissolved Aβ1-42, AβpE3-42 
and Aβ4-42 displayed monomers, dimers and aggregates most likely presenting trimers or 
tetramers, while Aβ4-38 and Aβ4-40 formed monomers and dimers but no other oligomers. 
After 24 and 72 hours of aging Aβ1-42, AβpE3-42 and Aβ4-42 peptides showed in addition 
higher molecular weight oligomers. In contrast, aged Aβ4-38 and Aβ4-40 retrained their 
pattern and did not exhibit additional higher molecular weight aggregates. Aged and fresh 







FIGURE 3.1 Freshly dissolved Aβ1-42, AβpE3-42, Aβ4-38, Aβ4-40 and Aβ4-42 rapidly formed stable 
aggregates. All peptides displayed dimeric oligomers and monomers under reducing conditions. 
Furthermore Aβ1-42, AβpE3-42 and Aβ4-42 developed SDS-stable tri- or tetrameric oligomers. Aged  
Aβ1-42, AβpE3-42 and Aβ4-42 peptides retained this pattern and exhibited also higher molecular weight 
aggregates. SDS-PAGE Western blot of Aβ peptides using the polyclonal antiserum 24311. 
 
3.1.2 Early intraneuronal Aβ4-X accumulation in 5XFAD transgenic mice 
 
N-truncated Aβ4-42 is next to AβpE3-42 the major N-truncated Aβ variant in the AD brain 
(Portelius et al., 2010). In order to determine whether Aβ4-42 or AβpE3-42 precedes the other 
in the AD pathology 5XFAD mice were analyzed with the new NT4X-167 antibody. 
Cortical sections of hemizygous and homozygous 5XFAD mice were studied as this brain 
area is known for abundant intraneuronal Aβ (Oakley et al., 2006; Antonios et al., 2013). 
The staining pattern of NT4X-167 (against Aβ4-x and pyroglutamate Aβ3-x) was compared 
with 1–57 (against AβpE3-x) and IC16 (against Aβ1-x). Homozygous 5XFAD mice were used 
in order to observe an aggravated amyloid pathology at an earlier time point as compared 
to hemizygous mice (Antonios et al., 2013). As expected, intraneuronal Aβ1-x accumulation 




C). Homozygous 6 week-old 5XFAD mice showed an higher intraneuronal signal 
compared to hemizygous mice (FIGURE 3.2 A vs. B). Aged mice demonstrated abundant 
Aβ1-x accumulation in amyloid plaques (FIGURE 3.2 C). NT4X-167 recognized 
intraneuronal Aβ in 6 week-old homozygous 5XFAD mice (FIGURE 3.2 E). Intraneuronal 
Aβ could not be detected with the AβpE3-x specific antibody 1–57 in 6 week-old 
homozygous 5XFAD (FIGURE 3.2 H). Therefore the signal was due to Aβ4-x accumulation, 
which represents the earliest N-truncated Aβ species. Using the 1–57 antibody no 
intraneuronal signal could be detected at any ages analyzed. Amyloid plaques were 
detected with both NT4X-167 and 1–57 in aged mice (FIGURE 3.2 F and I). 
 
FIGURE 3.2 Immunohistochemical staining of cortical sections of 5XFAD transgenic mice. (A) 
Immunostaining with IC16 demonstrating intraneuronal Aβ accumulation in 6 week old 
hemizygous 5XFAD. (B) Homozygous 5XFAD mice exhibited more intensive intraneuronal staining 
at the same age. (C) Abundant extracellular plaque staining with IC16 at the age of 12 months. (D) 
No signal was detected using NT4X-167 in 6 week old hemizygous 5XFAD. (E) In homozygous 
5XFAD mice significant intraneuronal staining was observed with NT4X-167. (F) Abundant 
extracellular plaque staining with NT4X-167 at the age of 12 months. (G) No intraneuronal Aβ was 
observed with the pyroglutamate specific antibody 1–57 in 6 week-old hemizygous and (H) 
homozygous 5XFAD mice. (I) Extracellular plaque staining with 1–57 at the age of 12 months. At 
12 months only hemizygous 5XFAD were used. Abbreviations: w = week; m = month. Scale bar in I 




3.1.3 Characterization of Tg4-42 mice  
 
The Tg4-42 mouse model represents the first mouse model that exclusively expresses 
Aβ4-42 under the control of the Thy-1 promoter without additional overexpression of mutant 
PSEN-1 or APP. Tg4-42 mice neuronally express human Aβ4-42 fused to the murine 
thyrotropin releasing hormone (TRH) signal peptide. The fusion peptide routes Aβ4-42 
through the secretory pathway facilitating its extracellular release (Wirths et al., 2010; 
Alexandru et al., 2011). In order to reach its final form, the Aβ4-42
 produced in Tg4-42 mice 
does not need to go through additional enzymatic modification with the exception of the 
removal of the TRH signal peptide (Wittnam, 2012). 
 
3.1.3.1 Generation of homozygous Tg4-42 mice 
 
Hemizygous Tg4-42 mice expressing human Aβ4-42  were previously generated in our lab 
(Wittnam, 2012; Bouter et al., 2014). In addition, homozygous Tg4-42 mice were bred and 
named Tg4-42hom. Therefore, hemizygous mice were crossed to produce potential 
homozygous mice. Potential homozygous mice were identified by qRT-PCR (FIGURE 3.3) 
and backcrossed with wild-type mice to test for true homozygosity. Once homozygous 
males and females were confirmed, they were re-mated to each other as the founders for 
the new homozygous transgenic line Tg4-42hom.  
 
FIGURE 3.3 Identification of potentially homozygous Tg4-42 mice through qRT-PCR. All animals 
were compared to the hemizygous mouse number 1. Transgene expression was quantified 
relative to APP. Mice number 4, 5, 6 and 13 were identified as potential homozygous males and 






3.1.3.2 Amyloid beta expression in Tg4-42 mice 
 
Transgene expression in Tg4-42 and Tg4-42hom mice was analyzed using 
immunohistochemistry. 
FIGURE 3.4 Immunohistochemical staining profile of Tg4-42 mice. Abundant intraneuronal Aβ 
immunoreactivity was observed Tg4-42 mice in the CA1 pyramidal cell layer of the hippocampus 
starting at (A, B, D) 2 months of age. (D-F) Aβ42 immunostaining declined with age. (G) Aβ 
accumulation was also detected intraneuronally in the CA1 of Tg4-42hom starting at 2 months. (G-
H) Aβ staining decreased with age in Tg4-42hom. Next to the (D-H) Aβ42-specific antibody Aβ42, the 
(A-B) polyclonal antiserum 24311 and (C) Aβ4-x binding antibody NT4X-167 detected Aβ 
accumulation in the CA1. Other brain regions with Aβ42 staining were (I) occipital cortex, (J) 
piriform cortex, (K) striatum and (L) superior colliculus of 2-month-old Tg4-42 mice. Antibody: (A-
B) polyclonal antiserum 24311; (C) NT4X-167; (D-L): Aβ42. Abbreviations: m = months, hom = 




Aβ expression in Tg4-42 mice was detected with the polyclonal antiserum 24311 
recognizing pan-Aβ and the Aβ42-specific antibody Aβ42. Furthermore, the novel 
monoclonal antibody NT4X-167, that recognizes the N-terminus of N-truncated Aβ was 
used to analyze the transgene expression (Antonios et al., 2013). 
Tg4-42 and Tg4-42hom mice brain sections showed strong intraneuronal Aβ 
immunoreactivity predominantly in the CA1 region of the hippocampus beginning at two 
months of age (FIGURE 3.4 A, B, D and G). No difference in Aβ expression was observed 
between the polyclonal antiserum 24311, the Aβ42-specific antiserum Aβ42 and the 
monoclonal NT4X-167 antibody (FIGURE 3.4 B and D). Aβ expression in the CA1 
pyramidal cell layer of the hippocampus declined during aging in Tg4-42 (FIGURE 3.4 D-
F) and Tg4-42hom mice (FIGURE 3.4 G-I).  
Intraneuronal Aβ staining was also observed in Tg4-42 mice in the occipital cortex 
(FIGURE 3.4 I), piriform cortex (FIGURE 3.4 J), striatum (FIGURE 3.4 K) and superior 
colliculus (FIGURE 3.4 L) starting at two months of age.  
 
3.1.3.3 Gliosis in Tg4-42 mice 
 
DAB immunohistochemistry was used to analyze gliosis in Tg4-42 mice (FIGURE 3.5). 
 
 
FIGURE 3.5 Reactive microglia and astroglia in Tg4-42 mice. (A-C) Microgliosis with IBA1 staining 
was detected at 2 months in (B) hemizygous Tg4-42 and (C) homozygous Tg4-42 mice. (D-F) 
Increased astrogliosis with GFAP staining was seen as early as 2 months of age in (E) hemizygous 
Tg4-42 and (F) homozygous Tg4-42 mice. No significant astro- and microgliosis were observed in 




Astrogliosis was examined with GFAP (glial fibrillary acidic protein) staining, while 
microgliosis was examined with IBA1 (ionized calcium binding adaptor molecule 1) 
staining. Reactive microglia were seen in the CA1 region of the hippocampus beginning at 
2 months of age in Tg4-42 and Tg4-42hom mice (FIGURE 3.5 B-C). Furthermore, visible 
increased astrogliosis was observed around the hippocampus in transgenic mice as early 
as two months (FIGURE 3.5 E-F). No significant astro- and microgliosis were detected in 
same-aged wild-type control mice (FIGURE 3.5). 
 
3.1.3.4 Physical and behavioral characterization of Tg4-42 mice 
 
The progressive memory decline is probably the most striking sign in AD patients 
(Alzheimer's Association, 2012). Therefore, a valid AD mouse model should reflect some 
of the behavioral changes observed in AD patients. In order to determine if the Aβ 
pathology in Tg4-42 mice was sufficient to induce functional impairments, cohorts of 3-, 8- 
and 12-month-old Tg4-42 mice were subjected to a basic physical examination and a 
battery of behavioral tests. Furthermore, 3- and 8-month-old Tg4-42hom were analyzed. All 
analyzed groups were sex-matched.  
 
3.1.3.4.1 General physical assessment of Tg4-42 mice 
 
Tg4-42 mice were subjected to a basic physical assessment to determine potential  
impairments caused by the Aβ pathology. The physical examination revealed no 
abnormalities in Tg4-42 and Tg4-42hom mice, respectively. Mice showed no tremor or 
clasping phenotype during the tail suspension task regardless of sex and age. Transgenic 
mice tried to escape the grip by kicking their paws and twisting their whole body similar to 
healthy wild-type mice. 
In order to determine possible effects on the physiological development, the body 
weight of Tg4-42 and wild-type mice was measured at three, eight and twelve months of 
age. Furthermore, the body weight of Tg4-42hom was measured at three and eight months 
of age. The sex distribution was balanced in all cohorts (n = 12 - 15 mice per group).   
Tg4-42 and Tg4-42hom demonstrated no altered body weight compared to wild-type mice 
at all tested time points (FIGURE 3.6). Two-way repeated measures ANOVA revealed that 
there was no significant main effect of genotype (genotype: p = 0,064207). Furthermore, 








3.1.3.4.2 Intact motor function in Tg4-42 mice 
 
Motor function in Tg4-42 mice was examined using the balance beam (FIGURE 3.7 B) 
and string suspension task (FIGURE 3.7 D). The balance beam task assesses fine motor 
coordinating and balance of mice (Hau and Schapiro, 2002; Luong et al., 2011). Grip and 
muscle strength as well as motor coordination of mice can be tested in the string 
suspension task (Hullmann, 2012; Arendash et al., 2001b). No significant difference 
between transgenic and wild-type control mice was detected at three, eight or twelve 
months of age in either motor test (FIGURE 3.7 A and C). Two-way repeated measures 
ANOVA revealed that there was no significant main effect of genotype (genotype: balance 
beam: p = 0,184313; string suspension: p = 0,084051) and Tg4-42 and Tg4-42hom 
performed equally to same-aged wild-type control mice. Furthermore, performance in both 
tests declined with age independent of the genotype (two-way repeated measures 
ANOVA, age: balance beam: p = 0,000264; string suspension: p = 0,008633). In 







FIGURE 3.6 Body weight of Tg4-42 mice. 3-, 8- and 12-month-old Tg4-42 as well as 3- and              
8-month-old Tg4-42hom mice displayed normal body weight compared to aged-matched WT mice. 
Two-way repeated measures ANOVA, n = 12-15 mice per group (equal sex distribution); data 








3.1.3.4.3 Anxiety behavior in Tg4-42 mice 
 
The elevated plus maze test was used to assess anxiety-like behavior in Tg4-42 mice 
(Campos et al., 2013). The time spent in the open arms was used as an indication of open 
space-induced anxiety. Anxiety reduction is indicated by an increased stay in the open 
arms (Komada et al., 2008). The anxiety levels of 3-, 8- and 12-month-old Tg4-42 as well 
as 3- and 8-month-old Tg4-42hom were examined. Transgenic mice showed no altered 
anxiety phenotype compared to same-aged wild-type mice (FIGURE 3.8 A, two-way 
repeated measures ANOVA, genotype: p = 0,169783). In addition, the distance travelled 
did not differ between Tg4-42, Tg4-42hom and same-aged WT mice (FIGURE 3.8 B, two-
way repeated measures ANOVA, genotype: p = 0,138556). All mice showed an equal 
age-dependant decreased anxiety behavior (two-way repeated measures ANOVA, age: p 
FIGURE 3.7 No motor deficits in Tg4-42 mice. Tg4-42 and Tg4-42hom showed no deficits in the (A, 
B) balance beam and the (C, D) string suspension task. 3, 8 and 12 months old Tg4-42 mice 
performed comparably to same-aged wild-type mice. Furthermore, no significant difference was 
detected between 3 and 8 months old Tg4-42hom and wild-type controls. Two-way repeated 




= 0,001841) and decreased agitation with age (two-way repeated measures ANOVA, age: 
p = 0,012224). 
 
 
3.1.3.4.4 Working memory in Tg4-42 mice 
 
Working memory in Tg4-42 mice was assessed in the cross maze by examining the 
alternation behavior of mice. Healthy mice tend to alternate between the arms of the maze 
and typically prefer to explore the least recently visited arm of the maze rather than 
returning to the one previously visited (Wietrzych et al., 2005). Working memory of 3-, 8- 
and 12-month-old Tg4-42 as well as 3- and 8-month-old Tg4-42hom was investigated in the 
cross maze. No significant difference was detected between transgenic and wild-type 
animals in spontaneous alternation independent of age (FIGURE 3.9 A two-way repeated 
measures ANOVA, genotype: p = 0,784478, age: p = 1,000001). In addition, Tg4-42 and 
Tg4-42hom travelled an equivalent distance as same-aged wild-type mice at all ages 
examined (FIGURE 3.9 B, two-way repeated measures ANOVA, genotype: p = 0,445393, 






FIGURE 3.8 Unaltered anxiety behavior in Tg4-42 mice. (A) There was no significant difference 
between Tg4-42 and WT in the time spent in open arms and the (B) distance travelled at 3, 8 and 
12 months of age. Furthermore, Tg4-42hom performed not significantly different to WT mice at 3 
and 8 months in (A) the percentage time spent in open arms and (B) the distance travelled. Two-









3.1.3.4.5 Spatial memory deficits in Tg4-42 mice 
 
Spatial reference memory in Tg4-42, Tg4-42hom and wild-type mice was assessed using 
the Morris water maze. Hemizygous Tg4-42 mice and wild-type littermates were tested at 
three, eight and twelve months of age. Homozygous Tg4-42 (Tg4-42hom) mice were 
examined at three and eight months of age.  
Testing began with three days of cued training, were mice familiarized with the 
pool and learned to locate a marked platform. All mice reached criteria by showing 
progressively decreased escape latencies or reaching the platform in under 15 seconds 
after three days of training (FIGURE 3.10 A-C; two-way repeated measures ANOVA, 3 m 
and 8 m: main effect of days: p < 0,000001; 12 m: main effect of days: p < 0,000226). 
Swimming speed did not differ between genotypes at any tested time point (FIGURE 3.10 
A-C; two-way repeated measures ANOVA, genotype: p = 0,271846). The cued training 
revealed that all mice are able to perform the water maze task as they have an intact 
vision and the motor abilities to swim. 
Twenty-four hours after the cued training, mice performed five days of acquisition 
training (FIGURE 3.11). Their learning abilities to find the location of a submerged 
platform by using proximal and distal cues was tested. For the escape latency a significant 
main effect of age could be found (two-way repeated measures ANOVA, age: p = 
0,036700). In contrast, swimming speed did not significantly alter between three, eight 
FIGURE 3.9 Intact working memory in Tg4-42 mice. (A) Alternation rate and (B) distance travelled 
did not alter between 3, 8 and 12 months old Tg4-42 and same-aged WT mice. Furthermore, no 
differences in alternation rate or distance travelled was detected between 3 and 8 months       
Tg4-42hom and WT mice. Two-way repeated measures ANOVA. n = 9-15 per group, data presented 




and twelve month old animals (FIGURE 3.11 A -C; two-way repeated measures ANOVA, 
age: p = 0,776269). These results show that younger mice performed superior to older 
animals while this difference was not due to differences in swimming speed due to age-
related motor deficits. Furthermore, the acquisition phase revealed a significant main 
effect of the factor genotype for the escape latencies (two-way repeated measures 
ANOVA, genotype: p = 0.012561), while the swimming speed was not significantly 
affected by the genotype of animals (two-way repeated measures ANOVA, genotype: p = 
0.214047). Across the five days of acquisition the animals, irrespective of genotype and 
age, showed a significant decrease in the escape latencies. At three months of age,    
Tg4-42, Tg4-42hom and WT mice improved significantly over the five days and showed no 
differences between the genotypes (FIGURE 3.11 A; two-way repeated measures 
ANOVA, days: p = 0,000001; genotype: p = 0.106729). At eight and twelve months of age, 
the escape latencies decreased significantly over the training days (FIGURE 3.11 B and 
C, two-way repeated measures ANOVA, 8 m days: p = 0,000001; 12 m days: p = 
0,000002). However, a significant difference between the groups was detected in both 
age groups (two-way repeated measures ANOVA, 8 m genotype: p = 0,004182; 12 m 
genotype: p = 0,010909). Eight months old Tg4-42hom performed significantly inferior to 
WT mice on day one, two, four and five of the acquisition training (FIGURE 3.11 B; t-test: 
day 1: p = 0,011037; day 2: p = 0,012627; day 4: p = 0,007121; day 5: p = 0,007482). 
Furthermore, twelve months old Tg4-42 showed significantly longer escape latencies on 
day four and five (FIGURE 3.11 C; t-test: day 4: p = 0,003086; day 5: p = 0,023866). 
These results suggest a slightly impaired spatial learning in twelve months old Tg4-42 and 
eight months old Tg4-42hom mice in the Morris water maze.  
Twenty-four hours after the last acquisition trial, a probe trial was conducted to 
assess spatial reference memory. At three months of age, WT, Tg4-42 and Tg4-42hom 
mice displayed a significant preference for the target quadrant, as indicated by the 
percentage time spent in the four quadrants of the pool (FIGURE 3.12 A, one-way 
ANOVA, WT: p < 0.001 target vs. all other quadrants; Tg4-42: p < 0.001 target vs. left 
quadrant, p < 0.01 target vs. right and opposite quadrant; Tg4-42hom: p < 0.001 target vs. 
all other quadrants). Eight months old Tg4-42 and WT mice also spent a significant higher 
percentage of time in the target quadrant in comparison to the other quadrants. However, 
eight months old Tg4-42hom mice displayed no significant preference for the target 
quadrant indicating spatial reference memory deficits (FIGURE 3.12 B, one-way ANOVA, 
WT: p < 0.001 target vs. all other quadrants; Tg4-42: p < 0.001 target vs. all other 
quadrants). Furthermore, twelve months old Tg4-42 mice showed no quadrant preference, 
while same-aged WT mice still demonstrated a significant preference for the target 




quadrants). Aged Tg4-42 and Tg4-42hom showed an impaired spatial learning reflected by 
the absence of a preference for the target quadrant during the probe trial. Swimming 
speed did not differ during the probe trial between the groups at any age tested (FIGURE 
3.12 A - C).  
In summary, the results of the acquisition training and the probe trial suggest that 
Aβ4-42 expression in the transgenic mice impairs spatial learning and spatial reference 
memory in the Morris water maze.  
 
FIGURE 3.10 Cued training of the water maze reveals that Tg4-42 exhibit intact eyesight and the 
motor abilities to perform the test. Hemizygous Tg4-42 mice and WT littermate controls were 
examined at (A) 3, (B) 8 and (C) 12 months of age. In addition, Tg4-42hom were tested at (A) 3 and 
(B) 8 months of age. All mice showed progressively shorter escape latencies in response to 
training and reached the criteria that allows continuation of the water maze. Swimming speed did 
not differ between genotypes at any tested time point (A)-(C). Escape latencies and swimming 
speed: two-way repeated measures ANOVA. n = 12-15 per group; data presented as mean ± 







FIGURE 3.11 Spatial learning was assessed in the acquisition training of the Morris water maze. 
Hemizygous Tg4-42 mice and WT littermate controls were examined at (A) 3, (B) 8 and (C) 12 
months of age. In addition, Tg4-42hom were tested at (A) 3 and (B) 8 months. Across the 5 days of 
acquisition all groups showed a significant decrease in the escape latencies. (A) Three months old 
Tg4-42 and Tg4-42hom displayed similar learning curves during the acquisition training. (B) At 8 
months Tg4-42hom performed significantly inferior to WT and Tg4-42 . Furthermore, (C) 12-month- 
old WT performed significantly better than same-aged Tg4-42 mice. Swimming speed did not differ 
between genotypes at any tested time point (A)-(C). Escape latencies and swimming speed: two-way 
repeated measures ANOVA, ***p < 0.001, **p < 0.01, *p < 0.05. n = 12-15 per group; data presented 





FIGURE 3.12 Spatial reference memory deficits in aged Tg4-42 and Tg4-42hom mice shown in the 
probe trial of the Morris water maze. Hemizygous Tg4-42 mice and WT littermate controls were 
tested at (A) 3, (B) 8 and (C) 12 months of age. In addition, Tg4-42hom were examined at (A) 3 and 
(B) 8 months of age. (A) At 3 months of age all groups spent a greater percentage of time in the 
target quadrant (WT: p <0.001 T vs. all other quadrants; Tg4-42: p < 0.001 T vs. L, p < 0.01 T vs. R 
and O; Tg4-42hom: p < 0.001 T vs. all other quadrants). (B) Probe trial revealed a significant reduced 
learning behavior for 8-month-old Tg4-42hom mice as they showed no preference for the target 
quadrant. WT and Tg4-42 mice showed no learning deficits at this age (WT and Tg4-42: p < 0.001 T 
vs. all other quadrants). (C) At 12 month of age, hemizygous Tg4-42 mice did not show a 
preference for the target quadrant. However, same-aged WT mice still had a significant 
preference for the target quadrant (WT and Tg4-42: p < 0.001 T vs. all other quadrants). (A-C) 
Swimming speed did not differ between the groups. Abbreviations: T = target quadrant; L = left 
quadrant; R = right quadrant; O = opposite quadrant. Quadrant preference and swimming speed: 
One-way analysis of variance (ANOVA) followed by Bonferroni multiple comparisons, ***p < 




3.1.3.4.6 Decreased contextual learning in Tg4-42 mice 
 
Contextual and tone fear conditioning were tested in 12-month-old Tg4-42 and WT mice. 
During the training session involving a tone-foot-shock pairing (CS/US) both genotypes 
exhibited comparable degrees of freezing (FIGURE 3.13 A). 
 
When mice were tested 24 hours after the training trial for context fear conditioning 
(FIGURE 3.13 C), Tg4-42 mice demonstrated no significantly increased freezing behavior 
in response to the conditioning chamber. In contrast, WT mice displayed significantly 
increased freezing (FIGURE 3.13 A, paired t-test, p < 0.001) as a response to the context. 
FIGURE 3.13 Impaired contextual conditioning in Tg4-42 mice. 12-month-old Tg4-42 and WT 
mice were trained with a CS/US pairing for contextual fear conditioning. (A, C) Mice were 
reintroduced to the original training context (CS) 24 hours post training and tested for 
contextual memory. Levels of freezing during the re-exposure were not significantly different 
from the training trial for Tg4-42 mice. In contrast, WT mice showed a significant increased 
freezing response to the context. (B, D) 48 hours post training mice were introduced to an 
altered chamber and tested for tone memory. Tg4-42 and WT showed an increased freezing 
response due to the tone (CS). (C, D): the blue line indicates the chamber, the red line the tone 
and the green line the altered chamber. CS = conditioned stimulus. US = unconditioned stimulus. 




Tg4-42 mice jumped and vocalized in response to the electric foot-shock to a similar 
degree as WT mice, suggesting normal pain perception in these mutant mice. However, 
transgenic mice were not able to attribute the pain of the foot-shock during the training 
trial to the context. Therefore, Tg4-42 showed an impaired contextual learning. 
Twenty-four hours after the context testing (48 hours after training), the same mice 
were tested for conditioned fear of the tone (FIGURE 3.13 D). Therefore mice were 
reintroduced to the altered fear conditioning chamber. When the tone was presented 
without the foot-shock, both Tg4-42 and WT mice exhibited similar freezing responses 
(FIGURE 3.13 B). In both mouse lines freezing increased significantly compared to the 
pre-tone period (paired t-test, WT p < 0.01; Tg4-42: p < 0.001). Therefore, all mice 
associated the tone with the previously received foot-shock and showed no impaired tone 
learning. 
 
3.1.3.5 Long-term exposure to N-truncated Aβ4-42 induces neuron loss 
 
In order to investigate the effects of long-term exposure to N-truncated Aβ4-42 in Tg4-42 
and Tg4-42hom mice the neuron number in the CA1 layer of the hippocampus was 
examined via DAPI staining and unbiased stereology. 
DAPI staining revealed an obvious neuron loss in the CA1 layer of the 
hippocampus between eight months old wild-type mice and same-aged Tg4-42 mice 
(FIGURE 3.14 B). An even more pronounced neuron loss was observed in eight months 
old Tg4-42hom mice (FIGURE 3.14 C).  
In order to quantify the neuron numbers in the CA1 in an unbiased way design-
based stereology was performed. The hippocampal pyramidal cell layer CA1 was 
quantified from Bregma -1.22 to -3.80. Stereology revealed an age- and genotype-
dependent neuron loss in Tg4-42 and Tg4-42hom mice (FIGURE 3.14 D, one-way repeated 
measures ANOVA, genotype: p = 0,000094; age: p = 0,000011). At three months of age 
no significant difference in the number of neurons could be detected between wild-type 
(mean = 304,805, SEM ± 12,560), Tg4-42 (mean = 309,600, SEM ± 17,570) and         
Tg4-42hom mice. However, Tg4-42hom (mean = 244,808, SEM ± 21,320) exhibited fewer 
neurons in the CA1 than same-aged Tg4-42 and WT mice. At eight months stereology 
revealed a 38 % neuron loss in hemizygous Tg4-42 mice (mean = 178.014, SEM ± 9,083, 
one-way ANONA: p < 0.01) compared to wild-type littermate controls (mean = 282.683, 
SEM ± 15,670). In same-aged homozygous Tg4-42hom mice the neuron loss was even 
more pronounced with a 65 % decline (mean = 97,600, SEM ± 14,300, one-way ANONA: 
p < 0.001) to WT controls. Homozygous 8-month-old Tg4-42 mice displayed 46 % fewer 




FIGURE 3.14 Age- and dose-dependent neuron loss in hippocampus of Tg4-42 mice. (A-C) DAPI 
staining revealed obvious neuron loss in the CA1 layer of the hippocampus in (B) eight months old 
Tg4-42 compared to same-aged (A) WT mice. (C) Neuron loss in eight months old Tg4-42hom was 
even more pronounced. (D-E) Quantification of neurons in CA1 using unbiased stereology. One-
way ANOVA; n = 3-5; **p < 0.01, ***p < 0.001; data presented as mean ± S.E.M; m = months. 





Furthermore, stereology revealed a 51 % loss in neuron number in the CA1 at the age of 
twelve months between hemizygous Tg4-42 (mean = 144,057, SEM ± 9,540, one-way 
ANONA: p < 0.01) and same-aged WT mice (mean = 291,053, SEM ± 37,530). Between 
eight and twelve months, the neuron loss in hemizygous mice increased by 20 %. In 
contrast, wild-type mice showed no age-dependant neuron loss. 
 In order to further investigate the neuron loss in Tg4-42hom mice the number of 
neurons was additionally counted at two, four, five and six months of age (FIGURE 3.14 
E). The number of neurons in 2-month-old Tg4-42hom (mean = 304,705, SEM ± 37,750) 
was comparable to 3-month-old old WT mice and not significantly different from 3-month-
old Tg4-42hom. However, 4-, 5- and 6-month-old homozygous mice displayed a significant 
neuron loss of 45 % , 55 % and 65 %, respectively (one-way ANONA: 4m: mean = 
165,244, SEM ± 10,660, p < 0.01; 5m: mean = 139,169, SEM ± 2,218, p < 0.001; 6m: 
mean = 107,377, SEM ± 5,760, p < 0.001). The neuron number in homozygous mice 
followed a exponential decay that seems to led to a plateau starting at six months with a 
neuron loss of 65 %.  
In summary, it can be stated that long-term exposure to N-truncated Aβ4-42 induces 
an age- and dose-dependent neuron loss hemizygous and homozygous Tg4-42 in the 






















3.2 Project 2: Deciphering the molecular profile of plaques, memory 
decline and neuron loss in Tg4-42 and 5XFAD mice by deep 
sequencing 
 
In the second part of the thesis, a comparative gene expression analysis of Tg4-42 and 
5XFAD brain tissue was performed using next-generation sequencing. The well-
established plaque developing 5XFAD mouse model (Oakley et al., 2006; Jawhar et al., 
2010) was compared with the Tg4–42 mouse model that solely expresses Aβ4-42 without 
extracellular plaque depositions (see section 3.1.3.2). Furthermore, memory deficits in 
these mouse models were analyzed and compared. In this part of the study only female 
mice were used. Young (3- to 4-month-old) and aged Tg4-42 (12-month-old) mice were 
compared with same-aged 5XFAD and wild-type mice. The aim of this study was to 
compare the behavior deficits and to elucidate the similarities and distinctions in 
expression profiles of these two AD mouse models. 
 
3.2.1 Amyloid beta accumulation in Tg4-42 and 5XFAD mice 
 
Transgene expression in Tg4-42 and 5XFAD mice was analyzed using 
immunohistochemistry. 
 
Immunohistochemical detection of Aβ, using the pan-Aβ antibody 2431-1, showed an 
abundant plaque-associated pathology in 3- and 12-month-old 5XFAD mice. Plaque 
FIGURE 3.15 Immunohistochemical staining of 5XFAD and Tg4-42 mice. (A-B) Immunostaining 
demonstrating A accumulation in cortex of 3 months old 5XFAD. (D-E) 12 months old 5XFAD 
mice exhibited more intensive cortical plaque staining. (C) Abundant intraneuronally Aβ staining 
in the CA1 of the hippocampus in 3 months old Tg4-42 mice. (F) Aβ immunostaining declined in 
12 months old Tg-42 mice. Antibody: (A-B) polyclonal antiserum 24311. Abbreviations: m = 




pathology increased with age (FIGURE 3.15 A-B vs. D-E). In contrast to 5XFAD mice, 
young Tg4-42 mice showed strong intracellular immunoreactivity predominantly in the 
CA1 region of the hippocampus (FIGURE 3.15 C). The CA1 Aβ expression declined 
during aging (FIGURE 3.15 F; section 3.1.3.2). 
 
3.2.2 Tg4-42 and 5XFAD mice display spatial memory deficits 
 
Spatial reference memory was assessed in three and twelve months old female Tg4-42, 
5XFAD and WT mice using the Morris water maze.  
To rule out effects from possible motor or sensory deficits and to familiarize with 
the pool mice performed three days of cued training with a marked platform. WT, Tg4-42 
and 5XFAD mice showed progressively decreased escape latencies at all ages tested and 
reached the goal platform after three consecutive training days in under 15 sec and 
therefore reached criteria (FIGURE 3.16). Furthermore, no overall differences in 
swimming speed could be detected between the genotypes (FIGURE 3.16, two-way 
repeated measures ANOVA, genotype: p = 0,1564). The cued training revealed that all 
mice had an intact vision and appropriate motor abilities to swim.  
Twenty-four hours after the cued training, mice were subjected to acquisition 
training in order to test their learning abilities to find the location of a submerged platform 
using distal and proximal cues. A significant main effect of genotype for escape latencies 
(two-way rrepeated measures ANOVA, genotype: p = 0.0414) was found. Young Tg4-42, 
5XFAD and WT mice showed a significant decrease in the escape latencies to reach the 
hidden platform (FIGURE 3.17 A, two-way repeated measures ANOVA, escape latency: p 
= 0.000011). Moreover, aged WT animals showed a significant decrease in the escape 
latencies while the escape latencies for aged Tg4-42 and 5XFAD did not improve over the 
five days of training (FIGURE 3.17 B, two-way repeated measures ANOVA, effect of 
genotype for escape latency: p = 0.0001). Aged 5XFAD mice performed significantly 
inferior to WT mice on day two, three, four and five of the acquisition training (t-test, 
escape latencies WT vs. 5XFAD: 2 day: p = 0,034007, 3 day: p = 0,037330, 4 day: p = 
0,003085, 5 day: p = 0,001532). Furthermore, aged Tg4-42 mice showed significantly 
longer escape latencies on day four and five (t-test, escape latencies WT vs. Tg4-42: 4 
day: p = 0,022892, 5 day: p = 0,007812). In contrast, the swimming speed across the five 
days of acquisition training showed no significant differences irrespective of genotype and 
age (FIGURE 3.17 A-B, two-way repeated measures ANOVA, p = 0.0566). Young Tg4-42 
and 5XFAD animals performed superior to older animals while this difference was not due 
to differences in swimming velocity due to age-related motor deficits. These results 




FIGURE 3.16 Cued training of the water maze reveals that Tg4-42 and 5XFAD exhibit intact 
eyesight and the motor abilities to perform the test. Female Tg4-42 and 5XFAD mice as well as 
WT littermate controls were examined at (A) 3 and (B) 12 months of age. All mice showed 
progressively shorter escape latencies in response to training and reached the criteria that allows 
continuation of the water maze. Swimming speed did not differ between genotypes at any tested 
time point (A-B). Escape latencies and swimming speed: two-way repeated measures ANOVA; n = 
8 - 11 per group; data presented as mean ± S.E.M.  
 
Twenty-four hours after the last acquisition trial, a probe trial was performed to 
assess spatial reference memory. Young Tg4-42, 5XFAD and WT mice displayed a 
significant preference for the target quadrant, as indicated by the percentage time spent in 
different quadrants of the pool (FIGURE 3.18, one-way ANOVA, WT: p < 0.001 target vs. 
all other quadrants; 5XFAD: p < 0.001 target vs. left and opposite quadrant, p < 0.01 
target vs. right quadrant; Tg4-42: p < 0.001 target vs. opposite quadrant, p < 0.01 target 
vs. right and left quadrant). No quadrant preference was found for aged Tg4-42 and 
5XFAD mice, while WT mice still demonstrated significant preference for the target 
quadrant at that time point (FIGURE 3.18, one-way ANOVA, WT: p < 0.001 target vs. left 
and opposite quadrant, p < 0.01 target vs. right quadrant). Aged 5XFAD mice showed a 
reduced swimming speed during the probe trial (one-way ANOVA, 5XFAD vs WT: p < 
0,05; 5XFAD vs Tg4-42: p < 0,01). The absence of a preference for the target quadrant as 
compared to the remaining quadrants during the probe trial demonstrates that aged Tg4-
42 and 5XFAD mice display a robust deficit in spatial reference memory.  
In summary, the results of the acquisition phase and the probe trial suggest that 





FIGURE 3.17 Spatial learning deficits in aged Tg4-42 and 5XFAD shown in the acquisition training 
of the Morris water maze. Female (A) 3- and (B) 12-month-old Tg4-42 mice, 5XFAD mice and WT 
littermate controls were tested. Animals tested underwent acquisition training to learn to use 
distal and proximal cues to navigate a direct path to a hidden platform. (A) Escape latencies of 
young mice decreased progressively over 5 days of training regardless of the genotype. 
Furthermore, (B) aged WT mice showed a progressive improvement in the escape latency over 
time. The escape latencies for aged Tg4-42 and 5XFAD did not improve over the five days of 
training. Swimming speed was not affected in all mice tested. Escape latency and swimming 
speed: two-way repeated measures ANOVA. **p < 0.01; *p < 0.05. n = 8 - 11 per group; data 


















FIGURE 3.18 Spatial reference memory deficits in aged Tg4-42 and 5XFAD mice shown in the 
probe trial of the Morris water maze. Female 3- and 12-month-old Tg4-42 mice, 5XFAD mice and 
WT littermate controls were tested. The probe trial was given at the end of learning phase 
(acquisition training) to assess spatial reference memory. Quadrant preference and swimming 
speed for the first 30s of the probe trial were analyzed. (A) Young Tg4-42, 5XFAD and WT mice 
showed no impairment in spatial reference memory. All groups spent a significant greater 
percentage of time in the target quadrant. (WT: p <0.001 T vs. all other quadrants; 5XFAD: p < 
0.001 T vs. L and O, p < 0.01 T vs. R; Tg4-42: p < 0.001 T vs. O, p < 0.01 T vs. R and L) The swimming 
speed did not differ between the groups. (B) Probe trial revealed a significant reduced learning 
behavior for aged Tg4-42 and 5XFAD mice as they showed no preference for the target quadrant. 
WT mice have no learning deficits at this age (WT: p < 0.001 T vs. L and O, p < 0.01 T vs. R). 5XFAD 
mice showed a reduced swimming speed during the probe trial. Abbreviations: T = target 
quadrant; L = left quadrant; R = right quadrant; O = opposite quadrant. Quadrant preference and 
swimming speed: One-way analysis of variance (ANOVA) followed by Bonferroni multiple 










3.2.3 Tg4-42 and 5XFAD mice exhibit decreased contextual learning 
 
During the initial training sessions involving a tone-foot-shock pairing (CS/US), 12-month-
old Tg4-42, 5XFAD and WT mice exhibited comparable degrees of freezing. When mice 
were tested for context fear conditioning 24 hours after the training trial, Tg4-42 and 
5XFAD mice demonstrated no significantly increased freezing behavior as a response to 
the conditioning chamber (FIGURE 3.9). In contrast, WT mice displayed significantly 
increased freezing (one-way ANOVA, p < 0.001) as a response to the context.  
Tg4-42 and 5XFAD mice jumped and vocalized in response to the electric foot-shock to a 
similar degree as WT mice, suggesting normal pain perception in the mutant mice strains. 
However, transgenic mice were not able to attribute the pain of the foot-shock during the 
training trial to the context. Therefore, Tg4-42 and 5XFAD show impaired contextual 
learning. 
FIGURE 3.19 Impaired contextual conditioning in Tg4-42 and 5XFAD mice. Aged 5XFAD, Tg4-42 
and WT mice were trained with a CS/US pairing for contextual fear conditioning. Mice were 
reintroduced to the original training context (CS) 24 hours post training and tested for contextual 
memory. Levels of freezing during the re-exposure were not different from the training trial for 
5XFAD and Tg4-42. In contrast, WT mice showed a significant increase on freezing response to the 
context. CS = conditioned stimulus. Freezing: paired t-test; ***p < 0.001. n=11-13 per group; data 
presented as mean ± S.E.M. 
 
3.2.4 5XFAD mice show impaired tone learning 
 
Twenty-four hours after the context testing (48 hours after training), the same mice were 
tested for conditioned fear of a tone. Therefore mice were reintroduced to the altered fear 
conditioning chamber. When the tone was presented without the foot-shock, both Tg4-42 




freezing increased significantly compared to the pre-tone period (one-way ANOVA, WT 
and Tg4-42: p < 0.001). However, 5XFAD mice demonstrated substantially less freezing 
behavior in response to the tone. 5XFAD mice did not associate the tone with the 
previously received foot-shock as freezing was not significantly different between the 
training and the tone trial. 
These results indicate that Tg4-42 mice exhibit a selective impairment of 
contextual fear learning, while their tone learning ability remains intact. 5XFAD mice on 
the other hand demonstrate both impaired contextual and tone fear learning.    
 
FIGURE 3.20 Impaired tone conditioning in 5XFAD mice Aged 5XFAD, Tg4-42 and WT mice at 12 
months of age were trained with a CS/US pairing for tone fear conditioning . Mice were placed in 
an altered fear conditioning chamber 48 hours post training and tested for freezing during tone 
presentation (CS). WT and Tg4-42 mice shock froze significantly more during tone presentation 
compared to the training trial. In contrast, 5XFAD mice did not associate the tone with the 
received foot-shock as freezing was not significantly different between the training and the tone 
trial. CS = conditioned stimulus, US = unconditioned stimulus. Freezing: paired t-test;                 













3.2.5 Deep sequencing of mouse brains 
 
In total, deep sequencing identified 15,711,910 and 16,143,760 sequence reads for young 
and old wild-type mice, respectively. For young wild-type mice, 6,230,197 reads (39.65 %) 
and for old wild-type mice, 5,512,056 reads (34.14 %) were mapped to exons. In young 
5XFAD mice, the read mapping revealed 8,570,239 (60.28 %) of 14,216,258 reads in 
exonic regions. Out of 18,288,161 reads, 9,163,060 (50.10 %) hit exons in old 5XFAD 
mice. The brain exome of young Tg4-42 mice was covered by 6,342,018 (47.28 %) out of 
13,414,301 reads. For old Tg4-42 mice, 12,488,206 reads were detected in total, of which 
4,976,552 (39.85 %) could be mapped to exons. The numbers of exonic reads are 
summarized in TABLE 3.1.  
 
 TABLE 3.1 Number of exonic reads in brain tissue of wild-type and transgenic mice 
Genotype Number of reads in exons 
young WT 6,230,197 
aged WT 5,512,056 
young 5XFAD 8,570,239 
aged 5XFAD 9,163,060 
young Tg4-42 6,342,018 
aged Tg4-42 4,976,552 
 
 
3.2.5.1 Deep sequencing (RNASeq) identified over-expressed transgenes 
 
5XFAD mice over-express human amyloid precursor protein (APP695) carrying the 
Swedish, London and Florida mutations as well as human presenilin-1 (PSEN-1) carrying 
the M146L/L286V mutations. Both peptides are expressed under the control of the 
neuronal Thy-1 promoter (Oakley et al., 2006). As expected, sequence reads pertaining to 
PSEN-1, APP and a Thy-1 promoter sequence (Moechars et al., 1996) were over-
represented in both young and aged 5XFAD brains (TABLE 3.2) and therefore served as 
a positive and internal control for RNA-Seq.   
In Tg4-42 mice a Thy-1 promoter sequence (Moechars et al., 1996) was found to 
be over-expressed in both young and aged mice (TABLE 3.2). Again, this was expected 
as Tg4-42 mice express human Aβ4-42 fused to the murine TRH signal peptide under the 





TABLE 3.2 Over-expressed transgenes in 5XFAD and Tg4-42 mice identified through RNASeq 
Genotype Gene name Log2 fold change Adjusted p-value 
young 5XFAD App 0.90 3.51E-02 
young 5XFAD Psen1 1.06 3.51E-02 
young 5XFAD Thy1 1.65 1.16E-08 
aged 5XFAD App 0.90 5.41E-03 
aged 5XFAD Psen1 1.40 2.29E-05 
aged 5XFAD Thy1 2.91 2.45E-30 
young Tg4-42 Thy1 1.58 3.02E-08 
aged Tg4-42 Thy1 2.00 2.28E-14 
 
 
3.2.5.2 Differentially regulated genes in Tg4-42 and 5XFAD mice 
 
The total number of differentially regulated genes (DEG) in each mouse model is listed in 
TABLE 3.3 (excluding transgenes). Aged 5XFAD demonstrated the highest number of 
DEG followed by aged Tg4-42 and young 5XFAD. In contrast young Tg4-42 mice showed 
- except of the promoter sequence (section 3.2.5.1) - no genes that were significantly 
changed.  
 
TABLE 3.3 Number of DEGs in 5XFAD and Tg4-42 
Genotype Number of up-regulated genes Number of down-regulated genes 
young 5XFAD 13 6 
young Tg4-42 - - 
aged 5XFAD 62 69 
aged Tg4-42 49 7 
 
In order to demonstrate the expression changes volcano plots were created (FIGURE 
3.21). Each dot represents one gene that is significantly differentially regulated when 
compared to same-aged WT mice. Red dots demonstrate down-regulated genes while 









FIGURE 3.21 Volcano plots of the significant gene expression changes in Tg4-42 and 5XFAD 
mice. Fold changes in gene expression of (A) young 5XFAD, (B) aged 5XFAD and (C) aged Tg4-42 
mice. Each dot represents one gene. Dashed lines illustrate statistical significance (p = 0.05). Red: 
down-regulated; green: up-regulated. 
 
 
3.2.5.3 Gene expression in young Tg4-42 and 5XFAD mice 
 
Nineteen genes were identified as significantly differentially expressed between young 
5XFAD and age-matched WT mice. Thirteen genes were up-regulated, while six genes 
were down-regulated (FIGURE 3.21 A). DEGs encoded proteins from diverse functional 




and hydrolases (TABLE 3.4). In contrast, no differentially expressed genes could be 
detected in young Tg4-42 mice. 
 
3.2.5.4 Gene expression in aged Tg4-42 mice 
 
Fifty-six genes were differentially expressed in aged Tg4-42 mice. Seven genes were up-
regulated and 49 down-regulated (FIGURE 3.21 C). Twenty genes were solely 
differentially expressed in aged Tg4-42 (TABLE 3.5), among these only three genes were 
found to be up-regulated (Uqcc2, Beta-S and Kif1a). The 17 genes that were significantly 
down-regulated are involved in diverse biological processes including regulation of gene 
expression, nervous system development, cell communication, metal ion transport, 
neurogenesis and regulation of synaptic plasticity.  
 
3.2.5.5 Gene expression in aged 5XFAD mice 
 
In aged 5XFAD mice 131 genes with significant expression changes were identified. While 
62 genes were up-regulated, 69 genes were down-regulated (FIGURE 3.21 B). 87 of the 
genes were only found to be altered in aged 5XFAD mice (TABLE 3.7), while 36 showed 
an overlap with aged Tg4-42 mice (TABLE 3.6) and eight were also differentially 
expressed in young 5XFAD mice (FIGURE 3.22).  
According to the Gene Ontology (GO) annotation a notable group DEGs is 
involved in immune system processes and inflammation. These include, among others, 
innate immune response and adaptive immune response, immune effector processes, 
activation and regulation of immune response as well as immune system development. 
Furthermore, DEGs were also involved in cell communication and system development, 
signal transduction, synaptic transmission as well as regulation of gene expression and 
transcription.  
 
3.2.5.6 Genes similarly expressed in both aged Tg4-42 and 5XFAD mice 
 
Of the 56 DEGs in aged Tg4-42 mice, 36 were also found to be differentially expressed in 
aged 5XFAD mice (TABLE 3.6, FIGURE 3.22). Of these 36 genes four were up-regulated 
and 32 were down-regulated in aged Tg4-42 and 5XFAD mice and most showed similar 
expression levels in the two models.  
The biggest differences between aged Tg4-42 and 5XFAD could be detected in 
the expression of Gfap and Xist. The intermediate filament protein GFAP encoding gene 
was found to be four times higher over-expressed in 5XFAD compared to Tg4-42. The 




5XFAD mice. Apart from Gfap, Calmodulin 3, Fbxo2 and Gpm6a were also up-regulated 
in both aged mouse lines. The functional annotation of the jointly down-regulated genes 
includes the following GO (Ashburner et al., 2000) categories: regulation of cell 
differentiation and anatomical structure development, regulation of gene expression and 
transcription, histone modification, ion binding and protein methyltransferase activity, 
nervous system development and neurogenesis.  
Two genes were similarly down-regulated in aged Tg4-42 and 5XFAD but also 
young 5XFAD animals (FIGURE 3.22). First, Ubqln2 which encodes a member of the 
ubiquilin family (Ubiquilin 2) that is involved in the protein degrading pathway as it 
regulates the degradation of ubiquitinated proteins (Ko et al., 2004). Second, the RNA 
binding protein neuro-oncological ventral antigen 2 encoding gene (Nova2). 
 
FIGURE 3.22 Venn diagram analysis for significantly regulated genes in Tg4-42 mice compared to 
5XFAD mice. The numbers outside each circle represent the number of genes that were 
significantly differentially expressed in the respective mouse line (compared to WT mice). The 
numbers in the spaces of overlapping circles represent the number of genes that were affected in 
more than one condition. p < 0.05. 
 
3.2.5.7 Genes similarly expressed in both young and aged 5XFAD mice 
 
Eight genes were found to be differentially expressed in both young and aged 5XFAD 
mice (FIGURE 3.22). Of these genes four were up-regulated and four down-regulated. 
The up-regulated genes are the ribosomal protein Rpl21, Aldolase A, Snora68 and the 






3.2.5.8 Validation of differentially expressed genes identified by RNA-Seq 
using qRT-PCR 
 
Deep sequencing results were validated through qRT-PCR analysis. 
FIGURE 3.23 Validation of deep sequencing results through quantitative real-time polymerase 
chain reaction (qRT-PCR) analysis. To confirm the deep-sequencing data qRT-PCR experiments for 
various genes were performed on (A) young 5XFAD, (B) aged 5XFAD and (C) aged Tg4-42 mice. 
Expression levels of were compared to age-matched WT animals (dashed red line represents WT 
standard). Normalization was performed against the housekeeping gene β-Actin. ***p < 0.001; 




The quality of the isolated RNA is crucial for obtaining reliable qRT-PCR results. 
Therefore, the quality of the RNA samples isolated from the mice brains was evaluated by 
assessing the integrity and purity of the RNA. All samples displayed A260/A230 ratios 
greater than 1.8 and A260/A280 ratios higher than 2.0 (data not shown) indicating an 
acceptable RNA purity.  
Genes with more than 200 reads were successfully verified by real-time 
quantitative PCR and are listed in the following tables: TABLE 3.4, TABLE 3.5, TABLE 3.6 
and TABLE 3.7 . Genes with an expression level lower than 200 reads are not shown. For 
young 5XFAD (FIGURE 3.23 A), aged 5XFAD (FIGURE 3.23 B) and Tg4-42 (FIGURE 
3.23 C) mice at least seven DEGs were randomly selected and validated using qRT-PCR. 
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 actin binding 
 cytoskeletal protein binding 







MGI:2148181 Snora68 small nucleolar RNA, H/ACA 
box 68 
 non-coding RNA 
 uridine modifications 
 
1.60 7.99E-07 
MGI:105110 Rps2  ribosomal protein S2  mRNA binding 
 fibroblast growth factor 
binding 




MGI:96412 Ide insulin degrading enzyme  insulysin activity 
 metalloendopeptidase 
activity 
 protein homodimerization 
activity 
 hydrolase activity 
 beta-amyloid binding 
 glycoprotein binding 
 ATP binding 
 zinc ion binding 
 ubiquitin binding 
 
1.22 2.92E-03 
MGI:1353472 Rpl7a ribosomal protein L7a  RNA binding 




MGI:98865 Ttr transthyretin  hormone activity 
 protein heterodimerization 
activity 
 retinol binding 
 
1.18 6.09E-04 
MGI:1340062 Sgk1 serum/glucocorticoid regulated 
kinase 1 
 kinase activity 
 potassium / calcium 
channel regulator activity 
 ATP binding 




MGI:1278340 Rpl21 ribosomal protein L21  structural constituent of 
ribosome 
 RNA binding 
 
1.12 3.65E-02 
MGI:108415 Pafah1b2 platelet-activating factor 
acetylhydrolase, isoform 1b, 
subunit 2 
 hydrolase activity 
 1-alkyl-2 acetylglycero- 
phosphocholine esterase 
activity 
 homodimerization activity 
 
1.09 5.67E-03 
MGI:99845 Gdi2 guanosine diphosphate (GDP) 
dissociation inhibitor 2 
 Rab GDP-dissociation 
inhibitor activity 




MGI:1934664 Rpph1 ribonuclease P RNA 
component H1 
 endoribonuclease activity 
 
0.90 3.51E-02 
MGI:97783 Psap prosaposin  glycoprotein 
 lipid binding 
 enzyme activator activity 
 
0.90 3.51E-02 
MGI:97591 Pkm pyruvate kinase, muscle  magnesium ion binding 
 ATP binding 
 potassium ion binding 






MGI:108391 Kif1a kinesin family member 1A  ATP binding 
 phospholipid binding 
 motor activity  





Atp1a2 ATPase, Na+/K+ transporting, 




 ATP binding 
 metal ion binding 
 hydrolase activity 
 
-0.90 3.51E-02 
MGI:1860283 Ubqln2 ubiquilin 2  protein binding 
 cell death 
 
-1.07 2.82E-02 
MGI:1313261 Spnb3 spectrin beta, non-erythrocytic 
2 
 phospholipid binding 
 actin binding 













































GO Biological Process 












reductase complex assembly 
factor 2 
 
 regulation of insulin 
secretion 








hemoglobin, beta adult s chain 
 
 iron ion binding 
 oxygen binding 
 
1.14 1.31E-02 
MGI:108391 Kif1a kinesin family member 1A  microtubule motor activity 
 ATP binding 
 
0.90 1.77E-02 
MGI:2153272 Trrap transformation/transcription 
domain-associated protein 
 
 phosphotransferase activity 
 regulation of transcription 
 
-0.86 4.74E-02 
MGI:1194504 Kcnj10 ATP-sensitive inward rectifier 
potassium channel 10 
 
 potassium channel activity 




lemur tyrosine kinase 3 
 
 
 protein tyrosine kinase 
activity 
-0.94 3.98E-02 







 neuropeptide hormone 
activity 
 synaptic plasticity 
 neurosecretory protein 
(Jahn et al., 2011) 
 regulation of energy 
balance (Jahn et al. 2011) 
 important for modulating 






zinc finger MIZ domain-
containing protein 2 
 
 
 zinc ion binding 




MGI:1194488 Slc32a1 Vesicular inhibitory amino acid 
transporter 
solute carrier family 32 (GABA 
vesicular transporter), member 
1 
 
 glycine transporter activity 
 amino acid-polyamine 
transporter activity 
 neurotransmitter transport 
-1.02 3.76E-02 
MGI:1277171 Dcx doublecortin  microtubule binding 








 regulation of transcription 
 RNA binding and telomeric 
DNA binding 
-1.04 1.99E-02 
MGI:109591 Nfic nuclear factor I/C 
 
 
 transcription factor activity 
 DNA binding 
-1.10 1.90E-02 
MGI:2441726 BC005537 cDNA sequence BC005537 
 
 unknown -1.11 9.46E-03 
















Cyclin-dependent kinase 5 
activator 2 (p39) 
 ipid binding 
 cyclin-dependent protein 
kinase 5 










RIKEN cDNA 2900060B14 
gene 




synapsin III  catalytic activity 











virus type I enhancer binding 
protein 3 
 DNA binding 
 zinc ion binding 
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 ion channel binding 
 calcium ion binding 
 G-protein coupled receptor 












F-box protein 2  ubiquitin-protein ligase 
activity 
 glycoprotein binding 
 beta-amyloid binding 
 carbohydrate binding 
 






 calcium channel activity 
 involved in neuronal 
differentiation 
 role in neuronal plasticity 
 
0.90 1.77E-02 0.90 5.39E-03 
MGI:95697 Gfap 
 
glial fibrillary acidic protein  integrin binding 
 kinase binding 
 structural constituent of 
cytoskeleton 
 
0.88 3.76E-02 3.64 2.36E-42 
MGI:1860283 Ubqln2 ubiquilin 2  ubiquitin-binding 
 protein modification 
 proteolysis 
 
-0.92 4.35E-02 -1.27 8.71E-05 
MGI:97495 Pbx1 pre-B-cell leukemia 
transcription factor 1 / pre B 
cell leukemia homeobox 1 
 transcription factor activity  
 protein heterodimerization 
activity 
 involved in the regulation of 
osteogenesis 




-0.92 3.79E-02 -0.86 2.85E-02 
MGI:3647820 Gm15800 
 
predicted gene 15800  ubiquitin-protein ligase 
activity 
 
-0.96 1.04E-02 -0.83 1.84E-02 
MGI:96669 Kcnc3 potassium voltage gated 
channel, shaw-related 
subfamily, member 3 
 voltage-gated potassium 
channel activity 
 delayed rectifier potassium 
channel activity 
 
-0.99 3.47E-02 -1.04 6.53E-03 
MGI:96828 Lrp1 low density lipoprotein 
receptor-related protein 1 
 endocytic receptor or 
receptor activity 
 lipoprotein binding 
 calcium ion binding 
 apolipoprotein binding 
 beta-amyloid clearance 
 apoptotic cell clearance 
 
-1.00 5.80E-03 -0.83 1.77E-02 
MGI:2183691 Nav2 neuron navigator 2  heparin binding 
 helicase activity 
 ATP binding 
 role in neuronal 
development 
 
-1.04 1.29E-02 -0.89 2.33E-02 
MGI:1890563 Wasf1 
 
WAS protein family, member 1  actin binding 
 





 calcium ion binding 
 zinc ion binding 
 chromatin binding 
 histone methyltransferase 
activity  
 regulation of transcription  
 
-1.05 4.97E-03 -0.81 3.37E-02 
MGI:2446229 Tet3 tet methylcytosine  methylcytosine 
dioxygenase activity 




 dioxygenase 3  oxidoreductase activity 
 metal ion binding 





zinc finger homeobox 3  GTP binding 
 sequence-specific DNA 
binding transcription factor 
activity 
 zinc ion binding 
 
-1.06 3.98E-02 -1.12 7.24E-03 
MGI:1347464 Foxg1 
 
forkhead box G1  sequence-specific DNA 
binding 
 negative regulation of 
neuron differentiation 
 regulation of transcription  
 brain development 
 forebrain marker (Yahata et 
al.  2011) 
 
-1.06 4.30E-02 -1.11 9.22E-03 
MGI:1919847 Auts2 
 
autism susceptibility candidate 
2 
 
 unknown -1.07 2.00E-02 -1.05 7.45E-03 
MGI:1915467 Prrc2a proline-rich coiled-coil 2A  unknown 
 
-1.07 4.33E-03 -0.85 2.24E-02 
MGI:1917685 Inf2 
 
inverted formin, FH2 and WH2 
domain containing 
 Rho GTPase binding 
 actin binding 
 
-1.07 7.70E-03 -0.87 2.60E-02 
MGI:2158663 Inpp5j inositol polyphosphate 5-
phosphatase J 
 SH3 domain binding 
 hydrolase activity 
 phosphatase activity 
 






 histone methyltransferase 
 
-1.12 1.90E-03 -1.05 1.48E-03 
MGI:3026647 Flrt1 
 
fibronectin leucine rich 
transmembrane protein 1 
 receptor signaling protein 
activity 
 
-1.18 1.53E-02 -1.25 1.89E-03 
MGI:1888520 Brd4 
 





 mRNA binding 
 promotes alternative 
splicing and inclusion of 
neural-specific exons in 
target mRNAs 
 
-1.22 2.43E-02 -1.25 6.20E-03 
MGI:1926106 Fam163b 
 
family with sequence similarity 
163, member B 
 
 unknown -1.27 9.85E-03 -1.60 2.91E-05 
MGI:2685951 Myo16 
 
myosin XVI  motor activity 
 ATP binding 
 protein phosphatase 
binding 
 
-1.27 1.57E-03 -1.09 4.62E-03 
MGI:1923304 Prrc2b 
 





 C2H2 zinc finger domain 
binding 
 RNA binding 
 involved in pre-mRNA 
splicing 
 
-1.33 8.92E-06 -1.04 7.25E-04 
MGI:1337080 Ncor2 
 
nuclear receptor co-repressor 
2 
 chromatin binding 
 regulation of transcription  
 transcription corepressor 
activity 
 Notch binding 
 





 structural molecule activity 
 microtubule assembly 
 perception of sound 
 






atrophin 1  toxin receptor binding 
 transcription corepressor 
activity 
 








 RNA binding -1.49 4.27E-05 -1.64 7.71E-07 
MGI:3613677 Shank1 
 
SH3 and multiple ankyrin 
Repeat Domains 1 
 SH3 domain binding 
 identical protein binding 
 synapse maturation 
 
-1.57 9.26E-08 -1.53 7.43E-08 
MGI:2679002 Prr12 
 
proline rich 12  DNA binding -1.59 3.68E-04 -1.68 2.80E-05 
MGI:2143886 Dot1l 
 
DOT1-like histone H3 
methyltransferase 
 transcription factor binding 













 ATP binding 
 metal ion binding 
 hydrolase activity 
 
-1.73 1.31E-10 -1.90 1.70E-13 
































GO Biological Process 
















 endopeptidase inhibitor 
activity 
 Inflammatory response 
 complement activation 





MGI:88225 C1qc complement component 1. q 
subcomponent. C chain 
 complement activation 








 phosphate transport 
 complement activation 
 immune response 
 
2.99 1.31E-24 




 cysteine-type peptidase 
activity 
 hydrolase activity 
 proteolysis 
 immune response 
2.75 5.00E-21 
MGI:88224 C1qb complement component 1. q 
subcomponent. beta 
polypeptide 
 phosphate transport 
 complement activation 
 immune response 
 
2.72 2.22E-19 
MGI:1891190 Ctsz cathepsin Z 
 
 
 cysteine-type peptidase 
activity 
 hydrolase activity 
2.49 1.01E-15 




 structural constituent of 
cytoskeleton 
 identical protein binding 
 apoptotic process 
2.27 8.36E-13 
MGI:96074 Hexb hexosaminidase B  cation binding 









MGI:88562 Ctsd cathepsin D  aspartic-type 
endopeptidase activity 
 hydrolase activity 
 
2.13 1.66E-16 
MGI:2148181 Snora68 small nucleolar RNA. H/ACA 
box 68 
 non-coding RNA 
 uridine modifications 
 
2.11 4.37E-14 




 actin binding 
 fructose-bisphosphate 
aldolase activity 
 cytoskeletal protein binding 








 MHC class I receptor 
activity 
 cellular defense response 
 innate immune response 
1.86 5.03E-10 
MGI:108046 Laptm5 lysosomal-associated protein 
transmembrane 5 
 






















 chemokine receptor activity 
 G-protein coupled receptor 
activity 
 transmembrane protein 
 signal transduction 
1.66 9.43E-07 
MGI:99554 Lgals3bp lectin. galactoside-binding. 
soluble. 3 binding protein 
 
 
 scavenger receptor activity 
 isomerase activity 
 cellular defense response 




RIKEN cDNA 4632428N05 
gene 
 
 receptor activity 1.63 1.48E-06 
MGI:96614 Itgb5 integrin beta 5 
 
 
 integrin binding 
 receptor activity 
 cell adhesion 
 
1.56 1.05E-06 
MGI:1914877 Olfml3 olfactomedin-like 3 
 












 protein heterodimerization 
activity 
 hydrolase activity 
1.51 3.85E-06 







stimulating factor receptor 
activity 
 protein homodimerization 
activity 
 ATP binding 
 immune response 
1.45 1.58E-06 
MGI:107387 Aqp4 aquaporin 4 
 
 
 porin activity  
 water transmembrane 
transporter activity 
1.42 8.90E-07 
MGI:1918089 P2ry12 purinergic receptor P2Y.  




 ADP receptor activity 
 guanyl-nucleotide 
exchange factor activity 
 G-protein coupled 
adenosine receptor activity 
 signal transducer activity 
1.40 2.68E-04 
MGI:1278340 Rpl21 ribosomal protein L21  structural constituent of 
ribosome 
 RNA binding 
 
1.37 2.20E-04 
MGI:107286 Man2b1 mannosidase 2. alpha B1 
 
 
 carbohydrate binding 
 alpha-mannosidase activity 
 hydrolase activity 
 
1.35 4.77E-05 
MGI:1096881 Eef1a1 eukaryotic translation 
elongation factor 1 alpha 1 
 
 
 GTPase activity 
 translation elongation 
factor activity 
 regulation of transcription 
1.32 6.22E-06 
MGI:1915213 Npc2 Niemann Pick type C2  cholesterol binding 
 enzyme binding 
 
1.27 1.20E-03 




 cysteine-type peptidase 
activity 
 hydrolase activity  
 immune response 
 
1.25 1.21E-05 




 cysteine-type peptidase 
activity 
 hydrolase activity  
 histone binding 







MGI:1934664 Rpph1 ribonuclease P RNA 
component H1 
 
 endoribonuclease activity 
 
1.23 1.21E-05 
MGI:1920174 Anln anillin 
 
 
 actin binding 
 phospholipid binding 
 
1.22 1.53E-03 
MGI:95832 Grn granulin 
 
 
 growth factor activity 
 cytokine activity 
 signal transduction 
1.21 1.00E-03 
MGI:98729 Tgfbr2 transforming growth factor. 






 ATP binding 
 transmembrane receptor 
protein serine/threonine 
kinase activity 
 transferase activity 
 receptor activity 
 SMAD binding 
 signal transduction 
1.18 4.94E-03 





 glutathione peroxidase 
activity 
 oxidoreductase activity 
 antioxidant activity 
 response to oxidative 
stress 
1.17 2.21E-04 







exchange factor activity 
 calcium ion binding 
 receptor signaling protein 
activity 
 hydrolase activity 
 signal transducer activity 
 
1.15 5.42E-03 





 SH3 domain binding 
 PTB domain binding 
 hydrolase activity 
 signal transducer activity 
 immune Response 
1.14 1.96E-02 







 peptidase activity 
 immune Response 
 hydrolase activity 
1.07 1.82E-03 
MGI:1917329 Golm1 golgi membrane protein 1 
 
 
 protein modification 
 nucleus organization 
1.03 2.85E-02 





 heparin binding 
 heparan sulfate 
proteoglycan binding 
 complement activation 
 immune response 
1.02 4.65E-02 
MGI:95640 Gapdh glyceraldehyde-3-phosphate 
dehydrogenase 
 
 microtubule binding  
 NADP Binding 
1.01 3.07E-03 




 structural constituent of 
ribosome 
 RNA binding 
 translation regulator activity 
1.01 1.59E-02 




 organic cyclic compound 
binding  
 hormone binding 






MGI:97591 Pkm pyruvate kinase. muscle 
 
 
 magnesium ion binding 
 pyruvate kinase activity 
 ATP Binding 
1.00 1.56E-03 





 ATPase activity 
 ubiquitin protein ligase 
binding 
 misfolded protein binding 
 immune response 
0.96 2.50E-03 





 protein-arginine deiminase 
activity 
 calcium ion binding 
 hydrolase activity 
 immune response 
0.95 4.86E-02 






 structural molecule activity 
 GTPase Activity 
 double-stranded RNA 
binding 
 structural constituent of 
cytoskeleton 
 unfolded protein binding 
0.93 2.03E-02 
MGI:2445114 Pisd phosphatidylserine 
decarboxylase 
 
 lyase activity 0.93 1.94E-02 
MGI:96247 Hsp90ab1 heat shock protein 90 alpha 






 unfolded protein binding 
 GTP binding 
 ATP binding 
 double-stranded RNA 
binding 
 ion channel binding 
 immune response 
 negative regulation of 
neuron apoptotic process 
0.90 6.13E-03 
MGI:1925017 Ermn ermin. ERM-like protein  actin filament binding 
 
0.90 3.02E-02 
MGI:105959 Cox8a cytochrome c oxidase subunit 
VIIIa 
 




MGI:96748 Lamp2 lysosomal-associated 
membrane protein 2 
 
 
 membrane glycoprotein 
 TRNA ligase activity 
 ATP binding 
 hemostasis 
0.88 2.94E-02 




 enzyme activator activity 
 serine-type 
carboxypeptidase activity 
 hydrolase activity 
0.86 3.15E-02 
MGI:103099 Cox6a1 cytochrome c oxidase subunit 
VIa polypeptide 1 
 
 cytochrome-c oxidase 
activity 
0.85 2.02E-02 
MGI:1346074 Fxr2 fragile X mental retardation. 
autosomal homolog 2 
 
 RNA binding 
 identical protein binding 
0.84 3.11E-02 
MGI:99607 Abca1 ATP-binding cassette. sub-
family A (ABC1). member 1 
 
 
 apolipoprotein binding 
 phospholipid binding 
 cholesterol binding 
 ATP binding 
0.82 4.37E-02 





 iron ion binding  
 calcium ion binding 
 hormone binding 
 mRNA binding 
 regulation of transcription 
 signal transduction 












 transporter activity 
 calcium ion binding 
 cholesterol binding 
 syntaxin-1 binding 
 SH2 domain binding 
 synaptic vesicle maturation 
 synaptic transmission 
0.79 2.74E-02 




 extracellular matrix binding 
 calcium ion binding 
 signal transduction 
 hemostasis 
0.78 4.37E-02 




 MHC class II protein 
complex binding 
 regulation of immune 
response 
0.77 4.93E-02 
MGI:1915347 Dynll2 dynein light chain LC8-type 2 
 
 
 cytoskeletal protein binding 
 motor activity 
-0.86 2.10E-02 
MGI:1277955 Bsn bassoon 
 
 
 metal ion binding 
 Synaptic Transmission 
-0.87 1.10E-02 
MGI:3648294 Tnrc18 trinucleotide repeat containing 
18 
 
 DNA binding 
 
-0.87 3.34E-02 
MGI:2145310 Rnf44 ring finger protein 44 
 
 zinc ion binding -0.89 3.49E-02 




 zinc ion binding 
 DNA binding 
 transcription factor  
-0.90 2.82E-02 





 cell adhesion molecule 
binding 
 calcium channel regulator 
activity 
 metal Ion Binding 
 synaptic Transmission 
-0.90 1.19E-02 





Atp1a2 ATPase. Na+/K+ transporting. 




 metal ion binding 
 hydrolase activity 
 ATP binding 
 
-0.90 5.39E-03 
MGI:96667 Kcnc1 potassium voltage gated 
channel. Shaw-related 
subfamily. member 1 
 
 
 rectifier potassium channel 
activity 
 voltage-gated ion channel 
activity 









 transcription regulation 
 cell differentiation 
 DNA binding 
 Mg-ion binding 
-0.94 3.02E-02 
MGI:106190 Bcl11a B cell CLL/lymphoma 11A 
(zinc finger protein) 
 
 B cell differentiation 
 T cell differentiation 
 regulation of transcription 
-0.96 3.73E-02 
MGI:1321395 Ltbp4 latent transforming growth 
factor beta binding protein 4 
 
 
 growth factor binding 
 hormone secretion 







MGI:2176606 Scrt1 scratch homolog 1. zinc finger 
protein  
 
 transcription regulation -0.96 2.09E-02 
MGI:1925589 Ttyh3 tweety homolog 3 
 
 
 chloride channel activity 
 transmembrane transport 
-0.96 7.91E-03 
MGI:2444218 Ahdc1 AT hook. DNA binding motif. 
containing 1 
 
 DNA binding -0.97 1.84E-02 
MGI:98460 Syn1 synapsin I 
 
 Neurotransmitter secretion 
 Synaptic vesicle transport 
 
-0.98 3.98E-03 
MGI:95617 Gabra5 gamma-aminobutyric acid 
(GABA) A receptor. subunit 
alpha 5 
 
 GABA- receptor 
 chloride transport 




MGI:2143099 AI593442 expressed sequence 
AI593442 
 
 unclassified -1.00 4.30E-03 
MGI:1346031 Tshz1 teashirt zinc finger family 
member 1 
 
 transcription factor 





RIKEN cDNA C530008M17 
gene 
 
 unknown -1.00 2.26E-02 
MGI:2441680 Tmem8b transmembrane protein 8B 
 
 
 cell cycle regulation 
 cell matrix adhesion 
-1.00 2.27E-02 
MGI:109169 Epas1 endothelial PAS domain 
protein 1 
 
 regulation of transcription 
 angiogenesis 
 transcription 
 signal transduction 
 cellular stress response 
 
-1.01 6.32E-03 
MGI:1351323 Snord33 small nucleolar RNA. C/D box 
33 
 







Stxbp1 syntaxin binding protein 1 
 
 release of 
neurotransmitters via 
syntaxin regulation 
 vesicle transport 
 exocytosis 







Sdk2 sidekick homolog 2  
 
 chemotaxis 
 protein targeting 





Tmem158 transmembrane protein 158 
 





Fosl2 fos-like antigen 2 
 
 regulation of transcription 
 cell regulation 
 fibroblasten proliferation 
-1.10 1.07E-02 




 DNA binding 









MGI:96434 Igf2 insulin-like growth factor 2  hormone activity 
 growth factor activity 
 cell proliferation 
 regulation of cell cycle 
 protein Metabolism 
 hemostasis 





RIKEN cDNA 9530091C08 
gene 




MGI:1313277 Vamp2 vesicle-associated membrane 
protein 2 
 
 vesicle mediate transport 
 synaptic vesicle exocytosis 




MGI:1890616 Scube1 signal peptide. CUB domain. 
EGF-like 1 
 inflammatory response 




MGI:2444210 Nr1d1 nuclear receptor subfamily 1. 
group D. member 1 
 transcription factor 
 insulin secretion 
 metabolic processes 
 inflammatory processes 
 
-1.23 6.34E-04 
MGI:2444521 Rnf165 ring finger protein 165  zinc ion binding 
 
-1.25 1.05E-02 
MGI:1351339 Grm2 glutamate receptor. 
metabotropic 2 
 synaptic transmission  
 glutamate secretion 
 
-1.27 2.12E-03 
MGI:102703 Gng4 guanine nucleotide binding 
protein (G protein). gamma 4 
 signal transduction 
 GTPase activity 
 hemostasis 
 synaptic transmission 
 glucagon response 
 transmembrane transport 





Egr1 early growth response 1 
 
 transcriptional regulator 
 immune response 









4.1 Project 1: Characterization of the Tg4-42 mouse model 
 
Aβ4-42 is one of the major Aβ isoforms in the AD brain. However, little is known about its 
contribution to the etiology of AD. The main objective of the first part of the thesis was to 
investigate the consequences of Aβ4-42 in vivo by examining Tg4-42 mice expressing   
Aβ4-42. 
Next to Aβ starting with aspartate as the first amino acid, a variety of modified and 
N-truncated Aβ variants have been characterized (Kummer and Heneka, 2014).              
N-truncated Aβ can be found plaque-associated as well as intraneuronal (Gouras et al., 
2000). Aβ4-42 has first been discovered in 1985 by Masters et al. They demonstrated that 
64 % of Aβ peptides started with a Phe-4 residue in plaque cores of two sporadic AD 
cases (Masters et al., 1985). Later it could be shown that Aβ4-42 is relatively prevalent in 
AD, vascular dementia patients and aged controls (Lewis et al., 2006). While the exact 
amount of Aβ4-42 is not clear, a recent study, using immunoprecipitation and mass 
spectroscopy, could show that Aβ4-42 is one of the major fractions in the cortex and 
hippocampus of AD patients (Portelius et al., 2010). Moreover, Aβ4-42 has also been 
identified in amyloid deposits from familial Danish dementia and vascular dementia 
patients (Tomidokoro et al., 2005; Lewis et al., 2006). To date, it is not fully understood 
whether N-truncated Aβ4-x is derived from full-length Aβ1-42 or directly from APP. It is 
proposed that the degrading enzyme neprilysin is responsible for the cleavage of Aβ1-42 
and the generation of Aβ4-42 (Howell et al., 1995; Iwata et al., 2001; Carson and Turner, 
2002). 
Pike et al. (1995b) showed that N-terminal deletions enhance aggregation and 
toxicity of Aβ. Peptides with N-terminal deletions including Aβ4-42 showed in comparison to 
full-length Aβ enhanced peptide aggregation into neurotoxic, β-sheet fibrils. Moreover, is 
has been demonstrated that the N-terminus specifies the fibrillization behavior (Haupt et 
al., 2012). In addition, it has also been reported that pyroglutamate Aβ is more toxic than 




N-truncated Aβ variants Aβ4-38, Aβ4-40, Aβ4-42 and AβpE3-42 rapidly form stable aggregates 
similar to Aβ1-42 under reducing conditions. All peptides displayed dimeric oligomers and 
monomers, while Aβ1-42, AβpE3-42 and Aβ4-42 also developed SDS-stable tri- or tetrameric 
oligomers. Moreover, aged Aβ1-42, AβpE3-42 and Aβ4-42 peptides retained this pattern and 
exhibited in addition higher molecular weight aggregates. In line with these observations, 
we could recently show that Aβ4-42, AβpE3-42 and Aβ1-42 are unstructured in the monomeric 
state and have a high propensity to form folded structures upon heating. Using NMR 
spectroscopy, far-UV CD spectroscopy and dynamic light scattering, we demonstrated 
that Aβ4-42 and AβpE3–42 have a higher tendency to form stable aggregates than Aβ1–42 
(Bouter et al., 2013). The observation that Aβ4–42 and AβpE3–42 have a more pronounced 
tendency to form aggregates than the N-terminally intact Aβ1–42 indicate that Aβ4–42 and 
AβpE3–42 aggregation may precede Aβ1–42 aggregation in vivo.  
There is increasing evidence, that N-truncated Aβ variants, like Aβ4-42, may 
contribute to the AD pathology (Jawhar et al., 2011; Bouter et al., 2013). The removal of 
the first three amino acids increases Aβ hydrophobicity of the N-terminal Aβ part and may 
influence its toxicity. We could lately demonstrate through short-term treatment of primary 
cortical neurons, that Aβ4-42 is as toxic as AβpE3-42 and Aβ1-42. Furthermore, treatment of 
wild-type mice using intraventricular Aβ injection with Aβ4-42 induced significant working 
memory deficits. These deficits were similar to the ones induced through AβpE3-42 and   
Aβ1-42 (Bouter et al., 2013). 
 
4.1.1 Aβ4-x precedes AβpE3-x accumulation in 5XFAD mice  
 
Next to human AD patients N-terminal truncated and modified Aβ variants have also been 
observed in several AD mouse models. In APP/PS1KI mice a variety of N-truncated Aβ 
peptides have been described. Applying two dimensional gel electrophoresis in 
combination with mass spectroscopy a complex pattern of N-truncated variants, including 
Aβ4/5-42, Aβ8/9/10/11-42 and Aβ2/3-42, were detected starting at 2.5 months of age. Moreover, 
pyroGlu-modified Aβ3-x could be shown at 6 months and increased with age (Casas et al., 
2004). Pyroglutamate Aβ peptides are a highly abundant N-truncated Aβ species in the 
brain of AD patients and have been detected in several other AD mouse models next to 
APP/PS1KI (Hartig et al., 2010; Jawhar et al., 2011; Frost et al., 2013). Harigaya et al. 
(2000) reported that 25 % of the total Aβx-42 in AD plaques consisted of AβpE3–42.  
As stated before, N-truncated Aβ variants show a higher toxicity compared to full-
length Aβ. To further analyze the in vivo toxicity of pyroglutamate Aβ several mouse 
models over-expressing Aβ3-42 were generated. TBA2.1 is an example for a mouse model 




position of Aβ. The alteration promotes the spontaneous and enzymatic catalyzed 
formation of  AβpE3-42. TBA2.1 mice exhibit abundant intracellular AβpE3-42 and neuron loss 
in AβpE3-42 accumulating neurons (Wirths et al., 2009; Alexandru et al., 2011). Using mass 
spectrometric analysis, high amounts of AβpE3-42 were detected in the widely used 5XFAD 
mouse model (Wittnam et al., 2012). Similar to APP/PS1KI mice, 5XFAD animals 
displayed a highly heterogeneous constitution of N-truncated and modified Aβ peptides. 
Interestingly, both transgenic lines develop a significant brain-area specific neuron loss 
(Casas et al., 2004; Oakley et al., 2006; Breyhan et al., 2009; Christensen et al., 2010; 
Jawhar et al., 2010; Bouter et al., 2013). The pathological observations in 5XFAD and 
APP/PS1KI mice might be at least partly triggered by truncated and modified Aβ including 
Aβ4-42. The following Aβ variants were detected in the brain of 5XFAD mice: Aβ1–42, Aβ1–40, 
AβpE3–40, AβpE3–42, Aβ3–42, Aβ4–42 and Aβ5–42. Strikingly, Aβ4–42 was the most abundant       
N-truncated Aβ form in 5XFAD mice (Wittnam et al., 2012). The newly generated antibody 
NT4X-167 recognizes the N-terminus of N-truncated Aβ with a preference for Aβ4–42. 
Therefore it allows to differentiate between the two major N-truncated Aβ variants, AβpE3–42 
and Aβ4–42 (Antonios et al., 2013). Here, NT4X-167 was used in 5XFAD mice in 
combination with IC16 that is specific for Aβ1-x and 1-57, an antibody that exclusively 
reacts with AβpE3-x. It could be shown that  Aβ4-x  preceded AβpE3-x accumulation in the 
brain of young 5XFAD mice. More importantly, Aβ4-x could be detected together with Aβ1-x 
intraneuronal in cortical neurons of 6 weeks old homozygous 5XFAD mice. Previously, it 
has been demonstrated that cortical neurons are prone to degeneration in aged 5XFAD 
mice (Jawhar et al., 2010; Eimer and Vassar, 2013). Transient and early intraneuronal 
accumulation of Aβ also correlates with neuron loss in a variety of other APP/Aβ mouse 
models (Casas et al., 2004; Christensen et al., 2008; Christensen et al., 2010; Alexandru 
et al., 2011). As expected, NT4X-167 also detected abundant Aβ4-x accumulation in 
amyloid plaques of 12-month-old 5XFAD mice. The results in 5XFAD mice using the 
NT4X-167 antibody emphasizes the important role of Aβ4-x in the pathology of AD. 
 
4.1.2 Intraneuronal Aβ expression in Tg4-42 mice 
 
In order to study the long-lasting neurotoxic effects of Aβ4-42 the transgenic mouse model 
Tg4-42 was generated (Bouter et al., 2012). This model is the first transgenic mouse 
model expressing exclusively N-truncated Aβ4-42. Tg4-42 mice express human                
N-terminally truncated Aβ42 in which the first three amino acids have been removed. A 
murine TRH signal peptide is fused to the Aβ N-terminus and routes Aβ4-42 through the 
secretory pathway. After release of the TRH signal peptide, Aβ4-42 is liberated into the 




region-specific manner consistent with the transgene expression driven by the murine 
Thy1 promoter (Caroni, 1997). Intracellular Aβ was predominantly expressed in the CA1 
of the hippocampus beginning at two months of age. Aβ4-42 expression in the CA1 
pyramidal cell layer of the hippocampus declined during aging in Tg4-42 and Tg4-42hom 
mice. The decrease of Aβ expression can be attributed to the extensive neuron loss in this 
brain region. Intraneuronal Aβ was also observed in Tg4-42 mice in the occipital cortex, 
piriform cortex, striatum and superior colliculus starting at two months of age.  
Next to Tg4-42 mice several other transgenic mouse models have been generated 
expressing major Aβ forms without over-expressing mutant APP or PSEN. The direct 
expression of Aβ42 in the APP48 mouse model and the G2 model led to specific 
intracellular Aβ42 expression in the brain. In both models intracellular toxicity of Aβ42 could 
be demonstrated, while extracellular Aβ deposits were mostly lacking (LaFerla et al., 
1995; Abramowski et al., 2012). Similar to these models, Tg4-42 mice showed 
intracellular Aβ accumulation in the absence of extracellular deposits. 
Growing evidence suggests that intraneuronal Aβ accumulation contributes to the 
pathological events in AD. Intraneuronal Aβ accumulation has also been detected in a 
variety of AD mouse models including Tg2576, 3xTg, APP/PS1KI and 5XFAD (Takahashi 
et al., 2002; Oddo et al., 2003; Oakley et al., 2006). Grundke-Iqbal et al. (1989) reported 
already 25 years ago that intracellular Aβ precedes Aβ plaque formation in AD patients. In 
addition, it has been shown that intracellular Aβ also appears before NFT (Gouras et al., 
2000; Fernandez-Vizarra et al., 2004). Later, it could be demonstrated that mainly longer 
Aβ42 variants accumulate within neurons in AD vulnerable regions. CA1 pyramidal 
neurons of sporadic and familial AD patients showed significantly increased Aβ42 levels 
compared to healthy individuals (Aoki et al., 2008). With increasing plaque pathology and 
cognitive impairments, the amount of Aβ within neurons decreased. It is hypothesized that 
intraneuronal Aβ causes early neuronal impairments (Gouras et al., 2000). Furthermore, it 
has been suggested that intraneuronal accumulation of Aβ42 might lead to cell lysis and 
thus contributing to increased extracellular amyloid deposits and neuron loss (D'Andrea et 
al., 2001; Wirths and Bayer, 2012).  
 
4.1.3 Neuron loss in Tg4-42 mice 
 
Neuron loss and atrophy are one of the major neuropathological hallmarks in AD patients. 
However, many transgenic AD mouse models lack this cardinal feature of AD. Most 
mouse models that do show a substantial neuron loss express multiple APP and PSEN-1 
mutations. For example, 5XFAD mice display a significant neuron loss in the fifth cortical 




demonstrate that 5XFAD mice develop a significant selective neuron loss in layer 5 of the 
cortex, while the overall neuron number of the total frontal cortex and hippocampus 
remained unaltered. Strikingly, these observations are in line with the accumulation of 
intraneuronal Aβ in the cortical layer 5, but not in the CA1 (Jawhar et al., 2010; Eimer and 
Vassar, 2013). Similar to 5XFAD mice, a massive neuron loss was observed in 
APP/PS1K1 mice. Neuron loss was found in the frontal cortex and in the CA1 of the 
hippocampus, both regions with extensive Aβ intraneuronal accumulation (Christensen et 
al., 2008; Breyhan et al., 2009). Strikingly, in both mouse models, despite the appearance 
of plaques, neuron loss occurred only in regions with intraneuronal Aβ. These 
observations argue against the role of extracellular plaques in terms of Aβ toxicity. 
A recently developed mouse model expressing human APP harboring the E693Δ 
mutation show neuron loss in the CA3 of the hippocampus. Intraneuronal Aβ oligomer 
accumulation preceded the neuron loss in these mice, while mice showed no extracellular 
plaques (Tomiyama et al., 2010). In line with these findings, long-term exposure to          
N-truncated Aβ4-42 induced an age- and dose-dependent neuron loss in hemizygous and 
homozygous Tg4-42 mice in the CA1 layer of the hippocampus. Unbiased stereology 
revealed a 38 % neuron loss in hemizygous Tg4-42 mice and a 65 % neuron loss in    
Tg4-42hom at eight months. Furthermore, 12-month-old Tg4-42 mice showed a 51 % 
decrease in neuron number in the CA1 compared to same-aged WT. To expand these 
findings and determine in greater detail the degree to which Tg4-42 mirror the progressive 
neuron loss observed in human AD, neurons were additionally counted at ages two, four, 
five and six months of age. Compared to 2-month-old Tg4-42hom mice 3-month-old mice 
already showed a decreased number of neurons, although this decrease was not 
significant. However, this trend suggests early neurodegeneration, even at a time when 
statistically significant neuron loss is not yet evident. Furthermore, the detailed 
stereological characterization of Tg4-42hom mice revealed a progressive neuron loss 
starting with four months of age. The hippocampus belongs to the brain areas that are 
known to be affected in AD and contributes to the learning and memory deficits observed 
in AD patients. Some of the earliest damages in AD brains have been reported in the 
hippocampus. AD patients display significant neuronal loss in the hippocampus. Padurariu 
et al. (2012) reported a decrease in neuronal density especially in the CA1 and CA3 
regions of the hippocampus, although the effects in the CA1 area were even more severe. 
The progressive loss of neurons in Tg4-42 and Tg4-42hom correlates strongly with 
intraneuronal Aβ4-42 accumulation in these mice. Tg4-42 and Tg4-42hom mice showed 
intracellular Aβ beginning at two months. Strikingly, intraneuronal Aβ in the CA1 of the 
hippocampus showed strong immunoreactivity at two months of age which decreased with 




mice, respectively. The decrease can be attributed to neuronal death occurring in cells 
with Aβ4-42 expression. It would be interesting to also determine the neuron number in the 
other brain areas expressing intraneuronal Aβ. Similar to Tg4-42, TBA2.1 transgenic mice 
expressing only AβpE3–42 develop a massive neuron loss in the CA1 of the hippocampus. A 
similar pattern has been described in this mouse model as neuron loss in the CA1 region 
was associated with an reduced intraneuronal Aβ signal (Alexandru et al., 2011). 
In summary, it can be stated that the progressive neuron loss in the hippocampus 
of Tg4-42 and Tg4-42hom mice correlates strongly with intraneuronal Aβ4-42. The 
observations point to an crucial role of intraneuronal Aβ in the process on 
neurodegeneration in AD. Furthermore, the results suggest that N-truncated Aβ4-42 may 
play an important role in triggering neuron loss in AD patients as Aβ4-42 is highly abundant 
in the brain of AD patients.  
 
4.1.4 Enhanced inflammation in Tg4-42 mice 
 
Neuroinflammation is a major pathological feature of AD and occurs in pathologically 
vulnerable regions of the AD brain. Activated microglia and astrocytes have been detected 
in abundance near neurons and plaques and may contribute to the progression of AD 
(Krause and Müller, 2010). Under physiological conditions, astrocytes act as 
'multifunctional housekeeping' cells. Among others, they control local pH and ion 
concentrations, remove neuronal waste and provide general metabolic support to 
neurons. Astrocytes are activated in response to neuronal injuries (Li et al., 2011). When 
activated, microglia and astrocytes produce several pro-inflammatory signal molecules, 
including cytokines, growth factors, complement molecules and chemokines (Rubio-Perez 
and Morillas-Ruiz, 2012). It has been demonstrated that Aβ is able to trigger astrocytes 
reactivation (Li et al., 2011). Furthermore, a direct role of astrocytes in the degradation of 
abeta has also been proposed (Wyss-Coray et al., 2003). Under pathological conditions in 
AD brains, neuroinflammatory processes become chronically active. Various inflammatory 
responses may contribute to the symptoms of AD (Rebeck et al., 2010).  
In several AD mouse models, reactive astrocytes were found around plaques 
similar to the observations made in human AD patients. Moreover, the amount of gliosis 
increased simultaneously with the plaque load in Tg2576 and 5XFAD mice (Hsiao et al., 
1996; Oakley et al., 2006). In contrast, TBA42 mice expressing AβpE3–42 exhibited strong 
astrogliosis in the region of the hippocampus without showing plaques. The activation of 
astrocytes appeared in close proximity to the accumulation of Aβ in these mice (Wittnam 
et al., 2012). Furthermore, in HOM TBA2.1 mice gliosis in the CA1 of the hippocampus 




al., 2011). Similar to these observations, activated astrocytes and microglia could be 
observed throughout the hippocampus in Tg4-42 and Tg4-42hom mice. Mice showed 
increased astrogliosis with GFAP staining and microgliosis with IBA1 staining in the 
hippocampus as early as two months of age. Inflammation could be associated with the 
intracellular Aβ accumulations in the hippocampus in these mice. The significant gliosis 
developed in the area of strong intraneuronal Aβ immunoreactivity and neuronal loss in 
the absence of plauqes. These observations are an indicator for neuroinflammation 
associated neurodegeneration as it has been reported in several AD mouse models 
(Games et al., 1995; Sturchler-Pierrat et al., 1997). It should be noted that the activation of 
astrocytes and microglia precede the neuron loss in the hippocampus. However, it 
remains ambiguous if gliosis aggravates neuropathology through excitotoxic mechanism 
or whether it has an contrary protective role in Aβ turnover (Domenici et al., 2002; Wyss-
Coray et al., 2003; Block et al., 2007; Alexandru et al., 2011). In summary, the data 
suggest that intraneuronal Aβ4–42 in vivo is a contributing factor to neuronal death as well 
as reactive gliosis in Tg4-42 mice. 
 
4.1.5 No weight loss in Tg4-42 mice 
 
Next to cognitive and behavioral deficits, AD is frequently associated with nutritional 
disorders including weight loss and eating disorders. Epidemiologic studies have shown 
that weight loss appears in about 40 % of patients (Guérin et al., 2005). It can occur in all 
stages of the disease but the odds of weight loss increase with the severity and 
progression of AD and is especially common in end-stage AD patients (Wallace et al., 
1995; Gillette-Guyonnet et al., 2000; Tamura et al., 2007). AD-associated weight loss 
leads to reduced muscle mass and contributes to the decline of general health. It can 
ultimately contribute to increased risk of systemic infection, falls and loss of autonomy 
(Riviere et al., 2001; Guérin et al., 2005). The cause of weight loss in not clear yet but it 
seems multifactorial. Weight loss has also been detected in several AD mouse models. 
For example, nine months old 5XFAD mice showed a significant reduced body weight in 
comparison to their WT littermates (Jawhar et al., 2010). Weight loss has also been 
detected in HOM TBA2.1 and TASTPM mice (Pugh et al., 2007; Alexandru et al., 2011). 
In contrast, Tg4-42 and Tg4-42hom mice did not show any weight loss as they showed a 
comparable body weight to same-aged WT mice. Furthermore, the Tg4-42 and Tg4-42hom 
experienced a similar body weight gain over time to WT mice. Previously, it has been 
reported that body weight significantly correlates with mice performance in the rotarod, a 
test that evaluates next to motor coordination grip strength and balance (Brown and 




potential muscle weakness might also influence the outcome of motor tests including the 
balance beam and string suspension task. Therefore the lack of weight loss seems 
beneficial for analyzing motor function in mice. 
 
4.1.6 No motor deficits or anxiety-behavior in Tg4-42 mice 
 
Mice were subjected to a battery of behavior tests that included cognitive and non-
cognitive tests. The assessment of motor function in AD mice is a crucial aspect, as some 
reference memory task including the Morris Water maze are highly influenced by any 
disturbance in motor performance. Therefore motor impairments can result in deficient 
findings in the cognitive tests. 
AD is characterized by progressive cognitive impairments. In addition, patients 
develop neuropsychiatric symptoms including motor impairments, depression and 
agitation. Motor dysfunctions have been particularly observed in the late stages of AD. 
However, deficits have also been reported in about 10 % of AD patients in the early 
stages of the disease (Scarmeas et al., 2004; Wirths and Bayer, 2008). Sensory-motor 
abilities were analyzed in Tg4-42 mice using the balance beam and string suspension 
task. The balance beam task assesses fine motor coordinating and balance of mice (Hau 
and Schapiro, 2002; Luong et al., 2011). The string suspension task evaluates,  besides 
motor coordination, grip and muscle strength of mice (Hullmann, 2012; Arendash et al., 
2001b). Tg4-42 and Tg4-42hom showed no motor deficits as they exhibited no deficits in 
grip strength, coordination or balance. Furthermore, motor performance declined slightly 
with age similar to WT mice.  
It is crucial to observe motor function and anxiety behavior before assessing 
cognitive functions in AD mice to avoid unwanted misinterpretations of the data. Several 
studies have described altered motor abilities in transgenic AD mice. APP/PS1KI as well 
as 5XFAD mice showed age-dependant motor impairments that are attributed to 
axonopathy (Wirths et al., 2008; Wirths and Bayer, 2008; Jawhar et al., 2010). In contrast, 
3xTg mice performed superior than WT control animals in the rotarod test, a test also 
designed to test motor skills (Filali et al., 2012). Motor coordination impairments might be 
due to pathology in various CNS regions including spinal cord and cerebellum, areas that 
do not express Aβ4-42 in Tg4-42 mice (Lalonde and Strazielle, 2007; Wirths and Bayer, 
2008).  
Furthermore, mice did not show a clasping phenotype. An abnormal clasping 
pattern has been observed in several mouse models including mice transgenic for mutant 
human APP and human four-repeat tau (Lalonde et al., 2012; Probst et al., 2000), as well 




et al., 2000; Wirths et al., 2007; Jawhar et al., 2010). Motor dysfunctions make it more 
difficult to study memory deficits, as several reference memory tasks including the Morris 
water maze can be highly influenced by impaired motor functions. Overall, Tg4-42 and 
Tg4-42hom mice showed no signs for impaired motor abilities. 
AD patients can suffer from a wide range of neuropsychological symptoms 
including anxiety, disinhibition and depression (Mega et al., 1996; Lyketsos et al., 2002). 
Patients may be very withdrawn due to anxiety, while other patients may act totally 
disinhibited showing socially unacceptable behavior and inappropriate euphoria (Nash et 
al., 2007). The elevated-plus maze test is widely used to study anxiety-related behavior in 
mice. More time spend in the open arms of the maze reflects reduced anxiety and 
disinhibition, while less time spend in the open arms indicated increased anxiety levels 
(Walf and Frye, 2007). No anxiety related behavior deficits were seen Tg4-42 and       
Tg4-42hom at any age tested. Mice showed an equal age-dependant decreased anxiety 
behavior and decreased agitation with age as same-aged WT mice. Interestingly, AD 
mouse models showed inconsisted anxiety profiles. APP/PS1, 5XFAD and Tg2576 mice 
showed reduced anxiety-behavior shown by increased time spent in the open arms 
compared to same-aged WT animals. Whereas, other mouse models like 3xTg, APP23 
and APP/PS1KI showed increased or unaltered anxiety levels (Lalonde et al., 2002; 
Espana et al., 2010; Webster et al., 2013). Elevated anxiety has been associated with 
intraneuronal Aβ in the amygdala, an area that is not affected in Tg4-42 mice (Espana et 
al., 2010).   
In summary, the results demonstrate that Tg4-42 and Tg4-42hom mice develop no 
deficits in either motor function or anxiety-behavior that could prevent or potentially 
confound memory testing of these mice.  
 
4.1.7 Age-dependant memory deficits in Tg4-42 mice 
 
Progressive memory decline is probably the most striking feature of AD. Therefore, a valid 
AD mouse model should exhibit cognitive deficits that can be correlated with the ones 
observed in human AD patients. A wide range of cognitive tests are available to assess 
learning and memory abilities in mice.   
Working memory in mice is widely investigated using maze type tasks like the Y-
maze, T-maze or cross maze. Working memory in rodents is related to spatial search 
strategies that are essential for foraging in the wilderness (Dember and Fowler, 1958; 
Dember and Richman, 1989). The cross maze task relays on the natural exploratory 
behavior of mice and is regarded as a rather rudimentary task to assess working memory. 




environment. Healthy mice typically prefer to explore the least recently visited arm of the 
maze rather than returning to the one previously visited (Olton et al., 1979; Wietrzych et 
al., 2005). Age-dependant decrease in the spontaneous alternation has been observed in 
several AD mouse models including Tg2576, 5XFAD and 3xTg (Hsiao et al., 1996; Carroll 
et al., 2007; Jawhar et al., 2010). In contrast APP+PS1 mice showed even at 16 months 
of age no such phenotype (Arendash et al., 2001a). Tg4-42 and Tg4-42hom showed, 
irrespective of age, comparable spontaneous alternation rates to WT mice. The 
hippocampus is critically involved in spontaneous alternation and lesions in this brain area 
have been reported to alter the alternation behavior of rodents (Lalonde, 2002). However, 
despite a significant neuron loss in Tg4-42 and Tg4-42hom no impairments in the working 
memory version of the cross maze task could be detected in these mice. It has been 
speculated that the cross maze task fails to recognize hippocampal damage as 
hippocampectomized animals show side preferences. Such a preference, for example 
turning always left in a maze, could lead to high spontaneous alternation levels and 
therefore similar scores to WT animals (Deacon and Rawlins, 2006). Furthermore, next to 
the hippocampus other brain areas including the thalamus, substantia innominata and 
cerebellum are highly involved in spontaneous alternation (Lalonde, 2002).  
In contrast, the Morris water maze (MWM) is a particularly sensitive test to 
examine age-related memory impairments in AD mice. This task allows to assess 
hippocampus-dependant spatial learning and memory (Morris, 1984). In contrast to other 
memory test, such as fear conditioning and cross maze, nearly all well established AD 
mouse models show age-related deficits the MWM. Mouse models carrying a single 
transgenic APP or tau mutation as well as mice carrying integrated APP and PSEN 
mutations or triple transgenic mice have been reported to display deficits in the MWM. 
APP23, Tg2576, 3xTg, 5XFAD and APP/PS1KI are only a few examples of mouse lines 
exhibiting spatial memory deficits (Westerman et al., 2002; van Dam et al., 2003; Billings 
et al., 2005; Webster et al., 2013; Bouter et al., 2014). The MWM consists of a large pool 
with a submerged platform in opaque water. Mice must learn to navigate to the hidden 
platform using spatial cues. This task is rather complex as it requires several cognitive 
processes simultaneously: adapting to a new and stressful situation, dropping ineffective 
search strategies, locating the escape platform based on spatial cues and encoding 
information to long-term memory (Tanila, 2012). The MWM allows to differentiate between 
spatial learning and long-term spatial reference memory. Furthermore, visual and motor 
performance can be evaluated in this behavior task, especially in the cued training. No 
differences were observed in Tg4-42, Tg4-42hom and WT mice in the cued training. 
Independently of age, mice demonstrated the appropriate skills to perform the MWM as 




dependant, a region that showed no neuron loss in Tg4-42 mice (Baldan Ramsey, 
Lissandra C. and Pittenger, 2010). Tg4-42 mice are not born with learning or memory 
deficits, as 3-month-old Tg4-42 and Tg4-42hom mice display normal spatial reference 
memory. However, spatial memory was slightly impaired in the acquisition training in       
8-month-old Tg4-42hom and 12-month-old Tg4-42, respectively. Furthermore, the lack of a 
quadrant preference in the probe trial revealed spatial reference memory deficits in         
8-month-old Tg4-42hom and 12-month-old Tg4-42 mice.  
Reference memory is highly dependent on the hippocampus, one of the heavily 
affected brain region in AD patients (West, 1993). The observed impaired spatial memory 
in eight months old Tg4-42hom mice is accompanied by a severe neuron loss in the CA1 
region (66 %). Despite a 38 % neuron loss in the CA1 eight months old hemizygous Tg4-
42 mice demonstrated no memory deficits in the MWM. Broadbent et al (Broadbent et al., 
2004) examined the relationship between hippocampal lesion size and spatial memory in 
rats. Spatial memory impairment started after bilateral dorsal hippocampal lesions 
covering 30 – 50 % of the total volume and as lesion size increased from 50 % to 100 % 
of total hippocampal volume, performance was similarly impaired. In addition, Moser et al 
(Moser et al., 1995) claimed that only 20 - 40 % of the total hippocampus is required for 
efficient spatial learning. These findings demonstrate that the hippocampus is important 
for spatial memory albeit a significant neuron loss can be compensated. Next to the 
hippocampus additional brain structures have been reported to affect spatial memory by 
influencing movement organization, spatial navigation or motor performance. Among 
these structures are amygdala, prefontal cortex, striatum, cerebellum, thalamic structures 
and locus coeruleus (D'Hooge and De Deyn, P P, 2001; Puzzo et al., 2014). The results 
from Tg4-42 mice are in good agreement with these observations as a 38 % neuron loss 
in the CA1 of the hippocampus in 8-month-old hemizygous Tg4-42 mice has no 
consequence on spatial reference memory performance. However, Tg4-42hom mice with a 
66 % neuron loss demonstrate significant impaired spatial learning in the MWM. Both the 
age-dependent deficits in spatial reference memory and the severe hippocampal neuron 
loss in Tg4-42hom mice are compatible with AD-typical changes. 
Twelve months old heterozygous Tg4-42 mice were also tested in the fear 
conditioning (FC) paradigm. FC is a form of associate learning that is based on 
conditioning (Puzzo et al., 2014). In patients with mild to moderate AD impaired 
conditioned fear responses have been shown (Hamann et al., 2002; Hoefer et al., 2008). 
Amygdala and hippocampus are crucial brain structures in FC learning. The amygdala is 
critical for the formation and storage of emotional memories, while the hippocampus is 
involved in remembering the context that triggered fear (Phillips and LeDoux, 1992; 




impaired context fear conditioning. The impairment is shown by the lack of freezing as a 
response to the context. In contrast, Tg4-42 mice exhibited a freezing response to the 
tone similar to WT mice. Freezing is a natural response mechanism of rodents to feign 
death in front of predators (Mongeau et al., 2003). Phillips and LeDoux (1992) reported 
that lesions of the hippocampus interfered with contextual fear conditioning but not with 
tone fear conditioning. In contrast, a functional amygdala is required for appropriate fear 
conditioning for both context and tone. These observations are well in line with the severe 
neuron loss detected in the hippocampus of twelve months old Tg4-42 mice and the lack 
of Aβ expression in the amygdala. Consistent with the observations in Tg4-42 mice, 
several other AD transgenic models, including Tg2576, APP/PS1, 5XFAD and 3xTg, 
displayed impaired context fear conditioning (Corcoran et al., 2002; Billings et al., 2005; 
Knafo et al., 2009). 5XFAD also mice showed an impairment in tone conditioning (see 
section 3.2.4) (Bouter et al., 2014). 
There is multiple evidence that soluble Aβ oligomers plays a role in the memory 
impairment of AD (Renner et al., 2010). It has been shown that soluble Aβ42 oligomers 
and not plaque-associated Aβ correlates best with the cognitive decline in AD (McLean et 
al., 1999; Naslund et al., 2000). Furthermore, synaptic changes and memory deficits have 
been detected in several mouse models before plaque pathology (Holcomb et al., 1998). 
Oligomers are preferentially formed intracellular within neurons and synapses (Walsh et 
al., 2000; Takahashi et al., 2004). The mode of Aβ toxicity, especially Aβ4-42, is not clear to 
date (Bouter et al., 2013). Glabe and Kayed (2006) proposed that membrane 
permeabilization by amyloid oligomers may initiate a common group of downstream 
pathologic processes. These processes include production of reactive oxygen species, 
altered signaling pathways intracellular calcium dyshomeostasis and mitochondrial 
dysfunction that represent key effectors of cellular dysfunction and cell death (Glabe and 
Kayed, 2006). Aβ oligomers can act as pathogenic ligands binding to particular synapses, 
disturbing their function, morphology and maintenance (Renner et al., 2010). Naturally 
secreted Aβ have been shown to impair hippocampal long-term potentiating (Haass and 
Selkoe, 2007). Furthermore, it has been demonstrated that Aβ1-42 oligomers induce the 
abnormal accumulation and over-stabilization of a glutamate receptor, thereby providing 
the molecular basis for Aβ oligomer-induced early synaptic failure (Renner et al., 2010). 
As soluble and aggregated Aβ4-42 is as toxic as Aβ1-42 a similar mechanism might be true 
for Aβ4-42. 
In conclusion, the behavior analysis of Tg4-42 and Tg4-42hom mice revealed 
hippocampus-dependant memory deficits similar to AD patients. Tg4-42 and Tg4-42hom 
are profoundly impaired in their spatial reference memory. Moreover, aged Tg4-42 




model induces severe age-dependant memory deficits that can be attributed to the 
massive neuron loss in the hippocampus.  
 
4.1.8 Summary - Is Tg4-42 a valid model for AD? 
 
To date, a wide range of animal models of AD have been generated and contributed to an 
better understanding of the pathogenesis of AD. Most of these models mimic certain 
aspects of the disease including amyloid plaques, NFTs, neuronal loss, gliosis or memory 
and cognitive deficits. However, so far no AD model represents the full range of 
pathological and degenerative alternations (Elder et al., 2010). For examples, as stated 
before, most transgenic mouse models expressing human APP show a robust plaque 
pathology but many of them lacking a significant neuron loss (Duyckaerts et al., 2008; 
Götz and Ittner, 2008; Cavanaugh et al., 2014). In most AD mouse models that do show 
neuron loss it is induced by a combination of multiple mutations that individually seem to 
be sufficient enough to cause AD in humans (Christensen et al., 2008; Breyhan et al., 
2009; Elder et al., 2010; Jawhar et al., 2010). Strikingly, in Tg4-42 mice a massive neuron 
loss in the CA1 is induced by long-term exposure to Aβ4-42 alone.  
Despite being one of the major Aβ isoforms in AD brains, little has been known 
about its contribution to the etiology of AD (Portelius et al., 2010). The Tg4-42 mouse 
model expressing human Aβ4-42 allows to investigate the neurotoxic effects of Aβ4-42 in 
vivo. N-truncated Aβ peptides are very abundant in brains of patients diagnosed with 
sporadic and familial AD. Of the N-truncated species Aβ4-x and AβpE3-X are the most 
consistently reported (Portelius et al., 2010; Bayer and Wirths, 2014). In many AD mouse 
model a accumulation of N-terminal cleaved Aβ was not been described. However, 
intraneuronal accumulation of N-truncated Aβ has been linked to neuron loss in some AD 
model including APP/PS1KI and 5XFAD mice. Moreover, Aβ4–42 was the most abundant 
N-truncated Aβ form in 5XFAD mice (Bayer and Wirths, 2008; Wittnam et al., 2012).  
AD is a multifactorial and heterogeneous disease (Iqbal et al., 2005b). Familial AD 
represent only a fraction of all AD cases, still nearly all models for AD are associated with 
FAD mutations. Around 99 % of all AD cases are sporadic and the causes underlying 
these cases are still unclear (Zetterberg et al., 2014). There is an urgent need to generate 
disease-relevant SAD animal models, however so far there has been nearly no success in 
the generation of such animal models (Iqbal et al., 2013). An animal model that shows at 
least some aspects of SAD has been generated by intracerebroventricular (icv) injection 
of streptozotocin (STZ). These rodents are generated based on the detection of an 
insulin-resistant brain state in SAD. STZ is injected to induce such a brain insulin resistant 




metabolism, neuroinflammation, altered synaptic proteins and increased 
hyperphosphorylated tau in the brain (Salkovic-Petrisic et al., 2006; de la Monte, Suzanne 
M. and Wands, 2008; Chen et al., 2012; Chen et al., 2013). The transgenic mouse model 
Tg4–42 is unique as it harbors no mutations in the Aβ sequence. Moreover, the Tg4-42 
mouse model can be considered as a model for sporadic AD, as no familial AD mutation 
in Aβ, APP, PSEN-1 or PSEN-2 is needed for inducing neurodegeneration in these mice. 
The over-expression of Aβ4-42 induces gliosis, neuron loss and behavior deficits in Tg4-42 
and Tg4-42hom mice. Therefore, the Tg4-42 mouse model shows many aspects of an SAD 
brain, however they do not develop amyloid plaques or NFTs. Tg4-42 and Tg4-42hom mice 
showed region-specific intraneuronal Aβ deposits predominantly in the CA1 of the 
hippocampus. The expression of Aβ4-42 was sufficient to induce neurodegeneration in  
Tg4-42 mice that is associated with gliosis and progressive and massive neuron loss in 
the hippocampus. Furthermore, Tg4-42 and Tg4-42hom mice develop an age-dependent 
hippocampus-related reference memory deficits in the Morris water maze due to the 
drastic CA1 neuron loss. Moreover, aged Tg4-42 show a decreased contextual learning in 
the fear conditioning task. Importantly, the observed memory deficits in Tg4-42 mice are 
not confounded by motor impairments or abnormal anxiety. Based on these findings, the  
Tg4-42 line represents a disease-relevant model of sporadic AD.  
Despite being a major isoform in the brain of AD patients, Aβ4–x has not received 
much attention as a potential therapeutic target. The massive neuron loss coupled with 
age- and disease related cognitive decline and the high physiological relevance of the 
Tg4-42 mouse model make it well-suited for utilization of preclicical testing of AD-relevant 
therapeutics. Intriguingly, the newly generated antibody NT4X-167 could be used for 
passive immunization of Tg4-42 mice. The antibody has been shown to significantly 
rescue Aβ4–42 toxicity in vitro, while no beneficial effects were observed against Aβ1–42 or 
AβpE3–42 toxicity (Antonios et al., 2013).  
In summary, the pathology of Tg4-42 mice is unique in its massive neuron loss and 
severe memory behavior deficits induced through intraneuronal accumulation of              
N-terminally truncated Aβ4-42 (FIGURE 4.1). It can be stated that Tg4-42 mice emphasize 
the toxicity of Aβ4-42 in vivo. Moreover, the resulting neurodegeneration associated with 
neuron loss, gliosis and memory deficits appears to be a direct consequence of 
intracellular neurotoxicity of Aβ. In summary, Tg4-42 is a valid AD mouse model showing 





FIGURE 4.1 Key features of the Tg4-42 mouse model. Intraneuronal Aβ is expressed 
predominantly in the CA1 of the hippocampus. Tg4-42 mice develop a massive neuron loss in the 
CA1 and severe memory deficits induced through intraneuronal accumulation of Aβ4-42. 
Inflammation could be associated with the intracellular Aβ accumulations in the hippocampus in 
these mice. The significant gliosis developed in the area of strong intraneuronal Aβ 
immunoreactivity and neuronal loss in the absence of plauqes. However, it remains unclear if 
gliosis aggravates neuropathology through excitotoxic mechanism or whether it has an contrary 



















4.2 Project 2: Deciphering the molecular profile of plaques, memory 
decline and neuron loss in Tg4-42 and 5XFAD mice by deep 
sequencing8 
 
The main objective of the second part of the thesis was to elucidate the similarities and 
distinctions in the expression profiles of the Tg4-42 and the 5XFAD mouse model. 
Therefore a comparative gene expression analysis of brain tissue of these AD mouse 
models was performed using next-generation sequencing. 
 
4.2.1 Advantages of RNA Deep Sequencing 
 
The transcriptome includes all RNA transcripts expressed in a given tissue and reflects 
the genes that are expressed at the studied time point. Altered gene expression profiles 
may therefore provide information about the genes and mechanisms involved in the 
molecular pathogenesis of diseases like AD and ultimately promote the search for new 
therapeutic drugs. 
Microarrays have been used in the past as a standard process for transcriptome 
profiling. The method has been proven to be valuable to quantify simultaneously large 
numbers of mRNA transcripts (Courtney et al., 2010). Commercially available microarrays 
can analyze up to 15,000 - 30,000 different mRNAs and facilitate genome-wide gene 
expression profiling (Altar et al, 2009). Oligonucleotide and cDNA microarrays are both 
affordable and offer a high-throughput approach. However, due to the use of indirect 
signal detection by hybridization microarray techniques possess several limitations 
(Courtney et al., 2010). The limitations include reliance upon knowledge of already known 
sequences, poor range of quantification and relative low sensitivity and specificity (Choi et 
al., 2013). Furthermore, non-specific binding of samples make the detection of low 
expressed transcripts against the background noise difficult (Sutherland et al., 2011) and 
unsuitable for quantification of over- and under-expressed genes with fold changes 
smaller than two (Wang et al., 2009). Bakel and colleagues (2010) reported that 
hybridization signals from microarrays can lead to a high number of false positive signals 
especially from transcripts with low expression levels. 
Several microarray studies on amyloid mouse models for AD have been reported 
(Stein and Johnson, 2002; Dickey et al., 2003; Wu et al., 2006; Selwood et al., 2009; Wirz 
et al., 2013). The transgenic models included APP/PS1∆Ex9, PDAPP, Tg2576 and 
combinations with different mutant PSEN-1 genetic variants. All of these models represent 
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models for familial AD and abundant plaque formation without severe neuron loss. 
Therefore, in this study two models were compared that do show a robust behavioral 
deficit and in addition harbor a significant neuron loss.  
RNA-Seq (deep-sequencing) allows to cope with many of the problems described 
for microarrays and has a number of advantages over microarray technology. Most 
importantly, deep sequencing does not rely on known genome sequence data and 
therefore novel transcripts can be detected (Courtney et al., 2010). It is possible to detect 
billions of nucleotide information within a single experiment (Cheng et al., 2013). 
Furthermore, problems with saturation and background signal do not exist as each 
molecule is individually sequenced and mapped to unique regions of the genome. RNA-
Seq offers a larger dynamic range than microarray technology as no upper or lower levels 
exist in this quantification technique (Courtney et al., 2010). In comparison to microarrays 
deep sequencing has a low false positive rate and is moreover highly reproducible 
(Nagalakshmi et al., 2008). 
 
4.2.2 Comparison of Tg4-42 and 5XFAD mice  
 
Using deep sequencing technology the RNA profiles from the two AD models 5XFAD and 
Tg4-42 were analyzed (TABLE 4.1). These two models were compared as they show a 
robust behavioral deficit and develop a significant neuron loss.  
5XFAD is a model for familial AD that shows massive and early plaque formation, 
intraneuronal Aβ aggregation, behavioral deficits and neuron loss in the cortical layer 5 
(Oakley et al., 2006; Jawhar et al., 2010). In many aspects 5XFAD represents a very good 
AD model. Due to the massive plaque formation in 5XFAD, many molecular pathways that 
are exclusively correlating to plaque formation may cover those pathways directly 
connected to neuron loss. Using mass spectrometric analysis, it could previously been 
demonstrated that 5XFAD mice exhibit high amounts of pyroglutamate AβpE3-42 and other 
Aβ isoforms. Besides Aβ1-42, the following peptides were also identified in 5XFAD mice, in 
order of abundance: Aβ1-40, Aβ4-42, pyroglutamate AβpE3-42 and Aβ3-42 (Wittnam et al., 
2012). 
In vitro and in vivo analysis of amyloid deposits in AD revealed N- and C-terminal 
variants of the Aβ peptide (Masters et al., 1985; Prelli et al., 1988; Miller et al., 1993). 
Masters et al. (1985) discovered that the majority (64 %) of the peptides in amyloid 
plaques of AD begin with a phenylalanine residue corresponding to position 4 of the full-
length sequence. Moreover, they detected dimeric and tetrameric Aβ aggregates from the 
HPLC separations of plaques from AD having the same ragged NH2-terminal ends. The 




fraction in the hippocampus and cortex of AD patients (Portelius et al., 2010). In addition, 
Lewis et al. (2006) reported that Aβ4-42 is a relatively abundant species in AD, aged 
controls and vascular dementia patients.  
In order to investigate the long-lasting neurotoxic effect of Aβ4-42, the novel mouse 
transgenic mouse model Tg4-42 expressing exclusively Aβ4-42 was recently generated 
(Bouter et al., 2013). The model is unique as it harbors no mutations in the Aβ sequence 
and therefore it can be regarded as a model for sporadic AD. Tg4-42 mice develop severe 
hippocampal neuron loss and memory deficits that correlate well with the hippocampus-
specific intraneuronal expression of Aβ4-42 (see section 4.1.2). These findings are 
corroborated by previous mouse models expressing full-length mutant APP. For example, 
APP/PS1KI mice exhibit neuron loss in the CA1 region of the hippocampus (Casas et al., 
2004; Breyhan et al., 2009), the frontal cortex (Christensen et al., 2008), and in distinct 
cholinergic nuclei (Christensen et al., 2010). The APP/PS1KI model is characterized by 
age-dependent accumulation of heterogeneous N-terminal truncated Aβ peptides with 
Aβ4-42 being one of the most abundant variants (Casas et al., 2004). In 5XFAD mice a 
heterogeneous mixture of full-length, N-truncated and modified Aβ peptides, including  
Aβ4-42, was found (Wittnam et al., 2012). Hence, the pathological events observed in the 
APP/PS1 KI and 5XFAD mouse models might be at least partly triggered by N-terminal 
truncated Aβ4-42.  
 
 
  TABLE 4.1 Comparison of the two transgenic mouse models 5XFAD and Tg4-42 
Features 5XFAD Tg4-42 
Mutations APP695 (Swedish, Florida, London) 
PSEN-1 (M146L and L286V) 
None 
Genetic background C57Bl6 C57Bl6 
Transient intraneuronal Aβ Yes Yes 
Prevalence of Aβ variants Aβ1-42>1-40> 4-42>pyroglutamate3-42 only Aβ4-42 
Plaques Plaque deposits starting at 3 months None 
Neuron loss 38 % loss in cortical layer 5 49 % loss in CA1 
Gliosis Yes Yes 







4.2.3 Learning and memory deficits in 5XFAD and Tg4-42 mice 
 
In the present work it could be shown that Tg4-42 mice and 5XFAD mice feature 
comparable learning and memory deficits. Both mouse lines exhibited age-dependent 
spatial reference memory deficits assessed by the Morris water maze. Aged Tg4-42 and 
5XFAD mice have also been tested in the contextual fear conditioning paradigm and 
exhibited deficits in this hippocampus-dependent memory task. Tg4-42 and 5XFAD mice 
displayed hippocampus-dependent memory deficits similar to those of other AD 
transgenic models (Chen et al., 2000; Stover and Brown, 2012; Kishimoto et al., 2013). 
Furthermore, 5XFAD mice demonstrated an impairment in conditioned learning in 
response to a tone stimulus.  
Classical fear conditioning is assumed to be highly dependent on the hippocampus 
(Bast et al., 2003). Phillips and LeDoux (1992) reported that lesions of the hippocampus 
interfered with contextual fear conditioning but not with cue and tone fear conditioning. In 
contrast a functional amygdala is required for appropriate fear conditioning for both 
context and tone. Moreover, anxiety behavior was claimed to correlate with the presence 
of intraneuronal Aβ in the amygdala (España et al., 2010). These observations are in 
agreement with the impairment in conditioned learning in response to a tone stimulus of 
aged 5XFAD mice, but not of age matched Tg4-42 animals. 
 
4.2.4 Deep sequencing in 5XFAD and Tg4-42 mice 
 
It could be shown that 5XFAD and Tg4-42 mice do develop comparable AD typical 
learning deficits at 12 months of age. Both mouse models also exhibit two cardinal 
features of AD: accumulation of intraneuronal Aβ and neuron loss (Oakley et al., 2006). In 
order to detect gene expression changes in the two AD mouse models deep sequencing 
analysis was performed on young as well as aged 5XFAD and Tg4-42 mice. A wide range 
of differentially expressed genes (DEGs) could be identified in aged Tg4-42 as well as in 
young and aged 5XFAD mice compared to age-matched wild-type controls, respectively. 
Even though the potential for false positive results cannot be eliminated completely, more 
than 25 transcript changes detected by RNA-Seq could be successfully confirmed by 
qRT-PCR and therefore validated the deep sequencing results. Furthermore, the 
detection of the transgenic human PSEN-1 and APP sequences in young and aged 
5XFAD mice as well as the promoter sequences through deep sequencing is also an 
indication for the quality of the method. 
The expression changes detected in the transgenic mice give a broad picture of 
the profound physiological changes that accompany the neuron loss and the detected 




before, while many genes are described for the first time in the context of AD. The 
observed parallel expression of these genes now offers new perspectives in 
understanding the pathology of AD. 
 
4.2.5 Differentially expressed genes in young 5XFAD and Tg4-42 mice 
 
In young 5XFAD mice a substantial number of genes is differentially expressed prior to 
robust amyloid deposition and neuron loss. The 19 DEGs encoded proteins from diverse 
functional categories, including translation, glycolysis and ATP-binding, kinases and 
hydrolases. The 5XFAD model has been reported to develop plaque deposition starting 
already at the age of 3 months (Jawhar et al., 2010). Intraneuronal Aβ is evident at 1.5 
months of age, just before the first appearance of amyloid deposits (Oakley et al., 2006). 
The data of young 5XFAD mice elucidate the expression profile at the commencement of 
plaque formation, before learning and memory deficits are apparent. Several DEGs that 
are involved in the clearance of Aβ. For example, transthyretin (Ttr) (Li and Buxbaum, 
2011) and insulin-degrading enzyme (Ide) (Farris et al., 2003; Miners et al., 2009) are 
found up-regulated. The serum- and glucocorticoid-inducible-kinase-1 (SGK1) participates 
among others in the regulation of neuroexcitability, inflammation, cell proliferation and 
apoptosis. It is assumed that it takes part in the signaling of brain-derived neurotrophic 
factor (BDNF) which is involved in neuronal survival and plasticity (Lang et al., 2010).  
No DEGs were detected in young Tg4-42 mice, which suggests that the pathology 
is weak at that age and points to a later onset of the pathological events underlying the 
phenotypic changes observed at later ages.  
 
4.2.6 Common molecular signature of Tg4-42 and 5XFAD mice 
 
Interestingly, 36 genes were differentially expressed in both mouse models indicating 
common disease pathways associated with behavioral deficits and neuron loss occurring 
in these mouse models. Nearly half of the DEGs in aged Tg4-42 were also differentially 
expressed in 5XFAD mice. 
Many of the genes that showed differential regulation in 5XFAD alone belong to 
neuroinflammatory processes typically found associated with plaques. As Tg4-42 mice do 
not develop any plaques, but massive neuron loss, it can be assumed that the genes 
isolated in both models and those in Tg4-42 alone are defining the molecular signature 
underlying memory decline in AD.  
The DEGs that were found in both models fall in a broad range of functional 




regulation of gene expression and transcription, histone modification, ion binding and 
protein methyltransferase activity, nervous system development and neurogenesis. 
Together with Calm3, Fbxo2 and Gpm6a only Gfap was found to be up-regulated in both 
aged 5XFAD and Tg4-42 mice. The astrocyte marker glial fibrillary acidic protein gene 
(Gfap) was found to be similarly up-regulated in both mouse lines. Increased astrogliosis 
was previously described in both mouse lines (Bouter et al., 2013; Oakley et al., 2006). 
Increased astrogliosis, measured by GFAP concentration, is also found in cortex, 
thalamus, brainstem and cerebellum in AD brains (Delacourte, 1990).  
Next to the up-regulated genes 32 genes were commonly down-regulated in aged 
transgenic mice compared to same-aged WT mice. Among others Lrp1 was altered. 
Kanekiyo et al. (Kanekiyo et al., 2013) demonstrated that receptor-mediated endocytosis 
in neurons by LRP1 plays a critical role in Aβ clearance in the brain. Decreased levels of 
Shank1 RNA were also found in both mouse lines. The levels of the postsynaptic proteins 
SHANK1 and SHANK3 are also regulated in patients with Alzheimer’s disease and in the 
brains of amyloid precursor protein transgenic mice. It has been proposed that Aβ reduces 
Shank levels in the dendrites (Pham et al., 2010). 
The gene coding for the lysine (K)-specific methyltransferase 2D (Mll2), also 
known as Kmt2b, that is highly expressed throughout development as well as in adult 
tissue (Glaser et al., 2006) is down-regulated in aged 5XFAD and Tg4-42. Kerimoglu et al. 
(Kerimoglu et al., 2013) showed that mice lacking Mll2 in the adult forebrain displayed 
impaired hippocampus-dependent memory function. Furthermore, the loss of MLL2 leads 
to down-regulation of genes implicated in neuronal plasticity. 5XFAD and Tg4-42 also 
showed hippocampus-dependent memory impairments. The down-regulation of Mll2 that 
is reported to be crucial for memory consolidation and regulation of hippocampal plasticity 
genes is well in line with these findings. 
Besides the RNA binding protein neuro-oncological ventral antigen 2 gene, 
Ubiquilin 2 (Ubqln2) was similarly down-regulated in aged Tg4-42 and both young and 
aged 5XFAD mice. UBQLN2 is a member of the ubiquilin family that is involved in the 
protein-degrading pathway as it regulates the degradation of ubiquitinated proteins (Ko et 
al., 2004). Ubiquilin has recently been linked to intraneuronal inclusions in amyotrophic 
lateral sclerosis (ALS), a rapidly progressive motoneuron disease. Around 20 % of ALS 
patients also develop a frontotemporal dementia (Deng et al., 2011). Noticeable, in the 
hippocampus of patients with sporadic and familiar ALS ubiquilin 2 pathology correlates 
with dementia (Deng et al., 2011). Furthermore, ubiquilin 1 and ubiquilin 2 protein levels 
have been shown to be reduced in the brains of AD patients (Stieren et al., 2011; Nölle et 
al., 2013). It could be shown that ubiquilin 1 modulates γ-secretase cleavage 




amyloid precursor protein (APP) fragments (Stieren et al., 2011). It was suggested that 
ubiquilin 2 decline contributes to the AD pathology via APP processing as well and that 
ubiquilin 2 may be generally involved in the pathology of neurodegenerative dementias 
(Nölle et al., 2013). 
 
4.2.7 Differentially expressed genes in aged Tg4-42 mice 
 
Up-regulated genes in aged Tg4-42 mice 
 
Twenty genes were solely differentially expressed in aged Tg4-42. Among these, only the 
genes Uqcc2, Beta-S and Kif1a were found to be up-regulated. Kif1a is a member of the 
kinesin family (KIFs) (Takemura et al., 1996) and has previously been connected to AD 
(Kondo et al., 2012). These microtubule-based motor proteins transport membrane 
organelles, mRNA and proteins (Hirokawa et al., 2009). By transporting those complexes 
KIFs play important roles in neuronal function and plasticity as well as morphogenesis and 
survival (Hirokawa et al., 2010). In neurons KIF1A transports components of synaptic 
vesicles containing synaptic vesicle proteins such as synaptophysin and synaptotagmin 
(Hirokawa et al., 2010). Recently, Kondo et al. (2012) showed that an up-regulation of 
KIF1A contributes to synaptogenesis in the hippocampus. 
 
Down-regulated genes in aged Tg4-42 mice 
 
The 17 genes that were significantly down-regulated in aged Tg4-42 are involved in 
diverse biological processes. These include regulation of gene expression, nervous 
system development, cell communication, metal ion transport, neurogenesis and 
regulation of synaptic plasticity. The gene encoding the nerve growth factor inducible 
protein (VGF), which is down-regulated in aged Tg4-42, is a neurosecretory protein that is 
solely expressed in neurons (van den Pol et al., 1994). Adult VGF is detected in several 
areas in the brain including the olfactory system, cerebral cortex, hypothalamus and 
hippocampus as well as the adrenal medulla and motorneurons of the spinal cord (van 
den Pol et al., 1994; Snyder and Salton, 1998; Thakker-Varia and Alder, 2009). Several 
groups proposed VGF as a potential biomarker for AD (Carrette et al., 2003; Jahn et al., 
2011). They detected lower protein levels of VGF in the cerebrospinal fluid (CSF) of AD 
patients compared to healthy controls. Recently, it has been proposed that VGF plays a 
role in the regulation of energy balance as knockout mice are hypermetabolic and thin 
(Levi et al., 2004). It could be speculated that the down-regulation of VGF is connected to 
the weight loss observed in some AD patients (Carrette et al., 2003). Tg4-42 mice 




Another notable down-regulated gene in aged Tg4-42 mice codes for doublecortin (Dcx). 
Doublecortin is a microtubule-associated protein that is expressed in migrating neuronal 
precursors of the developing CNS and immature neurons (Couillard-Despres et al., 2005). 
DCX is often used as a marker for neurogenesis (Couillard-Despres et al., 2005; Verwer 
et al., 2007). In AD mouse models expressing mutant forms of APP or PSEN-1 
neurogenesis was found to be impaired. Aβ was found to disrupt neurogenesis in the 
subventricular zone and the hippocampus in these mice (Haughey et al., 2002a; Haughey 
et al., 2002b). Jin et al. (2004) however described increased levels of doublecortin in the 
hippocampus of AD patients brains and therefore suggested that neurogenesis is 
increased in AD hippocampus.  
Furthermore, the pathology of AD has recently been linked to the deregulation of 
cyclin-dependent kinase 5 (CDK5) (Shukla et al., 2012). CDK5 is regulated by the neuron-
specific cyclin-related proteins p35 (CDK5R1) and p39 (CDK5R2). Activated CDK5 plays 
an important role in neurogenesis, synaptic plasticity and neuronal survival (Nikolic et al., 
1996; Tan et al., 2003; Shukla et al., 2012). CDK5 phosphorylates tau and the CDK5 
complex is involved in posttranslational modification of APP and PSEN (Rademakers et 
al., 2005). Various neurotoxic events, including oxidative stress and elevated Aβ levels, 
result in calpain cleavage of the regulatory proteins p39 and p35. The resulting C-terminal 
truncated proteins p29 and p25 lead to hyperactivation and mislocalization of CDK5. The 
introduction of p25 in primary neurons leads to the deregulation of CDK5 causing, among 
others, phosphorylation of tau and neuronal cell death (Cruz and Tsai, 2004; Rademakers 
et al., 2005). It can be hypothesized that the over-expression of Aβ4-42 in Tg4-42 mice 
stimulates activation of calpain and therefore down-regulation of Cyclin-dependent kinase 
5 activator 2. 
It is noticeable that several DEGs in aged Tg4-42 mice have an ion binding 
function. The proteins ZMIZ2 and ZFP609 bind to zinc ions while Beta-S is an iron ion 
binding protein. Furthermore, the metal ion binding proteins MLL1, ZFHX3, SRRM2 and 
ATP1A are down-regulated in both aged Tg4-42 and 5XFAD mice. The binding targets 
zinc and iron, in addition to copper, have been shown to be involved in the pathology of 
AD. Zinc promotes the aggregation of Aβ (Watt et al., 2010) and was found to be enriched 
in AD plaques (Lovell et al., 1998; Leskovjan et al., 2011; Roberts et al., 2012). While the 
overall zinc level in the aging brain is relatively constant, the zinc transporter ZnT3 has 
been shown to decrease with age (Roberts et al., 2012). Furthermore, disruption of zinc 
homeostasis in the brain leads to synaptic and memory deficits (Watt et al., 2010). Aged 
5XFAD mice also displayed a variety of DEGs involved in metal binding, for example Bsn, 





4.2.8 Differentially expressed genes in aged 5XFAD mice 
 
In aged 5XFAD mice 131 genes with significant expression changes were identified. 87 of 
these genes were only found to be altered in this mouse line and not in Tg4-42. 
Compared to aged Tg4-42 mice a significant larger number of genes were differentially 




A large number of DEGs are involved in regulation of immune system processes and 
inflammation. The respective transcripts are involved, among others, in adaptive immune 
response, regulation and activation of immune response as well as immune system 
development. Inflammatory processes in the brain are a well-described feature of AD. It 
has been shown that plaque deposition in AD brains is associated with chronic 
inflammation characterized by increased inflammatory cytokine expression and activation 
of microglia, astrocytes and complement factors (Akiyama et al., 2000). Inflammation is 
thought to be a downstream process appearing after Aβ plaques, NFT and neuron 
degeneration (Arnaud et al., 2006). 5XFAD mice display distinct neuroinflammatory 
features. The number of reactive astrocytes and microglia increases proportionally to the 
amyloid burden in this mouse line (Oakley et al., 2006; Kalinin et al., 2009).  
5XFAD mice also show a dramatic increase in Aβ42 in comparison to Aβ40. This 
results in an early pathology onset with plaque deposition seen as early as three months 
of age. The plaque pathology increases dramatically in an age-dependent manner 
(Oakley et al., 2006; Jawhar et al., 2010). Aggregation of Aβ results in activated microglia 
and induces the production of reactive-oxygen species, pro-inflammatory cytokines, 
chemokines and prostaglandines leading to degenerative changes in neurons (Akiyama et 
al., 2000). A large number of DEGs in aged 5XFAD mice have a role in inflammatory 
pathways (including Scube1 and Nr1d1). Strikingly, four genes of the complement system 
(C4b, C1qa, C1qb and C1qc) are highly up-regulated in 12-month-old 5XFAD mice. 
Complement activation is a major inflammatory process and is thought be activated in AD 
by the interaction of complement proteins with the aggregated forms of Aβ and tau 
(Rogers et al., 1992; Shen et al., 2001). Furthermore, it  is assumed that soluble, non-
fibriallar Aβ peptides are also able to activate the complement system but to a smaller 
extent (Bergamaschini et al., 1999). The activation of complement enhances other toxic 
processes (Loeffler et al., 2006). 
Notably, five genes, encoding the cysteine proteases Cathepsin B, Cathepsin L, 




regulated in aged 5XFAD mice. Cathepsin D is a lysosomal enzyme found in neuritic 
plaques and is considered to be involved in APP processing (Schuur et al., 2011). Cataldo 
et al. (Cataldo et al., 1995) showed an up-regulation of Cathepsin D mRNA in the 
pyramidal neurons of AD brains. The cysteine protease Cathepsin B has been proposed 
as an alternative candidate β-secretase in the regulated secretory pathway of neurons, 
where it produces Aβ by cleavage of the WT β-secretase site of APP (Hook et al., 2009; 
Wang et al., 2012). Hook et al. (2009) demonstrated that deletion of Cathepsin B in a 
hAPPwt transgenic mouse model significantly reduced the levels of Aβ40 and Aβ42. 
Therefore, Cathepsin B might be a valid target for developing inhibitors to lower brain Aβ 
levels in AD patients.  
Another interesting gene that showed an up-regulated expression in aged 5XFAD 
mice is clusterin (Clu) also known as apolipoprotein J. Clusterin is a chaperone 
glycoprotein that affects many cellular processes, including inflammation. Clusterin is 
elevated in AD affected brain regions and CSF from AD patients (Lidström et al., 1998; 
Nilselid et al., 2006). Furthermore, it was found to be associated with AD in several large 
genome-wide association studies (GWAS) (Harold et al., 2009; Lambert et al., 2009; 
Carrasquillo et al., 2010). Recent studies suggest that Clusterin contributes to the 
pathology to AD through various pathways, including lipid metabolism, neuroinflammation 
and apoptosis. Interestingly, it is reported to increase Aβ aggregation as well as Aβ 
clearance (Yu and Tan, 2012). 
It should be noted that Inpp5d RNA was found to be differentially expressed in 
5XFAD mice. This gene was recently described as a new locus for AD in a GWAS 
(Lambert et al., 2013). Inpp5d encodes a member of the inositol polyphosphate-5-
phosphatase family of enzymes involved in second messenger signaling in myeloid cells. 
INPP5D influences pathways that are associated with cell proliferation and inflammatory 
responses (Medway and Morgan, 2014).  
 
Evidence for diverse molecular pathways 
 
In addition to genes involved in inflammatory processes, DEGs in aged 5XFAD mice were 
also involved in cell communication and system development, signal transduction, 
synaptic transmission as well as regulation of gene expression and transcription. 
Significant transcriptional changes of genes with synaptic function in aged 5XFAD mice 
could be observed. For instance, the gene products of Bsn, Nrxn2, Kcnc1, Grm2 and 
Gng4 all play a role in synaptic transmission and are down-regulated in 12-month-old 
5XFAD mice. Syn1, the gene encoding Synapsin1, a neuronal phosphoprotein associated 




5XFAD mice. It is involved in synapse formation and promotion of neurotransmitter 
release (Südhof, 1990; Jaffrey et al., 2002). Qin et al. (2004) showed that synapsin levels 
were also significantly decreased in the CA1 and the dentate gyrus in AD patients.  
Wirz et al. (2013) studied the genome-wide gene expression of another AD double 
transgenic APP/PS1 mouse model using microarrays. A vast range of genes was altered 
in these APP/PS1∆Ex9 mice that are involved in immune response and inflammation. In 
contrast to the observations in 5XFAD mice, no changes in the expression of genes 
involved in synaptic plasticity or transmission were found. However, in AD patients 
dominant gene expression changes concerning synaptic plasticity or transmission were 
recently described in a genome-wide gene expression study of the prefrontal cortex 
(Bossers et al., 2010). It can be argued that deep sequencing and the use of 5XFAD mice 
are more informative and better suited to identify the expression changes in a model 
system of AD. 
 
4.2.9 Limitations of the study 
Finally, it can be stated that RNA-Seq is a powerful technique to analyze the expression 
profiles in AD mice. The detection of hundreds of differentially expressed genes may offer 
a new perspective on the biological processes underlying the pathology of AD. However, 
even though there is a strong correlation between gene expression levels and 
abundances of the respectively corresponding proteins in mammalian cells (Lundberg et 
al., 2010), it has to be kept in mind that proteins, rather than mRNAs, are the main 
mediators of physiological processes and that there is a considerable body of data that 
suggests a major role for post-transcriptional processes in controlling protein abundances 
(Vogel and Marcotte, 2012). 
While investigating the role of DEGs on the protein level is beyond the scope of 
this study, the presented dataset could provide an important source of information for the 
validation in both mouse and human tissue in independent studies. A wide  range of 
detected genes were previously shown to be regulated in AD, however, a variety of DEGs 
in the studied mouse models were not previously associated with AD in humans. It 
remains to be seen if these genes are also regulated in AD cases.  
 
4.2.10 Conclusions 
In conclusion, (1) the Tg4-42 model could be validated as a valuable model for AD. The 
comparison with 5XFAD, an established plaque-developing AD mouse model, revealed a 
remarkable overlap in the molecular signature. The jointly differentially expressed genes 




memory decline apparent at twelve months of age in both transgenic models. (2) The pool 
of genes that showed differential expression exclusively in Tg4-42 is likely associated to 
soluble Aβ as no extracellular plaques are found in this model. In addition, the robust CA1 
neuron loss could also contribute to the differential expression profile. (3) As most of the 
genes with expression levels exclusively altered in 5XFAD mice belong to inflammation-
associated pathways, it can be concluded that the majority of these genes are regulated in 
connection with plaque formation in this model and are not associated with neuron loss 
and memory decline. (4) As expected the deep sequencing approach identified a plethora 
of genes that have so far not been linked to AD, which might opens up new avenues of 




























Besides Aβ staring with an aspartate at position 1, a variety of modified and truncated Aβ 
forms have been detected in AD brains. Together with full length Aβ1-42 and Aβ1-40,          
N-truncated AβpE3-42 and Aβ4-42 are major variants in AD (Bayer and Wirths, 2014). Aβ4-42 
has been identified as a particular abundant Aβ species in the hippocampus and cortex of 
AD patients and was discovered as early as 1985 (Masters et al., 1985; Portelius et al., 
2010). Sedimentation studies indicate that Aβ4-42 exhibits fast aggregation kinetics (Pike et 
al., 1995b). Interestingly, short-term treatment of primary cortical neurons revealed that 
Aβ4-42 is as toxic as pyroglutamate Aβ3-42 and Aβ1-42. Moreover, treatment of wild-type mice 
using intraventricular Aβ injection with Aβ4-42 induced significant working memory deficits. 
These deficits were similar to the ones induced through pyroglutamate Aβ3-42 and Aβ1-42 
(Bouter et al., 2013). However, relatively little is known about the contribution of Aβ4-42 to 
the development and progression of AD. In this study, it could be shown that Aβ4-x 
precedes AβpE3-x accumulation in the brain of young 5XFAD mice by using the novel 
antibody  NT4X-167. Moreover, Aβ4-x could be detected together with Aβ1-x intraneuronal in 
cortical neurons of six weeks old homozygous 5XFAD mice. The results emphasize the 
significance of Aβ4-42 in AD pathology.   
In the present work, the effects of chronic exposure of Aβ4-42 in vivo were studied. 
Nearly all transgenic mouse models for AD rely on artificial combinations of mutations. 
However, the vast majority of AD patients do not possess mutations and suffer from the 
sporadic form of the disease (Elder et al., 2010; Zetterberg and Mattsson, 2014). 
Therefore, direct expression of a specific Aβ species in vivo may demonstrate a more 
physiologically relevant AD model. Given these considerations the Tg4-42 mouse model, 
that exclusively expresses human Aβ4-42, was recently generated in our lab. (Bouter et al., 
2013). Here, the new homozygous Tg4-42 line was generated (Tg4-42hom) in addition to 
heterozygous mice. Using immunohistochemistry, it could be shown that Tg4-42 and  
Tg4-42hom mice develop region-specific intraneuronal accumulation of Aβ accompanied by 
gliosis. Tg4-42 and Tg4-42hom mice showed strong intraneuronal Aβ immunoreactivity 




months of age. Intraneuronal Aβ was also detected in Tg4-42 mice in the occipital cortex, 
piriform cortex, striatum and superior colliculus starting a two months of age. Aβ4-42 
expression in the CA1 declined during aging in Tg4-42 and Tg4-42hom mice. The decrease 
of Aβ expression can be attributed to the extensive neuron loss in this brain region. Long-
term exposure to N-truncated Aβ4-42 induced an age- and dose-dependent neuron loss in 
hemizygous and homozygous Tg4-42 mice in the CA1 layer of the hippocampus. At eight 
months unbiased stereology revealed a 38 % neuron loss in hemizygous Tg4-42 mice and 
a 65 % neuron loss in Tg4-42hom. Furthermore, 12-month-old Tg4-42 mice showed a 51 % 
decrease in neuron number in the CA1 compared to same-aged WT.  
The behavior analysis of Tg4-42 and Tg4-42hom mice revealed that mice develop 
no deficits in either motor function or anxiety-behavior that could prevent or potentially 
confound memory testing of these mice. Strikingly, mice showed hippocampus-dependant 
memory deficits similar to AD patients. Tg4-42 and Tg4-42hom were profoundly impaired in 
their spatial reference memory. Moreover, aged Tg4-42 showed a decline in contextual 
fear memory. The over-expression of Aβ4-42 in this mouse model induces severe age-
dependant memory deficits that can be attributed to the massive neuron loss in the 
hippocampus.  
In summary, the pathology of Tg4-42 mice is unique in its massive neuron loss and 
severe memory behavior deficits induced through intraneuronal accumulation of              
N-terminally truncated Aβ4-42 albeit without plaque formation. It can be stated that Tg4-42 
mice emphasize the toxicity of Aβ4-42 in vivo. Moreover, the resulting neurodegeneration 
associated with neuron loss, gliosis and memory deficits appears to be a direct 
consequence of intracellular neurotoxicity of Aβ. In summary, Tg4-42 is a valid AD mouse 
model showing key features of sporadic AD.  
 
One of the central research questions on the etiology of AD is the elucidation of 
the molecular signatures triggered by the amyloid cascade of pathological events. Next 
generation sequencing allows the identification of genes involved in disease processes in 
an unbiased manner. A comparative gene expression analysis of brain tissue of Tg4-42 
and 5XFAD mice was performed using next-generation sequencing. As stated before, 
Tg4.42 mice express N-truncated Aβ4-42 and develop intraneuronal Aβ aggregation, 
neuron loss and behavioral deficits albeit without plaque formation. The widely used 
5XFAD model, which is based on the expression of mutant amyloid precursor protein and 
presenilin-1 genes, is a typical model for early plaque formation, intraneuronal Aβ 
aggregation, neuron loss and behavioral deficits (Oakley et al., 2006; Jawhar et al., 2010).  
Interestingly, the results showed that learning and memory deficits in the Morris water 




the deficits in 5XFAD animals. This suggested that comparative gene expression analysis 
between the models would allow the dissection of plaque-related and -unrelated disease 
relevant factors. Therefore brain transcriptomes of young and old Tg4-42, 5XFAD, and 
wild-type control mice were analyzed by deep-sequencing of non-ribosomal RNA (RNA-
Seq). Differentially expressed genes represented by more than 200 deep sequencing 
reads (DEGs) were verified by qRT-PCR. Nineteen DEGs were identified in 
presymptomatic young 5XFAD mice, while no DEGs could be isolated in young Tg4-42 
mice. In the aged cohort, 131 DEGs were found in 5XFAD and 56 DEGs in Tg4-42 mice. 
Intriguingly, 36 DEGs were identified in both mouse models indicating common disease 
pathways associated with behavioral deficits and neuron loss. The pool of genes that 
showed differential expression exclusively in Tg4-42 is likely associated to soluble Aβ as 
no extracellular plaques are found in this model. In addition, the robust CA1 neuron loss 
could also contribute to the differential expression profile as 5XFAD mice display no 
neuron loss in this brain region. Many of the DEGs specific to the 5XFAD model belong to 
neuroinflammatory processes typically associated with plaques. As Tg4-42 mice do not 
develop any plaques, but still show massive neuron loss, it can be concluded that only the 
DEGs common to both models together with those specific to Tg4-42 are defining the 
molecular signature underlying memory decline in AD. 
Taken together, the results of this thesis demonstrate Aβ4-42 as a toxic Aβ variant 
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